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1. Introduction 
Midbrain dopaminergic neurons (MbDNs) are involved in regulating many important brain 
functions including motor control, reward behavior and cognitive tasks. Degeneration or 
dysfunction of MbDNs is implicated in several common human disorders. In Parkinson‘s 
disease (PD), degeneration of MbDNs in the substantia nigra pars compacta (SNpc) results in 
severe motor deficits (Hirsch et al., 1988; German et al., 1989; Marsden, 1994). 
Dysregulation of dopamine transmission in the forebrain has been linked to the emergence of 
substance disorders (Kelley et al., 2002; Wightman et al., 2002), depression (Dailly et al., 
2004) and the psychotic and cognitive symptoms in schizophrenia (Sesack et al., 2002; 
Winterer et al., 2004). There is increasing evidence that functional and molecular diversity of 
MbDNs correlates with their relative vulnerability to disorders, for example to cell death in 
PD. 
 
 1.1 Dopaminergic neurons in the mammalian central nervous system 
Dopamine (DA) belongs to the family of catecholamines (CA) and as a modulatory 
neurotransmitter it is involved in regulating diverse brain function. DA neurons are widely 
distributed in the mammalian central nervous system (CNS) with the largest population 
located in the ventral midbrain (vMb). The first study to identify the CA neurons in the brain 
was carried out in the early sixties (Dahlstrom and Fuxe, 1964). Immunohistochemical 
detection of the CA-synthesizing enzyme, tyrosine hydroxylase (TH), made it possible to 
detect and map the DA neurons in the mammalian brain. Thus, nine distinctive cell groups 
(A8-A16), distributed from the midbrain to the olfactory bulb (OB), were identified in the 
adult brain (Dahlstrom and Fuxe, 1964). The A11-A15 groups of DA neurons are located 
within the posterior aspect of the hypothalamus (A11), the arcuate nucleus (A12) and the 
periventricular nucleus (A13-A15). DA neurons of A16 are located in the OB. They play 
crucial regulatory roles in many neural functions, including sensorimotor integration and pain 
control at the spinal level (A11), neuroendocrine hormone release (A12–A14), as well as male 
sexual behavior (A13–A15) (Barraud et al., 2010). The MbDNs constitute about 75% of the 
total number of DA neurons and are categorized as A8, A9 and A10. MbDNs form an 
extensive network of connections throughout the forebrain, including the neocortex and 
striatum, as well as limbic system. MbDNs in group A9 contribute to the neurons of the SNpc 
(Figure 1A). The A10 DA neurons represent the ventral tegmental area (VTA), while the A8 
group of MbDNs forms the retrorubral field (RRF). SNpc MbDNs project predominantly to 
the dorsal striatum and are involved in control of movement. The VTA neurons project to the 
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prefrontal cortex (PFC) and the limbic system, and regulate cognitive function and reward 
behavior, respectively (Figure 1B). 
 
 
Figure 1 MbDN subpopulations and their projections. (A) Plane of section represents 
distinct subpopulations of MbDNs in the vMb. IF: nucleus intrafasciculus; PB: nucleus 
parabrachialis; PN: paranigral nucleus; RLi: rostral linear nucleus; SN: substantia nigra; 
SNpc: SN pars compacta; SNl: SN lateralis; dlVTA: dorsolateral ventral tegmental area; 
vmVTA: ventromedial VTA. (B) MbDN projections of SN and VTA. BLA: basolateral 
amygdala; CAN: central amygdaloid nucleus; LHb: lateral habenular nucleus; CPu: caudate-
putamen complex; NAc: nucleus accumbens; OTu: olfactory tubercle; PrL: prelimbic cortex; 
Cg1: cingular cortex; M: motor cortex; AID: agranular insular cortex. 
 
MbDN subpopulations are diverse on different levels, including somatic localization, axonal 
projections, electrophysiological activity and the susceptibility to death in PD. The different 
levels of diversity are described in the following sections and are summarized in Table 1. 
 
 1.2 Neuroanatomy of MbDNs 
MbDN subpopulations are diverse in their anatomical position. Thus, MbDNs of the SNpc are 
located in the lateral vMb, whereas DA neurons of the VTA can be found in the medial vMb. 
Based on their localization, MbDNs of the VTA can be further divided into five 
subpopulations (Figure 1A, Table 1). The medially located nuclei form the ventromedial VTA 
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(vmVTA): these are the intrafascicular nucleus (IF), the rostral (RLi) and caudal (CLi) linear 
nucleus and the paranigral nucleus (PN). The parabrachial pigmented nucleus (PBP) is 
located laterally and forms the dorsolateral VTA (dlVTA). Both PN and IF, as well as CLi, 
are cell-body-rich zones, whereas PBP and RLi are cell-body-poor zones (Ikemoto, 2010). In 
addition, the MbDNs of the SN can be further divided into the SNpc and the SN lateralis 
(SNl); the SNl forms the most lateral aspect of the SNpc. 
 
 1.3 Morphology of MbDNs 
Cells of different MbDN subpopulations can be defined morphologically. While the cell 
bodies in the SNpc are large, angular and elongated, with an average mean diameter of ~19 
µm, the VTA MbDNs are small, rounded cells, with an average diameter of ~13 µm (Tork, et 
al., 1984; Thompson et al., 2005). In addition, MbDNs in the SNpc and VTA can be further 
distinguished by their dendritic morphology. Whereas the dendrites in the SNpc are organized 
in horizontal and vertical planes, there are no vertical dendrites in the VTA (Phillipson, 1979). 
Interestingly, different cell and dendrite morphology was demonstrated within the SNpc. 
Thus, MbDNs located in the dorsal regions of the SNpc are typically fusiform with 2-5 
dendrites emanating from the pole of the neuron, branching sparsely within the area. In 
contrast, MbDNs located more ventrally are multipolar in shape with dendrites emanating 
from the soma and extending laterally. The neurons in the VTA have also 3-5 dendrites 
emanating radially from the soma (Phillipson, 1979). A recent study showed however no 
differences in dendritic size, complexity and relative extension into SN reticulata (SNr) 
between MbDNs of the SNpc and the VTA (Henny et al., 2012). The morphology of the RRF 
MbDNs has not been described. 
 
 1.4 Molecular marker profile expression of MbDNs 
In addition to their anatomical position and morphology, MbDNs can be further distinguished 
by their expression of distinct molecular markers. It has been shown that MbDNs of the SNpc 
and the VTA differ in their expression of DA receptors. There are two families of G-protein-
coupled DA receptors: the D1 and D2 family. The D1 family, which includes D1 and D5 
receptors, stimulates adenylyl cyclase and activates cyclic AMP-dependent protein kinase, 
whereas receptors of D2 family (D2, D3 and D4) inhibit adenylyl cyclase (Missale et al., 
1998). Both types of DA receptors are found in the MbDNs of the SNpc. However, MbDNs 
of the vmVTA do not have any functional somatodendritic D2 autoreceptors and express very 
low mRNA levels of D2 receptors (Lammel et al., 2008). 
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Furthermore, G-protein-regulated inward-rectifier potassium channel 2 (Girk2) is only 
expressed in MbDNs of the SNpc and in some MbDNs in the lateral VTA. MbDNs in the 
vmVTA, some dlVTA, the RRF as well as RLi and CLi nuclei express the calcium-binding 
proteins calbindin and calretinin (McRitchie et al., 1996). In addition, the DA transporter 
(DAT) is also differently expressed in MbDN subpopulations. DAT is a plasma membrane 
transporter protein controlling extracellular DA concentrations through the recapture of DA 
into nerve terminals of MbDN. MbDNs, located in the PN, IF and RLi have lower DAT 
expression than neurons of PBP and SNpc (Lammel et al., 2008; Di Salvio et al., 2010; 
Simeone et al., 2011). A similar expression pattern was observed for vesicular monoamine 
transporter of the type 2 (VMAT2), which controls synthesis and packaging of DA. 
Finally, orthodentical homeobox 2 (Otx2), which plays an important role in the proper 
development of MbDN (Secsion 1.13) (Prakash et al., 2006) is exclusively expressed in a 
subset of dlVTA (PBP) MbDNs (Di Salvio et al., 2010). Interestingly, it is prevalently 
excluded from those neurons, which express Girk2 and high levels of glycosylated active 
form of DAT (Di Salvio et al., 2010; Simeone et al., 2011). 
 
 1.5 Subpopulation of MbDNs co-release other neurotransmitters 
Accumulating evidence over the last ten years indicates that MbDNs may also release other 
neurotransmitter. It has been shown that a subset of MbDNs is able for co-express the 
vesicular glutamate transporter, vGlut2 (Joyece and Rayport, 2000; Dal Bo et al., 2004; 
Mendez et al., 2008; Berube-Carriere et al., 2009). vGlut2 transports glutamate into synaptic 
vesicles for release at presynaptic terminals in DA neurons. MbDNs co-expressing vGlut2 
(MbDN-vGlut2) are primarily found in the VTA (Kawano et al., 2006; Yamaguchi et al., 
2007). Detailed analysis of the vGlut2 mRNA content showed that only some cell groups in 
the VTA co-express vGlut2. MbDN-vGlut2 neurons were found in the rostral VTA, PBP, IF 
and the RLi (Yamaguchi et al., 2011; Gorelova et al., 2012), while vGlut2 neurons (vGlut2-
only) are located in the PBP and PN (Yamaguchi et al., 2011). 
In addition, recent study has demonstrated that MbDNs in the SNpc projecting to the striatum 
are capable of co-releasing gamma-aminobutyric acid (GABA). Interestingly, these neurons 
use VMAT2 for GABA release instead of the vesicular GABA transporter (VGAT) (Trisch et 
al., 2012). 
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 1.6 Projections of MbDNs 
MbDN subpopulations are diverse in their projections to different target areas. Classically, the 
following projections have been allocated to different MbDN subtypes: MbDNs of the SNpc 
primarily project to the dorsal striatum and form the nigrostriatal pathway (Veening et al. 
1980; Gerfen et al., 1987), VTA neurons send their axons to the limbic structures, mainly to 
the ventromedial striatum (the Nucleus accumbens (NAc), the olfactory tubercle (OTu)), the 
amygdala and the PFC, giving rise to mesolimbic and mesocortical pathways, respectively 
(Berridge and Robinson, 1998; Salamone and Correa, 2002; Schultz, 2002; Wise, 2002; 
Ungless, 2004) (Figure 1B). MbDNs in the RRF primarily project to the SNpc and the VTA, 
but also to the hippocampal formation and the medullary and pontomedullary brainstem 
(Krosigk and Smith, 1991; Gasbarri et al., 1996). Accumulating evidence revealed that this 
type of distinction is oversimplified. Recent studies showed that there is a significant 
intermixing of MbDN subpopulations with different projection targets (Bjorklund and 
Dunnet, 2007; Ikemoto, 2007; Ferreira et al., 2008; Wise, 2009), which results in more 
complicated innervation of striatal and cortical areas. 
A more detailed analysis of the VTA projections based on anatomical and functional criterion 
(Ikemoto, 2010) shows a mediolateral gradient in their innervation. Thus, vmVTA (IF and 
PN) MbDNs primarily project to the ventromedial striatum, consisting of the medial 
accumbens shell, as well as to the medial OTu, whereas the dlVTA (PBP) innervates the 
ventrolateral striatum, consisting of the lateral shell and core of NAc, and the lateral tubercle 
(Ikemoto, 2005 and 2010). Retrograde tracing studies revealed that the RLi provides inputs to 
the lateral shell of the NAc as well (Swanson, 1982; Hasue and Shammah-Lagnado, 2002). In 
addition, MbDNs of the RLi project into the diagonal band, as part of the septal nuclei, as 
well as into the pallidal zone of the OTu (Del-Fava et al., 2007; Ikemoto, 2010). Del-Fava et 
al. showed that most of the mesocortical projections originate from the RLi MbDNs. Thus, 
the RLi innervates the infralimbic, prelimbic and anterior cingulate cortices, as well as the 
agranular insular and orbital areas (Table 1) (Del-Fava et al., 2007). 
In addition, MbDN subpopulations differ in their afferent connectivity, which subserves 
different behavioral functions. Areas projecting to MbDNs of the SNpc and the VTA are 
strongly segregated. Thus, MbDNs of the SNpc receive their inputs preferentially from dorsal 
regions, such as dorsal striatum, globus pallidus and entopeduncular nucleus, whereas 
projections to the VTA MbDNs originate from ventral areas, such as ventral striatum, OTu 
and ventral pallidum (Lammel et al., 2012; Watabe-Uchida et al., 2012). 
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 1.7 Physiology of MbDN subpopulations 
Electrophysiological studies using ex vivo brain slice preparation and in vivo recording show 
that MbDNs are spontaneous pacemakers that generate regularly spaced action potentials 
(AP) in frequencies between 1 and 10 Hz (Grace et al., 2007). However, MbDNs operate 
within two distinct frequency bands: tonic and phasic. Tonically firing MbDNs discharge at 
low frequencies individual AP without bursts (Grace and Bunney, 1984), whereas phasic 
MbDNs fire bursts of near 20 Hz and greater (Robinson et al., 2004). Patch-clamp recording 
from in vitro brain slices revealed that MbDNs of the SNpc and the dlVTA fire in tonic mode 
with typically broad single AP (1–3 Hz), while spontaneous discharge frequencies of the 
vmVTA neurons are much faster with the range upper limit of 10 Hz (Lammel et al., 2008). 
Interestingly, the vmVTA MbDNs with low DAT and VMAT2 mRNA expression are the 
fast-firing neurons (Lammel et al., 2008). 
Furthermore, several studies have highlighted the important role of voltage-gated L-type 
calcium channels for creating the basic subthreshold membrane potential oscillations that 
underlie pacemaker activity (Puopolo et al., 2007). However, the calcium dependence of the 
spontaneous pacemaker is not a homogenous property of all MbDNs (Chan et al., 2007; 
Puopolo et al., 2007). When Ca2+ is replaced by equimolar concentration of cobalt, or when 
calcium channels are blocked, MbDNs of the SNpc completely stop firing (Puopolo et al., 
2007; Khallq and Bean, 2010). In contrast, the inhibition of calcium channels does not 
prevent firing in MbDNs of the VTA (Chan et al., 2007). Moreover, it has been suggested that 
this difference in calcium currents between SNpc and VTA MbDNs is a possible mechanism 
for the selective vulnerability of SNpc MbDNs in PD (Section 1.9) (Chan et al., 2007). 
The presence of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels in the 
neurons of SNpc has been used in many studies as a functional criterion to identify and define 
MbDNs (Grace et al., 2007). The activation of HCN channels can be caused in response to 
injections of hyperpolarizing currents and leads to a so-called „sag-component“ (Seutin et al., 
2001; Neuhoff et al., 2002; Zolles et al., 2006). In contrast, MbDNs in the medioposterior 
VTA possess only few functional HNC channels, indicating that their electrophysiological 
properties might be very different from that of the MbDNs in the SNpc (Neuhoff et al., 2002). 
It has been also confirmed in in vitro study, that mesocortical MbDNs in vmVTA demonstrate 
no obvious „sag components“, which correspond to a lack of functional HCN currents (Table 
1) (Lammel et al., 2008, 2011). Moreover, mesocortical neurons also lack apamin-sensitive 
small-conductance calcium-activated potassium (SK) channel-mediated AP 
afterhyperpolarization compared to mesostriatal MbDNs (Wolfart et al., 2001). 
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Interestingly, it has been demonstrated, that VTA MbDNs display two different electrical 
activities. Thus, MbDNs in the vmVTA exhibit a smaller hyperpolarization-activated current 
than MbDNs in the dlVTA (Hnasko et al., 2012). dlVTA MbDNs also show larger and more 
prolongated afterhypopolarization than vmVTA MbDNs. 
 
 1.8 Functions of MbDNs 
Because of their position and the target structure the MbDN subpopulations innervate, they 
can be further separated into functionally distinct subgroups. Since neurons of the SNpc 
almost exclusively innervate the dorsolateral striatum, the SNpc serves mainly as an input to 
the basal ganglia circuit and supplies the striatum with DA. The basal ganglia circuit is 
involved in enabling practiced motor acts and in gaiting the initiation of voluntary movements 
by modulating motor programs stored in the motor cortex. Inputs from the cortex enter this 
circuit via the striatum. There are two pathways, which have opposite effect on cortical 
neurons. The direct pathway excites the cortex via the globus pallidus external, whereas the 
indirect pathway inhibits the cortex through the nucleus subthalamicus and globus pallidus 
internal. The role of the nigrostriatal projections is to keep those two pathways in balance. 
Direct pathway striatal neurons have D1 receptors, which depolarize the cell in response to 
DA. In contrast, indirect pathway striatal neurons possess D2 receptors, which hyperpolarize 
the cell in response to DA. Thus, SNpc MbDN projections have the dual effect of exciting the 
direct pathway while simultaneously inhibiting the indirect pathway. Loss of SNpc MbDNs 
causes an imbalance by increasing the activity of indirect pathway and decreasing the activity 
of direct pathway. This imbalance results in motor symptoms of PD (Section 1.9). 
VTA neurons, via projections onto forebrain structure such as the NAc, PFC, and amygdala, 
play a key role in operant conditioning (Pavlovian learning based on association of 
environmental stimuli with reward) and motivation. Electrophysiological and lesion studies 
have demonstrated that activation of MbDNs in the VTA have positive reinforcing properties, 
because pharmacological or electrical stimulation tends to facilitate reward seeking. In 
contrast, inhibition or lesion of the VTA MbDNs results in a reduced reward seeking (Cheer 
et al., 2007; Fields et al., 2007). Behavioral and pharmacological studies have identified 
different zones within the VTA, based on their projections to the striatal areas, which are 
differently responsible for rewarding effects or for drug abuse. For example, rats rapidly learn 
to self-administer psychomotor stimulants such as cocaine, amphetamine or DA receptor 
agonist into the medial OTu and medial accumbens shell, suggesting that axonal projections 
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from the vmVTA are involved in drug reward (Carlezon et al., 1995; Ikemoto et al., 1997; 
Rodd-Henricks et al., 2002; Ikemoto, 2003; Ikemoto et al., 2005). 
A number of studies revealed a critical involvement of DA in the modulation of neuronal 
activity related to cognitive processing. Electrophysiological studies on rodent and non-
human primates showed that VTA MbDNs innervation in the PFC potentiates the firing of 
delay-active neurons thought to be critical for working memory (Williams and Goldman-
Rakic, 1995; Goldman-Rakic, 1998). Moreover, MbDN projections from the VTA to the 
amygdala are implicated in learning and memory processes, particularly those involving 
behavioral responses to rewarding or aversive stimuli (Maren and Fanselow, 1996; Everitt et 
al., 1999; Koob, 1999). 
 
 1.9 Neurodegeneration of MbDNs in Parkinson’s disease 
Because of their different functions and involvement in several common human neurological 
disorders, MbDNs have been the focus of clinical interest and a subject of intensive studies 
for a long time. Degeneration of the SNpc MbDNs is associated with PD, which is 
characterized by the cardinal motor features of rigidity, bradykinesia and tremor at rest along 
with non-motoric symptoms like autonomic, cognitive and psychiatric problems (Marsden, 
1994). The classical neuropathological hallmark of PD is the pathogenetic fibrillization of the 
protein α-synuclein and the accumulation of abnormal cytoplasmatic inclusions, known as 
Lewy bodies that are present in the surviving MbDNs in SNpc (Spillamtini et al., 1997; 
Mezey et al., 1998). In the following decade numerous studies have established that the motor 
symptoms are attributed to the loss of MbDNs in the SNpc and the decline of DA in the 
striatum, which are responsible for most, if not all, motor symptoms (Fearnley and Lees, 
1991; Marsden, 1994). Intensive research of PD revealed that the majority of cases are 
sporadic and thought to be caused by environmental factors, a genetic causation or a 
combination of the two, while less that 10% of PD has a strict familial etiology. Numerous 
studies indicate that oxidative stress, inflammation, aberrant protein degradation and, in 
particular, mitochondrial dysfunction may be involved in the PD-associated neuronal 
degeneration (Moore at al., 2005; Abou-Sleiman et al., 2006). In recent years, mutations or 
polymorphisms in numerous nuclear genes (α-synuclein, parkin, UCHL1, DJ-1, LRRK2, 
Pink1, tau, HTRA2, NR4A2 and ATP13A2) have been identified as associated with familial 
PD (Ramirez et al., 2006; Klein and Schlossmacher, 2006; Schapira, 2006). 
Elevated intracellular Ca2+ concentrations and lack of intrinsic Ca2+ buffering capacity in the 
MbDNs SNpc create mitochondrial oxidant stress (Guzman et al., 2010). Furthermore, in 
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vitro studies demonstrated that DAT activity depends on its glycosylation status, with the 
glycosylated DAT form transporting DA more efficiently than the non-glycosylated form 
(Torres et al., 2003; Li et al., 2004). Interestingly, it has been shown that somata and terminals 
of the nigrostriatal compartment (ventrocaudal SNpc and dorsal striatum) have higher 
expression levels of glyco-DAT than those of the rostromedial SNpc (Afonso-Oramas et al., 
2009). In PD MbDNs located in ventrolateral and caudal region of the SNpc are more 
vulnerable than those in the rostromedial and dorsal region (German et al., 1989; Damier et 
al., 1999), suggesting that differences in DAT post-transcriptional regulation may be involved 
in the differential vulnerability of MbDNs (Gonzales-Hernandez et al., 2004). 
 
 1.10 MbDNs in psychiatric and neurological disorders 
The other important role of DA as a neuromodulator has been shown in abnormal 
neurotransmission of VTA MbDNs, which is thought to occur in a variety of psychiatric and 
neurological disorders, such as schizophrenia, attention-deficit/hyperactivity disorder 
(ADHD) and reinforcing effects of drug abuse. 
Schizophrenia is one of the most common mental disorders characterized by a breakdown of 
thought processes and by poor emotional responsiveness. Common symptoms include visual 
and auditory hallucinations, disorganized speech and thinking, or paranoid delusions. It has 
been proposed that an imbalance in DA levels in the PFC and ventral striatum underlie the 
symptoms in schizophrenia (“DA hypothesis”). It is thought that a functional excess of DA or 
oversensitivity of certain DA receptors contributes to the psychotic symptoms such as 
delusions and hallucinations (Birtwistle and Baldwin, 1998; Sesack and Carr, 2002). In 
schizophrenic patients the number of D1 receptors is decreased in PFC (Kaplan and Sadock, 
1995). This occurrence explains certain cognitive deficiencies and is thought to be responsible 
for the negative symptoms of schizophrenia such as restrictions in range intensity of emotion 
fluency and productivity of thought and speech, and goal-directed behavior. In contrast, DA 
receptors of the D2 family seemed to be abnormally increased in the basal ganglia and limbic 
system of schizophrenic patients (Sedvall and Farde, 1995; Kaplan and Sadock, 1995). 
Additional evidence for the DA hypothesis is that most antipsychotic drugs act by blocking 
the D2 receptor. 
Dysregulation of the DA transmission in the limbic system has been linked to development of 
the drug addiction (Kelley and Berridge, 2002; Wightman and Robinson, 2002) and 
depression (Dailly et al., 2004). The involvement of DA in drug reinforcement is well 
established, however its role in drug addiction is much less clear. Interestingly, it has been 
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demonstrated that increase of DA in the striatum can be caused by drug conditioned cues in 
cocaine-addicted subjects. Moreover, the magnitude of the DA increase was correlated with 
the subjective experience of craving (Wong et al., 2006; Volkow et al., 2010). However, the 
molecular mechanism of addiction might involve impaired serotonin or noradrenalin 
neurotransmission. Mice in which DAT was disrupted, failed to alter baseline extracellular 
DA levels and to induce behavioral effects such as enhanced locomotor activity (Giros et al., 
1996). However, these mice still can be trained to self-administer cocaine despite persistently 
high levels of DA in the striatum, suggesting a more complex basis for the reinforcement 
(Rocha et al., 1998). 
Not only dysregulation of DA neurotransmitter, but also dysfunction of some proteins 
involved in DA synthesis, release or uptake, have been shown to be implicated in a number of 
DA-related disorders, including ADHD, bipolar disorder, clinical depression, and alcoholism. 
ADHD is a psychiatric and a neurobehavioral disorder, characterized by either significant 
difficulties of inattention or hyperactivity and impulsiveness. There is converging evidence 
that increased DAT plays a major role in the pathophysiology of ADHD (Krause et al., 2003; 
Spencer et al., 2005; Krause, 2008). Knockout studies with mice lacking D2 receptor have 
demonstrated the reduction of hyperactivity, suggesting that D2 receptor-selective agonist is 
good candidate for a specific therapeutic approach that could provide better mechanistic 
resolution that psychostimulants in the treatment of ADHD (Fan et al., 2010). 
 
 1.11 Diversity of MbDNs 
The diversity of MbDNs can be described on many levels, ranging from classical anatomical 
and histological categories to molecular marker profiles, connectivity and functional 
electrophysiological properties (Liss et al., 2007; Lammel et al., 2008 and 2012). However, 
only little is known about whether and how these different levels of diversity are connected. 
There is evidence that the functional diversity is predominantly mediated by their specific 
inputs. For example, MbDNs in the dlVTA projecting to the lateral shell of NAc receive their 
afferents from the laterodorsal tegmentum and are involved in the reward behavior. Neurons 
of the lateral habenula form synapses with mesocorticolimbic neurons of the vmVTA, which 
project to the medial PFC and elicit aversion (Lammel et al., 2012). Furthermore, specific 
molecular profiles of MbDNs correlate with their projections and electrophysiological 
properties (Lammel et al., 2008). In addition, MbDNs show large differences in their 
susceptibility to cell death in PD, which is linked to their distinct molecular profiles. 
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Table 1 Distinct identities of MbDN 
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However, it still unclear how and when this diversity is established. To better understand the 
MbDN diversity in the vMb, there is still the need to gain deeper insights into the 
developmental and phenotypic characteristics of distinct subpopulations of MbDNs, based on 
their axonal projections and circuitry, synaptic connectivity and functional properties. 
Knowledge about how and when this diversity is established during development might help 
to connect the different levels of diversity. 
 
 1.12 Development of MbDNs 
A number of recent studies have conclusively shown that MbDNs arise from neuronal 
progenitors in the ventral midline (floor plate: FP) of the embryonic midbrain (Andersson et 
al., 2006; Ono et al., 2007; Kittappa et al., 2007; Bonilla et al., 2008; Joksimovich et al, 2009; 
Blaess et al., 2011). The development of MbDNs from proliferating neural precursors can be 
broadly divided into three stages (Figure 2) (Abelovich et al., 2007). 
 
 
Figure 2 The timescale of MbDN development. During regionalization vMb tissue is 
determined and self-renewing precursors at the ventricular zone (VZ) give rise to MbDN 
precursors (MbDNp, yellow). In the specification stage MbDNp exit the cell cycle, enter the 
intermediate zone (IZ) and become immature MbDNs (orange). In the differentiation stage 
immature MbDNs migrate into the mantel zone (MZ) and establish appropriate connections. 
The curved arrow indicates proliferating cells. v: ventricle; vMb: ventral midbrain. 
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First, precursors at the ventral ventricular zone (VZ) of the anterior neural plate that have self-
renewing properties and give rise to multiple cell types arise at embryonic day 7.5 (E7.5). In a 
second step, these are specified to a MbDN precursor (MbDNp) cell fate, and several 
molecular markers are associated with this population. In a third stage, the MbDNp exit the 
cell cycle, migrate into the mantel zone (MZ) and begin to display early MbDN markers 
(Figure 2). Finally, the early-differentiated MbDNs mature functionally, express mature 
MbDN markers, and establish appropriate connectivity. The development of MbDNs requires 
a complex combination of transcriptional regulators and diffusible signals to control both the 
acquisition and maintenance of the neurotransmitter-specific phenotype. However, little is 
known when and how different subgroups of MbDNs are specified during development. 
 
 1.13 Induction and regionalization of the ventral midbrain 
Regionalization of the vMb begins early in neural plate development. During neurulation the 
lateral edges of the neural plate roll up along its anteroposterior axis to form the neural tube 
(Gale et al, 2008). Neuronal induction and pattering start around E7.5 and are mediated by a 
precise molecular coding along the anteroposterior and dorsoventral axis, which provides 
positional cues that are crucial in pattern formation. The anteroposterior axis is set up before 
the dorsoventral axis dividing the developing CNS into forebrain, midbrain, hindbrain and 
spinal cord. Dorsoventral patterning subdivides the neural tube from spinal cord to midbrain 
into the FP, basal plate, alar plate and roof plate (RP) (Liu and Joyner, 2001; Prakash and 
Wurst, 2006). Induction of the vMb is refined by local organizer, which provides vMb cells 
with positional information by expression of different diffusible signals (Figure 3). 
The vMb (FP and alar plate) is induced by Sonic hedgehog (Shh) (Jessel, 2000; Lupo et al., 
2006). Shh is secreted first from the notochord, which underlies the neural plate, and later on 
from the FP. Shh as a long-range morphogen is critical for the induction of ventral cell fates 
in many parts of the nervous system and directs the pattern of neurogenesis by conferring 
positional information to ventral progenitors (Jessell, 2000; Lupo et al., 2006). The crucial 
role of Shh in MbDNp induction is apparent in Shh-null mutant mice, in which MbDNs are 
completely missing (Agarwala et al., 2002; Fedtsova et al., 2001; Ishibashi et al., 2002; Blaess 
et al., 2006). Furthermore, conditional inactivation of Shh signaling by depletion of 
Smoothened (Smo), a Shh receptor, at E9.0 results in severe reduction of MbDNs (Blaess et 
al., 2006). 
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Figure 3 Expression of molecules involved in the regionalization and induction of 
MbDNp. Schematic of sagittal section through the mouse embryo. The region in the 
developing CNS where MbDNs develop is indicated in red. Shh (yellow line) is expressed in 
the FP along the neural tube, Fgf8 (green line) is expressed at the mid-hindbrain border 
(MHB) and Wnt1 (purple line) is expressed in the FP and RP of the midbrain, and at the 
MHB. Tel: telencephalon, Mes: mesencephalon, Hb: hindbrain. 
 
Anteroposterior pattering is regulated by a neuroepithelial signaling center localized at the 
mid-hindbrain boundary (MHB) or isthmus. The isthmus is characterized by the expression of 
fibroblast growth factor (Fgf) 8 (Hynes et al., 1995a; Hynes et al., 1995b; Ye et al., 1998; Lee 
and Jessell, 1999; Andersson et al., 2006; Prakash et al., 2006). Conditional inactivation of 
Fgf8 in the midbrain and anterior hindbrain (aHb) results in cell death and failure in the 
midbrain development (Chi et al., 2003). Moreover, conditional inactivation of Fgf receptors, 
particularly Fgf receptor 1, results in midbrain and aHb defects (Trokovic et al., 2003 and 
2005). Interestingly, explant culture experiments have demonstrated that both, Shh and Fgf8 
are required for the induction of MbDNp before E9.5 (Ye et al., 1998), meaning that 
intersection of these secreted factors determines where the MbDNp domain will arise (Hynes 
et al., 1995; Jessel et al., 2000; Briscoe et al., 2001). 
Along with Fgf8 and Shh, Otx2 and gastrulation brain homeobox 2 (Gbx2) are essential for 
the correct positioning of the MbDNp domain. Gbx2 and Otx2 are transcriptional repressors, 
which are expressed in the presumptive hindbrain and in the presumptive mid- and forebrain, 
respectively (Prakash et al., 2004; Ono et al., 2007; Liu et al., 2001). Otx2 mutant mice show 
a complete depletion of the forebrain and midbrain (Ang et al., 1996). Furthermore, a subtle 
shifting of the Otx2 caudal expression boundary effects MbDN population in size (Acampora 
et al., 1997; Brocolli et al., 1999). Thus, expanded Otx2 expression in the caudal midbrain – 
aHb leads to a shift of MHB caudally and an increase of MbDNs (Brodski et al., 2003). 
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Furthermore, secreted molecule Wingless-type MMTV integration site family, member 1 
(Wnt1) is expressed at the rostral border of the MHB and is known to regulate midbrain 
morphogenesis (Figure 3). Wnt1 mutant mice show an abnormal posterior midbrain, isthmus 
and aHb, revealing its essential role in MHB formation (McMahon et al., 1990; Chilov et al., 
2010). Moreover, a temporal requirement for Wnt1 in the induction of distinct MbDNp 
domains was demonstrated. Thus, inactivation of Wnt1 at E9.0 results in almost complete loss 
of the medially positioned MbDNp domain (Yang et al., 2013). Furthermore, it has been 
shown that Wnt1 and Fgf8 cross-regulate each other (Matsunaga et al., 2002; Chi et al., 
2003). Since Fgf8 failed to induce ectopic MbDN in Wnt1 mutant embryos, it has been 
suggested that Wnt1, which can be induced by Fgf8, is a more direct regulator of initiation of 
the MbDNp field (Prakash et al., 2006). 
 
 1.14 Specification of MbDNs 
While vMb precursor identity is established, the most ventrally located precursors start to be 
specified towards a MbDN fate. The neuroepithelium of the vMb first thickens by cell 
proliferation and then becomes layered. The cells in narrow band adjacent to the VZ maintain 
their proliferative precursor properties while other cells move out into the intermediate zone 
(IZ) (Figure 2). The induction of the MbDNp identity occurs within the VZ of the ventral 
midline. A network of transcriptional factors such as Foxa1/2 (forkhead/winged helix 
transcription factor 1 and 2), Lmx1a/b (LIM homeobox transcription factor 1, alpha and beta), 
Msx1/2 (homeobox msh-like 1) as well as Wnt1 signaling regulate the induction of MbDNp 
(Figure 4). Diffusible signaling molecules described above mediate the activation of these 
factors. Thus, Shh secreted from the notochord has been shown to directly induce the Foxa1/2 
expression (Sasaki et al., 1997). Foxa2, in turn, directly induces vMb Shh expression through 
well-conserved Foxa2 binding sites in the Shh gene (Jeong and Epstein, 2003). Moreover, 
Foxa1/2 act downstream of Shh to alter a cell’s competence to respond to Shh signaling by 
directly repressing Gli2 expression (a main activator of Shh signaling, Section 1.17). In 
addition, Foxa1/2 regulate the pattering of vMb precursors by inhibiting the expression of 
Nkx2-2 (Figure 4) (Mavromatakis et al., 2011). 
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Figure 4 The genetic network regulating development of the MbDN. Arrows indicate the 
effect on expression: green = positive regulation, purple = autoregulatory loop, black = 
negative regulation. The factors are color-coded to indicate their role listed on the left side. 
VZ: ventricular zone; IZ: intermediate zone; MZ: mantel zone. 
 
Several lines of evidence indicate that Wnt1 not only regulates the induction of MbDNp, but 
is also involved in MbDNp specification (Figure 3). ES cell culture studies identified that 
Wnt1 directly regulates the expression of the transcriptional factors Lmx1a/b and that removal 
of Lmx1a results in complete loss of Wnt1 expression, revealing an autoregulatory loop 
between Wnt1 and Lmx1a (Chung et al., 2009; Yang et al., 2013). Lmx1a defines the MbDNp 
domain along with the aristaless related homeobox (Arx), transcriptional factor, which is 
expressed in the FP (Andersson et al., 2006; Joksimovic et al., 2009; Blaess et al., 2011; 
Hayes et al., 2011). Lmx1b null mice show a severe reduction in the number of MbDNs 
(Smidt et al., 2000), due to early loss of the midbrain (Guo et al., 2007). Furthermore, loss of 
Lmx1a results in pronounced loss of MbDNs (Andersson et al., 2006; Ono et al., 2007; Deng 
et al., 2011). Conditional inactivation of both transcriptional factors results in severe 
reduction in the MbDNp, suggesting that these two factors can compensate for each other’s 
function (Deng et al., 2011). Furthermore, it has been shown that Lmx1a indirectly regulates 
neurogenesis by inducing expression of Msx1/2 transcriptional factors. Msx1/2 appear to 
induce neurogenesis by activating the proneural factor Ngn2 (neurogenin 2) (Andersson et al., 
2006; Chung et al., 2009). Msx1 null mice exhibit a 40% reduction in the normal number of 
MbDNs, likely as a result of the downregulation of Ngn2 expression (Andersson et al., 2006). 
Moreover, premature expression of Msx1 in the vMb in transgenic mice also leads to the 
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precocious expression of Ngn2, and to the downregulation of Shh in the FP (Chung et al., 
2009) (Figure 4). 
The transition of cells from the proliferation to differentiation is mediated by Ngn2. Ngn2 is 
severely reduced in double mutant mice for Lmx1a/b (Yan et al., 2011). Loss-of-function 
studies show that Ngn2 is the major proneural factor required for MbDN neurogenesis. 
Inactivation of Ngn2 dramatically delays and reduces the number of MbDNs in the IZ (Kele 
et al., 2006; Andersson et al., 2006). Further findings suggest that Ngn2 controls 
differentiation of MbDNs through the regulation of Notch pathway genes, known to maintain 
precursor fate such as Hes5 (an effector of Notch signaling) and Dill1 (a Notch ligand) (Kele 
et al., 2006). Wnt1 regulates the development of MbDNs by controlling the cell cycle 
progression in the MbDNp. Thus, constitutive activation of Wnt/β-catenin (an intracellular 
signal transducer in the canonical Wnt pathway) results in an expansion of early MbDNp. 
However, it perturbs cell cycle progression in the progenitors and reduces the generation of 
MbDNs in vMb. Interestingly, further insights into the role of Wnt1/β-catenin pathway 
revealed that it is also required to maintain the integrity of radial glia, which actually give rise 
to MbDNs and provide scaffolds for newly generated MbDNs to migrate towards their final 
destination (Tang et al., 2009). Removal of β-catenin in MbDNp leads to a complete loss of 
cell polarity, which results in ectopic cell death and loss of MbDNs (Tang et al., 2009). 
 
 1.15 Differentiation of MbDNs 
After MbDNp exit the cell cycle, they migrate ventrally along radial glia towards the MZ and 
begin to differentiate (Figure 2). These postmitotic MbDNp are not yet fully differentiated 
and continue to express a large set of genes from early MbDNp specification, but start to 
express the orphan nuclear receptor Nurr1 (nuclear receptor subfamily 4, group A, member 2) 
(Zetterstrom et al., 1997). In Nurr1 knockout mice MbDNs fail to express genes, which are 
involved in DA synthesis, axonal transport, storage and release or reuptake of DA 
(Zetterstrom et al., 1997; Saucedo-Cardenas et al., 1998). Lmx1a/b directly regulate the 
expression of Nurr1 (Figure 4) (Chung et al., 2009). 
The next step in the differentiation of MbDNs is characterized by the expression of pituitary 
homeobox 3 (Pitx3) transcriptional factor and TH, the rate limiting enzyme of DA synthesis. 
Lmx1b is involved in the initiating the expression of TH and Pitx3. Thus, in Lmx1b null mice, 
medially derived MbDNs are lost and the majority of remaining MbDNs fail to express TH 
and Pitx3 (Deng et al., 2011). Pitx3 is required for the proper differentiation of MbDNs by 
regulating TH expression (Maxwell et al., 2005). Interestingly, MbDN diversity is apparent 
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already during development. MbDNs located at the ventrolateral position of the MZ express 
Pitx3 prior to TH, whereas the dorsomedial MbDNs express TH ahead of Pitx3 at E12.5 
(Maxwell et al., 2005). Later on, Pitx3 is expressed in all MbDN subpopulations. However, 
Pitx3 deficient mice display severe reduction of the SNpc MbDNs, whereas the VTA neurons 
are relatively intact (Smidt et al., 1997 and 2004; Zhao et al., 2004). 
A number of genes regulated by Pitx3 have been identified (Smits et al., 2006). One of these 
genes encodes the enzyme aldehyde dehydrogenase family 1 (Aldh 1a1: also known as 
Raldh1 or Ahd2). Ahd2 is under the transcriptional control of Pitx3, which binds to a highly 
conserved region of Ahd2 gene (Jacobs et al., 2007). Ahd2 is involved in the production of 
retinoic acid (RA) from retinol, which is crucial for neuronal pattering and differentiation 
(McCaffery et al., 2003) and it is exclusively expressed in the lateral parts of the MbDN area. 
Prenatal RA treatment (E10.5-E13.5) of Pitx3 deficient mice can rescue the phenotype and 
results in increased Ahd2 expression in the lateral parts of MbDNs at E14.5 (Jacobs et al., 
2007). 
Recent study suggested that Otx2 is also involved in the controlling of postmitotic aspects of 
MbDN differentiation and crucial for proper functioning of MbDNs in the adult brain (Di 
Salvio et al., 2010). Interestingly, Otx2 is expressed exclusively in a subset of MbDNs of the 
VTA and is completely excluded from the SNpc MbDNs in the adult brain. 
 
 1.16 Molecular heterogeneity of MbDNp domain 
The diversity of MbDN system is created by a controlled ontogenetic process of their 
specification, migration and differentiation. The Lmx1a expression defines the MbDNp in the 
ventral midline. Medial progenitor cells express, besides Lmx1a, the transcription factors 
Msx1/2 and the cell surface molecule Corin, whereas laterally located progenitor populations 
express only Lmx1a (Andersson, 2006; Ono, 2007; Deng, 2011; Mavromatakis et al., 2011; 
Blaess et al., 2011). Analysis of Lmx1a- and Lmx1b deficient mice confirmed that there are at 
least two distinct MbDNp domains, which might contribute to discrete MbDN subtype 
populations. Thus, deletion of Lmx1a results in a specific loss of the medial MbDNp domain, 
whereas the lateral MbDNp domain is not established in Lmx1b null mutants, suggesting a 
selective requirement for Lmx1a/b in the specification of two distinct MbDNp. It has 
previously been demonstrated that Shh expression is dynamic in the vMb (Joksimovic et al., 
2009; Blaess et al., 2011; Hayes et al., 2011 and 2013). First, Shh is released by cells in the 
notochord and induces Shh expression in the narrow medial domain overlying the notochord 
around E8.5. Gli1 expression is a well-established readout for high levels of Shh signaling 
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and precedes Shh expression by about a day. Thus, Gli is initially expressed in the ventral 
midline of the neural tube at E7.5, while Shh is expressed by the cells of notochord (Hui et al., 
1994). Once Shh expression is present in ventral midline cells around E8.5, Gli1 expression is 
downregulated in the Shh-expressing cells and excluded from the midline, indicating that Shh-
expressing cells cease responding to Shh signaling. The Shh domain expands more laterally 
until E10.5 and Shh expression begins to be downregulated medially (Ye et al., 1998; Prakash 
and Wurst, 2006; Blaess et al., 2011). The lateral expansion of Shh-expressing cells in the 
vMb over time results in gradually shifted lateral expression of Shh-responding cells (Gli1-
expressing). At later developmental stages (E11.5 and E12.5) weak Shh expression is still 
detected in the medial domain (Blaess et al., 2011; Hayes et al., 2011). Genetic inducible fate 
mapping (GIFM) studies have demonstrated that the spatiotemporally dynamic Shh 
expression defines multiple progenitor pools and can potentially give rise to the distinct 
neuronal cell populations (Blaess et al., 2011; Hayes et al., 2011). In addition, conditional 
inactivation of Shh signaling pathway demonstrates that the crucial time period for Shh 
signaling in establishing MbDNs is between E8.0 and E10.0 (Blaess at al., 2006 and 2011). 
Making use of the changing Shh-expressing domains, GIFM sequentially defined two 
spatially distinct vMb progenitor domains that give rise to different subpopulations of MbDNs 
(Blaess et al., 2011; Hayes et al., 2011) (Figure 5). 
 
Figure 5 Distinct MbDN precursor domains give rise to different MbDN subpopulations. 
(A) Schematic of medial (yellow) and lateral (orange) MbDNp domains at E9.5-E10.5. (B) 
The medial domain contributes preferentially to the MbDNs of the SNpc (yellow dots) and 
dlVTA. The lateral MbDNp give rise to the MbDNs of the vmVTA and RLi. 
After E9.5, precursor cells that continue to respond to Shh (express Gli1) are located in the 
lateroposterior aspects of the MbDNp domain and appear to adopt a certain fate of MbDN, 
since they preferentially give rise to MbDN in the vmVTA. Whereas MbDNp located at the 
ventral midline, which responds to Shh prior E9.5, show a bias to contribute to the SNpc 
(Blaess et al., 2011; Hayes et al., 2011). In addition, cells responding to Shh at E9.5 to E10.5 
give rise to other vMb neurons, including the neurons in the oculomotor nucleus (OM) and 
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the non-MbDNs in the SNr (Figure 7). These data further support the idea that there are 
distinct subsets of MbDNp and suggest that the time or length of exposure to Shh signaling 
might be involved in pre-determining MbDN subset fate. 
 
 1.17 Shh pathway transduction 
The transduction of Shh signaling occurs via the interaction of two cell surface receptors, the 
12-transmembrane-domain protein patched (Ptch) and the seven-pass G-protein-coupled 
receptor smoothened (Smo) (Marigo et al., 1996; Stone et al., 1996; Goodrich et al., 1997; 
Ingham and McMahon, 2001) (Figure 6). Genetic and biochemical data indicate that in 
absence of Shh ligand, Ptch constitutively represses Smo activity (Chen et al., 1996). When 
bound by Shh, the inhibition of Smo by Ptch is relieved, allowing Smo to transduce Shh 
signaling intracellularly (Alcedo et al., 1996). Smo acts intracellularly by activating or 
repressing Gli family zinc-finger transcriptional factors. In mouse, there are three Gli proteins 
that transduce the Shh signal. Gli3 functions primarily as a transcriptional repressor whereas 
Gli1 and Gli2 function as activators (Matise et al., 1998; Bai et al., 2002, 2004; Pan et al., 
2006). In the absence of Shh, Gli3 is proteolytically processed to generate a transcriptional 
repressor (Figure 6) and Gli2 is completely degraded (Pan et al., 2006). 
 
 
Figure 6 Schematic of canonical Shh signaling pathway. Shh signaling occurs in primary 
cilia. (A) In absence of Shh, the activity of Smoothened (Smo) is repressed by Patched (Ptch). 
Gli2 is degraded. Gli3 is processed into a Gli3 repressor (Gli3-R), which blocks the 
expression of Shh target genes. (B) Binding of Shh releases inhibition of Smo by Ptch and 
allows it to enter the cilium. Consequently, Gli2 and Gli3 are activated (Gli2A and Gli3A). 
Gli2A induces Shh target genes (e.g. Gli1 and Ptch). 
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Presence of Shh induces the formation of Gli2 and to a lesser extent Gli3 activators (Bai et al., 
2002; Persson et al., 2002). Moreover, Shh inhibits the proteolytic processing of Gli3 into a 
repressor form and decreases its expression on a transcriptional level. Gli2 activator function 
is essential for the induction of the ventral most cell types, including the FP, whereas the 
proper regulation of Gli3 repressor levels controls the patterning of more dorsal region. Gli1 
expression is completely dependent on Gli2/Gli3 activator function and is readout for high 
levels of Shh signaling. A number of recent in vivo and in vitro studies have shown that Shh 
signaling occurs in primary cilia. In the absence of Shh, Ptch is localized to the primary 
cilium, whereas Smo is localized to the plasma membrane of the cell body (Figure 6). Upon 
Shh exposure, Ptch allows Smo to enter the cilium, where it promotes the activation of Gli2 
and inhibits the formation of Gli3 repressor, resulting in the activation of target genes (Corbit 
et al., 2005). The formation of Gli3 in the absence of Shh signaling also requires primary cilia 
(Haycraft et al., 2005; Liu et al., 2005; May et al., 2005). 
 
 1.18 Other ventral midbrain cells regulated by Shh signaling 
A number of developmental studies have shown that the VZ of the vMb can be divided into 
three molecularly distinct domains at E10.5 (Figure 7A). As described previously, cells at the 
ventral midline express Lmx1a and give rise to MbDNs. Oculomotor (OM) and red nucleus 
(RN) neurons are generated immediately lateral to the Lmx1a positive MbDNp domain from 
cells that express Foxa2, Sim1, Nkx6-1 and Nkx6-2. Progenitors located lateral to the Foxa2 
domain express Nkx2.2 and differentiate into GABAergic neurons (Figure 7A) (Kala et al., 
2009). The neurons of the RN and OM complex are involved in the control of movement. The 
OM nucleus gives rise to the third (nIII) cranial nerve and innervates the ipsilateral 
extraocular muscles and ciliary ganglion, thereby controlling most eye movements, eye 
accommodation and pupil contraction (Figure 7B). The neurons of OM complex are 
characterized by expression of the LIM homeodomain transcriptional factor islet1 (Isl1) and 
the homeobox gene Mnx1 (motor neuron and pancreas homeobox 1), generic motor neuron 
markers (Ericson et al., 1992; Agarwala and Ragsdale, 2002). The crucial role of Isl1 for 
survival of motor neurons in the spinal cord was demonstrated in the loss-of-function study 
(Pfaff et al., 1996), but its function in OM development remains unknown. 
The RN consists of the anterior parvocellular and the posterior magnocellular part (Evinger, 
1988). Both parts of the RN contain excitatory glutamate and inhibitory GABA-synthesizing 
neurons, which project to the cerebellum, brainstem and spinal cord (Keifer and Houk, 1994). 
Together with the corticospinal tract, the rubrospinal tract plays a fundamental role in the 
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control of limb movements (Kennedy, 1990). The neurons of the RN can be identified by 
expression of the POU homeobox transcription factor Pou4f1 (also known as Brn3a), which is 
required for survival of postmitotic RN neurons (Turner et al., 1994; Fedtsova and Turner, 
1995; McEvilly et al., 1996; Xiang et al., 1996; Agarwala and Ragsdale, 2002). 
A       B 
 
Figure 7 vMb precursor domains give rise to different neurons. (A) Schematic view of 
vMb precursor domains at E10.5. Lmx1apos/Shhpos/Foxa2pos domain (orange) gives rise to 
MbDNs. Medial Lmx1apos/Corinpos/Msx1/2pos domain (red) gives rise to the VTA MbDNs, 
whereas Lmx1apos/Corinneg/Msx1/2neg domain (orange) gives rise to the SNpc MbDNs. 
Shhpos/Foxa2pos/Nkx6-1pos precursors (yellow) give rise to the neurons of the red nucleus 
(RN). The oculomotor nucleus (OM) is derived from the Foxa2pos/Nkx6-1pos domain (green), 
whereas GABAergic neurons arise from the Nkx2.2pos/Nkx6-1pos domain (blue). (B) RN (red) 
and OM (blue) projections into the cerebellum (Cb), pons and spinal cord (SC). 
 
Birthdating experiments demonstrated that OM neurons develop between E9.2 and E9.7, 
whereas RN neurons are generated between E10.2 and 10.7 (Prakash et al., 2009). Shh plays a 
crucial role in the induction of these neurons (Watanabe and Nakamura, 2000; Fedtsova and 
Turner, 2001; Agarwala and Ragsdale, 2002; Blaess et al., 2006; Bayly et al., 2007; Fogel et 
al., 2008). Nkx6-1 null mutant mice display a severe reduction in the number of RN and OM, 
demonstrating that Nkx6-1 is intrinsically required for the generation and identity of those 
neurons (Prakash et al., 2009). In addition, Otx2 plays an important role in the development 
of RN and OM nuclei. Conditional inactivation of Otx2 in the midbrain results in a complete 
loss of the RN and hypoplasia of the OM (Puelles et al., 2004). In contrast, ectopic expression 
of Otx2 results in ectopic expression of Nkx6-1 and ectopic generation of RN, suggesting an 
important role of Otx in induction and maintenance of Nkx6-1 expression in the vMb 
(Prakash et al., 2009). Notably, only ectopic RN neurons were detected in the rostral 
hindbrain, but not OM neurons, meaning that Otx2 is sufficient for the generation of RN but 
not of OM complex. 
Lmx1b and Foxa2 are also involved in the generation of OM and RN neurons (Deng et al., 
2011), since Lmx1b null and Foxa2 null mutants display an almost complete loss of OM 
neurons and a significant increase in the number of RN cells. The imbalance in Lmx1a and 
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Foxa2 expression determines the fate of these neurons. Thus, Lmx1b is necessary for the 
generation of OM and for the suppression of RN neurons at early developmental stages, 
whereas inactivation of Foxa2 results in a loss of OM and striking overproduction of RN 
neurons (Deng et al., 2011). 
 
 1.19 Shh signaling and its role in the development of the central nervous system 
In the nervous system, Shh has been studied in detail in the induction of different ventral cell 
types in the spinal cord (Fuccillo et al., 2006; Dessaud, et al., 2007). Shh acts as a morphogen 
in a concentration-dependent manner and determines spatially distinct progenitor domains 
along the ventrodorsal axis (Jessel, 2000). Distinct concentration levels of Shh induce 
expression of specific sets of homeobox transcription factors. Each progenitor domain 
generates one or more distinct neuronal subtypes, the identity of which is determined by the 
combination of transcription factors expressed by the precursors (Lupo et al., 2006). The 
progenitor domain in the ventral midline of the developing spinal cord receives the highest 
concentration of Shh from the notochord and develops into the FP. Once FP cells are 
determined, they begin to express Shh. Overall, six different progenitor domains/neuronal cell 
types are generated in response to different levels of Shh (Briscoe, et al., 2000). In Shh-
deficient mice neither the FP domain, nor six distinct cell types are generated (Wijgerde et al., 
2002). A number of recent studies in the spinal cord have demonstrated that Shh does not 
only elicit a concentration-dependent response (as expected from a morphogen), but that the 
duration of Shh signaling can also influence the cell’s fate decision (Dessaud, 2007 and 2008, 
Balaskas et al., 2012). A “temporal adaptation” model has been proposed, that relies on a 
progressive decrease in the sensitivity of receiving cells to ongoing Shh signaling (Dessaud et 
al., 2007). First, cells appear to be highly sensitive to Shh signaling and low concentration of 
Shh is sufficient to evoke high levels of Gli activity. With increasing time, cells become 
desensitized to ongoing Shh signaling and only high concentration of Shh can evoke the 
highest levels of Gli activity increases. Consistent with this model, gain-of-function 
experiments suggest that progressive changes in the level of Gli activity are sufficient to 
recapitulate the patterning activity of graded Shh signaling (Li et al., 2004). As a result, 
changes in the concentration or the duration of Shh have an effect on intracellular signaling in 
the spinal cord. 
Aim of the study 
 
 24 
2. Aim of the thesis 
MbDNs play pivotal roles in the regulation of many important brain functions including 
motor control, emotion and cognition. They form several subpopulations, which are divergent 
in their physiological and functional features as well as vulnerability to neurodegeneration in 
PD. The diversity of these subpopulations is partially correlated with their anatomical 
organization and incoming and outcoming connectives. However, little is known about how 
this diversity is established during development. Shh signaling is required for the generation 
of MbDNp between E8.0 to E10.5 (Andersson et al., 2006; Blaess et al., 2006). However, 
after E9.5 only precursors located in the lateroposterior aspects of the MbDNp domain 
continue to respond to Shh and preferentially give rise to MbDNs in the vmVTA (Blaess et 
al., 2011; Hayes et al., 2011). These data suggest that distinct subsets of MbDNp exist, and 
that their generation is governed by the temporospatial dynamics of Shh signaling. 
To investigate whether Shh signaling plays an instructive role in determining different subsets 
of MbDNp, high level Shh signaling shall be inactivated between E8.5-E9.0, about a day after 
MbDNp start to respond to Shh signaling and day before lateral MbDNp cease to respond to 
Shh. This shall be achieved by conditional removal of Gli2, the main downstream activator of 
Shh signaling. Immunohistochemical and RNA In Situ hybridization analysis of MbDNp shall 
provide important insights into the mode (direct or indirect) and timing of Shh signaling in 
specification of MbDNs. Examination of MbDNp domain in the developing vMb and MbDNs 
in the adult brains shall identify whether and which subpopulation of MbDNs is affected by 
Shh inactivation. In addition, optogenetic and immunohistochemical approaches shall 
ascertain whether loss of specific MbDN subpopulations disturbs innervation of the target 
area in adult brain. 
It is well known that MbDNs and their target structures are involved in the neural circuit 
modifications that underlie a variety of adaptive and pathological behaviors (Zhang et al., 
2001; Wiese et al., 2004; Lammel et al., 2012; Stamatakis et al., 2012). To examine whether 
and how the preferential reduction of MbDN subpopulations impacts on the formation of 
dopaminergic circuitry, MbDN-derived projections shall be examined using viral tracing, 
optogenetics and physiological approaches. 
Finally, to determine the temporal requirement of Shh signaling for the RN neuron 
specification, precursors in the ventral midline of the developing midbrain shall be analyzed 
using immunohistochemical and RNA In Situ hybridization approaches. 
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3. Materials and Methods 
 3.1 Technical equipment 
Appliance Name Manufacturer Registered office 
Autoclave DX-150 Systec Wettenberg, Germany 
Balance Atilon Sartorius Göttingen, Germany 
Block heater Dry bath Typ15103 Thermo Scientific Waltham, USA 
Centrifuge Labofuge 400R  Thermo Scientific Waltham, USA 
Centrifuge Pico 17 Thermo Scientific Waltham, USA 
Confocal microscope Fluoview 1000 
Dualscan 
Olympus Tokyo, Japan 
Cryostat CM3050S Leica Wetzlar, Germany 
Fluorescence lamp Illuminator HXP120C Zeiss Jena, Germany 
Galvanometer based 
scanning system 
UGA-40, DL-473 Rapp 
Optoelectronics 
Hamburg, Germany 
Gel chamber Model 41-1525 Peqlab Erlangen, Germany 
Horizontal puller Model P-97 Sutter Instruments Novato, USA 
Hotplate HI12220 Flattening 
Table 
Leica Wetzlar, Germany 
Hotplate Flattening Table 
OTS40 
Medite Burgdorf, Germany 
Hybridization oven InSlide Out 241000 Boekel Scientific Feasterville, USA 
Incubator AL01-07 Advantage-Lab Schilde, Belgium 
Laser 473 nm Omicron Rodgau-Dudenhofen, 
Germany 
Light fiber BF-22 Thorlabs New Jersey, USA 
Magnetic stirrer AGE 1200RPM VELP Scientifica Usmate, Italy 
Microscope Axio Observer. Z1 Zeiss Jena, Germany 
Microscope DM1000LED Leica Wetzlar, Germany 
Microscope camera AxioCam MRm Zeiss Jena, Germany 
Microscope camera AxioCam MRc Zeiss Jena, Germany 
Microwave R-939-A SHARP Electronic 
GmbH 
Hamburg, Germany 
Multiclamp amplifier 700 B Molecular Devices Sunnyvale, USA 
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PCR cycler DNA engine PTC-
200 
Biorad München, Germany 
pH Meter FE20 FiveEasy Mettler Toledo Gießen, Germany 
Pipettes horizontal 
puller 
P-97 Sutter Instruments Hofheim, Germany 
Power supply Power supply 231 Zeiss Jena, Germany 
Refrigerator/Freezer 
4°C and -20°C 
G 2013 Comfort Liebherr Lindau, Germany 
Reverse phase 
column 
C18 Thermo Scientific Waltham, USA 
Shaker Nutation mixer VWR Darmstadt, Germany 
Slides boxes Micro slide box 
(plastic) 
VWR Darmstadt, Germany 
Spectrophotometer Nanodrop 1000 Peqlab Erlangen, Germany 
Stereo microscope Modular 
stereomicroscope 
MZ10F 
Leica Wetzlar, Germany 
Thermal Shaker Thriller Peqlab Erlangen, Germany 
Ultrafast Ti:Sa laser 810 nm, Chameleon 
Ultra 
Coherent Santa Clara, USA 
Water bath WB Type 1012/1013 GFL Burgwedel, Germany 
Vacuum pump Vacuubrand Brand Wertheim, Germany 
Vibratome VT 1200 S Leica Wetzlar, Germany 
Vortex Vortex genius IKA Staufen, Germany 
 
 3.2 Consumables 
Appliance Name Manufacturer Registered office 
Butterfly needles Butterfly-25 Venisystems, 
Hospira 
Lake Forest, USA 
Dissection tools  Fine Science Tools Heidelberg, Germany 
Embedding cassettes Histosette 
embedding cassettes 
VWR Darmstadt, Germany 
Embedding molds Peel-A-Way Polysciences Inc. Warrington, USA 
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embedding molds 
Glass capillaries GB150F-8P Science Products Hofheim, Germany 
Hybridization cover 
slips 
HybriSlip HS 60 Sigma Aldrich  St. Louis, USA 
Beveled needles NanoFil NanoFil, WPI Sarasota, USA 
Injection needles 27G x ¾´´-Nr.20 
Microlance 3 
BD Bioscience Heidelberg, Germany 
Microinjection 
syringe 
0.001µL/hr-
21mL/min 
NanoFil, WPI Sarasota, USA 
Microscope Cover 
Glasses 
40 mm/ 60 mm Labomedic Bonn, Germany 
Microscope slides Superfrost Menzel-Gläser Braunschweig, 
Germany 
Microscope slides Superfrost ultra plus Menzel-Gläser Braunschweig, 
Germany 
Mini-pump Micro4MicroSyringe 
Pump Controller 
WPI Sarasota, USA 
Parafilm Laboraty film `M Pechiney Plastic 
Packaging 
Chicago, USA 
PCR tubes PCR strip tubes 0,2 
mL 
VWR Darmstadt, Germany 
Perfusion tools  Fine Science Tools Heidelberg, Germany 
Petri dishes Falcon petri dishes 
(15 mm) 
BD Biosciences Heidelberg, Germany 
Pipettes Pipetteman 
P10/20/200/1000 
Gilson Middleton, USA 
Pipetteboy Accu Jet Pro Brand Wertheim, Germany 
Pipette tips Gilson pipette Tipps 
(0,5-20 µL, 20-200 
µL, 200-1000 µL) 
Greiner Bio-One Frickenhausen, 
Germany 
Reagent tubes Eppendorf tubes (0,5 
mL; 1,5 mL; 2 mL) 
Eppendorf Hamburg, Germany 
Serological pipettes Costar plastic Sigma Aldrich St. Louis, USA 
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serological pipettes 
Syringes Plastipak 1 mL BD Bioscience San Jose, USA 
 
 3.3 Chemicals and reagents 
Chemicals Manufacturer Registered office 
2-Mercaptoethanol Sigma Aldrich St. Louis, USA 
Acetic anhydride (Ac2O) VWR International Darmstadt, Germany 
Acetone Roth Karlsruhe, Germany 
Acetonitrile Sigma Aldrich St. Louis, USA 
Agarose (ultrapur) Life Technologies Carlsbad, USA 
Albumin Boviene Serum (BSA) Sigma Aldrich St. Louis, USA 
Ampicillin VWR International Darmstadt, Germany 
Anti-DIG-AP Fab fragments Roche Applied Science Penzberg, Germany 
Aqua-PolyMount Polyscience Inc. Eppelheim, Germany 
Atipamezol Provet AG Lyssach b. Burgdorf, 
Switzerland 
Biocytin Sigma Aldrich St. Louis, USA 
Boric acid VWR International Darmstadt, Germany 
BM Purple Poche Applied Science Penzberg, Germany 
Bromodeoxyuridine (BrdU) Sigma Aldrich St. Louis, USA 
Bromphenol blue Sigma Aldrich St. Louis, USA 
Chloroform (CHCl3) VWR International Darmstadt, Germany 
Culture medium (LB) AppliChem Darmstadt, Germany 
ddH2O Ampuwa, Fresenius Bad Homburg, Germany 
dH2O MilliQ, Merch-Millipore Billerica, USA 
Deoxycholate AppliChem Darmstadt, Germany 
Dextran sulfate AppliChem Darmstadt, Germany 
Digoxigenin-labeled NTPs Roche Applied Science Penzberg, Germany 
Disodium phosphate (Na2HPO4) VWR International Darmstadt, Germany 
DMSO Sigma Aldrich St. Louis, USA 
DNA Ladder 1 kb plus Life Technologies Carlsbad, USA 
DNA loading buffer Life Technologies Carlsbad, USA 
dNTPs Peqlab Erlangen, Germany 
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DPBS Life Technologies Carlsbad, USA 
Eosin Solution Sigma Aldrich St. Louis, USA 
Ethidium bromide (EtBr) Life Technologies Carlsbad, USA 
Ethanol (EtOH) VWR International Darmstadt, Germany 
Ethylenediaminetetraacetic acid 
(EDTA) 
VWR International Darmstadt, Germany 
Ethylenediaminetetraacetic acid 
(EDTA) (HPLC grade) 
Sigma Aldrich St. Louis, USA 
Formamide Life Technologies Carlsbad, USA 
Glycerol Fisher Scientific Schwerte, Germany 
Hydrochloric acid (HCl) VWR International Darmstadt, Germany 
Hoechst 33258 Life Technologies Carlsbad, USA 
Isoflorane  Abbott Mumbai, India 
Isopropanol Sigma Aldrich St. Louis, USA 
Ketamine Bela-Pharm Vechta, Germany 
Levamisole Sigma Aldrich St. Louis, USA 
Lithium chloride (LiCl) Sigma Aldrich St. Louis, USA 
Magnesium chloride (MgCl2) VWR International Darmstadt, Germany 
Medetomidine Provet AG Lyssach b. Burgdorf, 
Switzerland 
Normal donkey serum (NDS) Sigma Aldrich St. Louis, USA 
Normal goat serum (NGS) Sigma Aldrich St. Louis, USA 
Octanesulfonic acid Sigma Aldrich St. Louis, USA 
OGB-1-AM dye Life Technologies Carlsbad, USA 
Orthophosphoric acid Sigma Aldrich St. Louis, USA 
Paraffin McCormick Scientific Richmond, USA 
Paraformaldehyde (PFA) VWR International Darmstadt, Germany 
PCR run buffer (10x) Life Technologies Carlsbad, USA 
Perchloric acid Sigma Aldrich St. Louis, USA 
Phenol AppliChem Darmstadt, Germany 
Phenol-Chloroform AppliChem Darmstadt, Germany 
Pluronic Life Technologies Carlsbad, USA 
Polymerase buffer (19x) Life Technologies Carlsbad, USA 
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Polysorbate 20 (Tween 20) VWR International Darmstadt, Germany 
Potassium chloride (KCl) VWR International Darmstadt, Germany 
Restriction enzyme New England Biolabs Ipswich, USA 
Restriction enzyme Roche Applied Science Penzberg, Germany 
RNase away Life Technologies Carlsbad, USA 
RNase inhibitor Roche Applied Science Penzberg, Germany 
Sodium acetate (NaOAc) Merck Darmstadt, Germany 
Sodium azide (NaN3) Sigma Aldrich St. Louis, USA 
Sodium citrate VWR International Darmstadt, Germany 
Sodium chloride (NaCl) VWR International Darmstadt, Germany 
Sodium dihydrogen phosphate 
monohydrate 
Sigma Aldrich St. Louis, USA 
Sodium diphosphate VWR International Darmstadt, Germany 
Sodium hydroxide (NaOH) VWR International Darmstadt, Germany 
Sodium tetraborate decahydrate VWR International Darmstadt, Germany 
Sucrose Sigma Aldrich St. Louis, USA 
Taq DNA polymerase GE Healthcare Buckinghamshire, UK 
RNA (SP6, T3, T7) polymerase Roche Applied Science Penzberg, Germany 
Tissue Tec O.C.T. Sakura Finetek Inc.  Torrance, USA 
Transcription buffer Roche Applied Science Penzberg, Germany 
Triethanolamine (TEA) VWR International Darmstadt, Germany 
Triethylamine Sigma Aldrich St. Louis, USA 
Tris-aminomethane (TRIS) Merck Darmstadt, Germany 
Triton X-100 Merck Darmstadt, Germany 
Xylol Arcos Organics Geel, Belgium 
 
 3.4 Buffer and solutions 
Acetylation solution 
125 µL acetic anhydride (Ac2O) 
650 µL HCL 
130 µL Triethanolamine (TEA) 
49 mL dH2O 
freshly prepared 
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Artificial cerebrospinal fluid (ACSF) 
60 mM NaCl 
100 mM sucrose 
2.5 mM KCl 
1.25 mM MaH2PO4 
26 mM NaHCO3 
1 mM CaCl2 
5 mM MgCl2 
20 mM glucose 
 
Blocking solution 
3 mL/10 mL NDS/NGS 
97 mL/90 mL PBS 
For the immunohistochemistry 0.1-0.2% triton is added, for RNA In Situ hybridization 0.1% 
Tween is added. The blocking solution is prepared freshly before use. 
 
Borate Buffer 
3.1 g boric acid 
4.8 g Sodium tetraborate decahydrate 
1 L dH2O 
stored at room temperature 
 
Ca2+-free Ringer 
150 mM NaCl 
2.5 mM KCl 
10 mM Hepes 
 
Citrate Buffer 
1.92 g Citric acid (anhydrous) 
1 L dH2O 
pH adjust to 8.0 
stored at room temperature 
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Hybridization Solution 
50 mL Formamide (deionized) (50%) 
20 mL 50% Dextran sulfate  
1 mL 100x Denhardt’s (1%) 
2.5 mL yeast tRNA (10 mg/mL) (10%) 
6 mL 5M NaCl (0.3 M) 
2 mL 1M Tris-HCl, pH 8 (20 mM) 
1 mL 0.5M EDTA (5 mM) 
1 mL 1M NaPO4 (pH 8) (10 mM) 
5 mL 20% Sarcosyl (1%) 
11.5 mL DEPC-H2O (1%) 
stored in 5 mL aliquots at -20°C 
 
Intracellular solution 
140 mM K-gluconate 
5 mM HEPES-acid 
0.16 mM EGTA 
0.5 mM MgCl2 
5 mM phosphocreatine 
0.3% biocytin 
 
LB medium 
10 g Tryptone/Peptone 
5 g Yeast extract 
10 g NaCl 
800 mL dH2O 
pH adjust to 7.5 
 
Loading buffer (10x) 
50% glycerol 
1xTE Buffer 
0.25% bromphenol blue 
0.25% xylene cyanol 
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Lysis Buffer 
2.5 mL 1M Tris pH 8.8 
0.1 mL 0.5M EDTA 
2.5 mL 10% Tween 
44.9 mL dH2O 
stored at room temperature 
 
NTMT 
2 mL 5M NaCl (100 mM) 
10 mL 1M Tris-HCl pH 9.5 (100 mM) 
5 mL 1M MgCl2 (50 mM) 
0.1 mL Tween-20 (0.1%) 
82.9 mL dH2O 
freshly prepared 
 
PBS (5x) 
40 g NaCl 
1 g KCl 
17,9 g Na2HPO4 * 12 H2O 
1.36 g KH2PO4 
1 L dH2O 
pH adjust to 7.4 
stored at room temperature 
 
PBS (1x) 
200 mL PBS (5x) 
800 mL dH2O 
stored at room temperature 
 
PBS-azide (0.1%) 
1 g Sodium azide 
1 L PBS (1x) 
stored at room temperature 
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PBS-Triton (0.1%) 
1 mL Triton X-100 
1 L PBS (1x) 
stored at room temperature 
 
PBS-Tween (0.1%) 
1 mL Tween-20 
1 L PBS (1x) 
stored at room temperature 
 
PFA (20%) 
500 g PFA 
2.0 L ddH2O 
8.0 mL NaOH 
stored in 5 mL aliquots at -20°C 
To prepare 2 L of 20% PFA, 500 mL of ddH2O was heated to 80°C under the hood. While 
stirring, 500 g PFA was added. 8 mL NaOH was added drop-wise until PFA crystals were 
dissolved. pH was adjusted to 7.4 with NaOH and the volume was filled up to 2 L with 
ddH20. Subsequently, the 20% PFA solution was filtered and aliquoted in 50 mL Falcon tubes 
(10 mL per tube), and stored at -20°C. To prepare 4% PFA, 5 mL of 20% PFA was heated up 
in a water bath at 65°C. 1xPBS was added to a total volume of 50 mL. 
 
RNase Buffer 
100 mL 5M NaCl (0.5M) 
10 mL 1M Tris-HCl, pH 7.5 (10 mM) 
10 mL 0.5M EDTA, pH 8 (5 mM) 
880 mL dH2O 
stored at room temperature 
 
SSC (20x) 
88.2 g Sodium citrate 
174 g NaCl 
1 L dH2O 
pH adjusted to 7.0 
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stored at room temperature 
 
SSC (5x) 
250 mL SSC (20x) 
750 mL dH2O 
stored at room temperature 
 
SSC (2x) 
100 mL SSC (20x) 
900 mL dH2O 
stored at room temperature 
 
SSC (0.1x) 
5 mL SSC (20x) 
995 mL dH2O 
stored at room temperature 
 
TAE (50x) 
242 g Tris-base 
57.1 mL Glacial acetic acid 
100 mL 0.5M EDTA, pH 8.0 
stored at room temperature 
 
TE Buffer 
1 mL 1M Tris-HCL pH 8.0 
200 µL 0.5 M EDTA 
98.8 mL dH2O 
 
 3.5 Primary antibodies 
ms = mouse, rb = rabbit, gt = goat, gp = guinea pig, rt = rat 
Epitope and origin Dilution Order # Manufacturer 
α-activated-Caspase-3 (rb) 
IgG 
1:200 9664 Cell Signaling, Danvers, USA 
α-BrdU (ms) IgG 1:50 555627 BD Bioscience, San Jose, USA  
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α-Calbindin (rb) IgG 1:2500 CB38 Swant, Bellinzona, Switzerland 
α-DAT (rt) IgG 1:1000 AB369 Merch-Millipore, Billerica, USA 
α-Foxa2 (gt) IgG 1:100 SC-6554 Santa Cruz Antibodies, Santa Cruz, 
USA 
α-GFP (gt) IgG 1:1000 AB5449 Abcam, Cambrige, UK 
α-GFP (rb) IgG  1:500 A11122 Life Technologies, Carlsbad, USA  
α-GFP (rt) IgG 1:2000 04404-26 Nacalai, San Diego, USA 
α-Girk2 (rb) IgG 1:100 APC-006 Alomone Labs, Jerusalem, Israel 
α-Lmx1a (rb) IgG 1:2500 AB10533 Merch-Millipore, Billerica, USA 
α-Ngn2 (gt) IgG 1:50 SC-19233 Santa Cruz Antibodies, Santa Cruz, 
USA 
α-Nkx6-1 (ms) IgG 1:50 F55A10 Developmental Studies Hybridoma 
Bank, Iowa-City, USA 
α-Nurr1 (ms) IgG 1:200 SC-990 Santa Cruz Antibodies, Santa Cruz, 
USA 
α-Pitx3 (rb) IgG 1:250 38-2850 Life Technologies, Carlsbad, USA 
α-Pou4fl (ms) IgG  1:100 SC-8429 Santa Cruz Antibodies, Santa Cruz, 
USA 
α-Tyrosine hydroxylase 
(TH) (ms) IgG 
1:500 MAB318 Merch-Millipore, Billerica, USA 
α-Tyrosine hydroxylase 
(TH) (rb) IgG 
1:500 MAB152 Merch-Millipore, Billerica, USA 
 
 3.6 Secondary antibodies 
Epitope and origin Dilution Order # Manufacturer 
anti-mouse, Alexa 488 1:500 A21202 Life Technologies, Carlsbad, USA 
anti-rabbit, Alexa 488 1:500 A21206 Life Technologies, Carlsbad, USA 
anti- guinea pig, Biotin 1:200 706-065-
148 
Jackson Immuno, West Grove, USA  
anti- mouse, Biotin 1:200 715-065-
150 
Jackson Immuno, West Grove, USA 
anti-goat, Cy3 1:200 715-165-
147 
Jackson Immuno, West Grove, USA 
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anti-mouse, Cy3 1:200 715-165-
150 
Jackson Immuno, West Grove, USA 
anti-rabbit, Cy3 1:200 715-165-
152 
Jackson Immuno, West Grove, USA 
anti-goat FITC 1:500 705-095-
147 
Dianova, Hamburg, Germany 
streptavidin Alexa 555  1:500 S323555 Life Technologies, Carlsbad, USA 
 
 3.7 Oligonucleotides 
Primer Sequence Tm °C: 
CreF 5´-TAAAGATATCTCACGTACTGACGGTG-3´ 58.4 
CreR 5´-TCTCTGACCAGAGTCATCCTTAGC-3´ 61.6 
Gli2-floxC 5´-AGGTCCTCTTATTGTCAGGC-3´ 57.8 
Gli2-floxD 5´-GAGACTCCAAGGTACTTAGC-3´ 55.4 
Gli2-AS 5´-CACCCCAAAGCATGTGTTTT-3´ 57.4 
Gli2-S 5´-AAACAAAGCTCCTGTACACG-3´ 55.6 
Gli2neo-pA 5´-ATGCCTGCTCTTTACTGAAG-3´ 54.7 
SmoM2-wt1 5´-TCCTTGAAGAAGATGGTGCG-3´ 58.8 
SmoM2-wt2 5´-GGAGCGGGAGAAATGGATATG-3´ 59.6 
SmoM2-mt1 5´-AAGTTCATCTGCACCACCG-3´ 58.8 
SmoM2-mt2 5´-TCCTTGAAGAAGATGGTGCG-3´ 58.8 
 
 3.8 Kits 
Name Manufacturer Registered office 
Hi Pure Plasmid Filter 
Maxiprep Kit 
Life Technologies Carlsbad, USA 
Innuprep Plasmid Mini Kit Analytik Jena Jena, Germany 
QIAquick PCR Purification 
Kit (50) 
Qiagen Hilden, Germany 
 
 3.9 Software 
Name Manufacturer Registered office 
Adobe Illustrator CS6 Adobe System Inc. San Jose, USA 
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Adobe Photoshop CS6  Adobe System Inc. San Jose, USA 
Axio Vision Rel 4.7 Zeiss Jena, Germany 
Excel for Mac 2011; Version 
14.2.3 
Microsoft Corporation Redmond, USA 
Fiji NIH Bethesda, USA 
IGOR WaveMetrics Portland, USA 
ImageJ NIH Bethesda, USA 
Keynote ’09; Version 5.1.1 Apple Inc. Cupertino, USA 
pClamp Software Molecular Devices Sunnyvale, USA 
Word for Mac 2011; Version 
14.2.3 
Microsoft Corporation Redmond, USA 
 
 3.10 Mouse keeping and breeding 
All mice were bred on a CD1 background. Experimental animals were housed in an animal 
facility with a 12 hrs dark/light cycle with lights on at 6 am and had access to food and water 
ad libitum. No more than 6 animals were kept in one cage. The room was temperature- and 
humidity-controlled. For maintenance of the lines as well as for experiments, two females (5-
40 weeks old) were bred with one male (6-40 weeks old). Timed embryos were obtained from 
overnight matings and noon of the day that a vaginal plug was detected was designated as 
E0.5. Pups were genotyped at postnatal (P) stage P14 and were separated from the mother at 
P21. Animal studies were approved by the local University of Bonn Animal Care and Use 
Committee, as well as the Animal Care and Use board of the country of Nordrhein-Westfalen. 
 
 3.11 Mouse lines 
  3.11.1 En1Cre/+ 
The En1Cre/+ mice were generated by Kimmel et al. (2000). To generate the mutant allele, the 
first 111 amino acids of the target gene were replaced by the Cre cDNA (Kimmel et al., 
2000). The insertion of the Cre cDNA interferes with the expression of the endogenous gene 
product. Therefore the En1Cre/+ allele is a null allele. Heterozygous mice are viable and fertile. 
Breeding En1Cre/+ mice with mice containing an allele with loxP-flanked sequence of interest 
results in the Cre-mediated recombination of the floxed sequences in En1-expressing tissues, 
particularly in the vMb and aHb around E9.0 (Li et al., 2002). 
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  3.11.2 Gli2zfd/+ 
Gli2zfd/+ (Gli2 zinc finger-deleted) mouse line was generated in the laboratory of A. Joyner by 
replacing the exons encoding for zinc fingers 3 to 5 with 2.5 kb of the 5’ and 5.0 kb of the 3’ 
Gli2 genomic sequences and a PGK neo cassette (Matise et al., 1998). The deletion results in 
an out-of-frame mutation, which causes disrupted transcription from the deletion site to the 3’ 
end of the Gli2 gene. The zinc fingers 4 and 5 are essential for DNA binding, therefore 
deletion of the sequence encoding for zinc fingers 3 to 5 results in translation of truncated 
protein, which is unable to bind to DNA (Pavletich and Pabo, 1993). 
 
  3.11.3 Gli2flox/flox 
The Gli2flox/flox mouse was generated in the laboratory of A. Joyner in 2006 (Corrales et al., 
2006). Two loxP sites flank exon 7 and 8 upstream exon encoding for the zinc finger exons. 
Gli2flox/flox mice show a wild-type phenotype. Gli2flox/flox mice were used in this study to 
generate conditional knockout mice. 
 
  3.11.4 R26SmoM2 
The R26SmoM2 allele contains a constitutively active mouse Smo (W539L, SmoM2) fused to 
the enhanced yellow fluorescent protein (EYFP) under the control of the endogenous Rosa26 
ubiquitous promoter. However, expression of SmoM2 and EYFP is normally blocked by a 
loxP-flanked stop cassette, which can be removed upon Cre-mediated recombination, 
allowing tissue-specific expression of SmoM2. The constitutively active W539L point 
mutation has been found in human basal cell carcinoma (Xie et al., 1998) and is a tryptophan-
to-leucine mutation, which results in translation of the correspondingly mutated protein 
capable of ligand-independent activation of the Hedgehog pathway (Taipale et al., 2000). 
Homozygous mice are viable, fertile and do not display any abnormalities (Jeong et al., 2003). 
 
  3.11.5 The Gli2 conditional knockout mouse (Gli2ΔMb>E9.0) 
To create viable mutant mice in which Gli2 was deleted from midbrain precursors, the 
En1Cre/+ knock-in mouse line was crossed with Gli2zfd/+ to generate En1Cre/+:Gli2zfd/+ mice. 
The En1Cre/+:Gli2zfd/+ were generated in the laboratory of A. Joyner. Those mice were crossed 
with Gli2flox/flox homozygotes to generate the conditional knockout mice En1Cre/+:Gli2flox/zfd, 
termed Gli2ΔMb>E9.0 throughout this study (Figure 8B). Gli2flox/+ littermate mice were used as a 
control. 
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  3.11.6 The SmoM2 conditional overactivation (SmoM2↑Mb>E9.0) 
To constitutively activate the Shh pathway in the midbrain precursors, the R26SmoM2 mouse 
line was crossed with the En1Cre/+ knock-in mouse line (Jeong et al., 2003). As a result, 
En1Cre/+:R26SmoM2 mice were generated (termed SmoM2↑Mb>E9.0 throughout this study), in 
which Shh signaling was permanently activated upon Cre-mediated recombination in the 
midbrain precursor cells expressing En1. These mice have enlarged midbrain and die at birth. 
En1Cre/+ littermates were used as control. 
 
 3.12 Genotyping of knockout mice 
For deoxyribonucleic acid (DNA) analysis, small pieces of tissue from the mouse tail (about 5 
mm) for E12.5-18.5, from the ear (ear punch) for postnatal mice and from yolk sac for E9.5-
11.5 embryos were obtained. To digest the tissue, 100 µL lysis buffer with 1 µL proteinase K 
was added and briefly vortexed. The samples were incubated at 60°C for 8 hrs or longer and 
subsequently heated at 95°C for 15 min to inactivate the proteinase K. Afterwards, the 
digested solution was centrifuged for 1 min at 13000 rpm to bring down moisture on sides of 
tubes and to precipitate digested tissue fragments. 1 µL of the supernatant was used for 
polymerase chain reaction (PCR). 
 
 3.13 Molecular biological methods 
  3.13.1 Polymerase chain reaction 
To determine the genotypes of the mice, polymerase chain reaction (PCR) approach was used. 
The first step (denaturation) requires high temperatures of 94°-96°C to denature double 
stranded DNA. It is a cyclic process based on the elongation of DNA strands in between two 
reverse oligonucleotide primers by a DNA polymerase. With repeated cycle of DNA melting 
and enzymatic replication of the DNA sequences in between the two primers, an amplification 
of the desired DNA sequence is achieved. 
 
  3.13.2 PCR Programs 
  3.13.2.1 Cre PCR 
PCR Sample solution  Program for Thermal Cycle 
2.00 µL PCR Buffer (1x)   
0.16 µL dNTPs (25 nM)  Step   Temp.  Time (min) 
1.00 µL P1: Cre-F (5 µM)  1. First Denaturing  95°C	   	   	  2:00 
1.00 µL P2: Cre-R (5 µM)  2. Denaturing   95°C	   	   	  0:40 
0.60 µL MgCl2 (1.5 mM)  3. Annealing   59°C	   	   	  1:00 
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14.04 µL dH2O   4. Extension   72°C	   	   	  0:50 
0.20 µL Taq Polymerase (1U) 5. Incubation     8°C	   	   	  ∞	  
19.00 µL Solution (total)  35 x Cycles step 2-4 
Agarose gel: 1.5% 
Mutant band: 300 nt 
 
  3.13.2.2 Gli2 flox PCR 
PCR Sample solution  Program for Thermal Cycle 
2.00 µL PCR Buffer (1x)   
0.16 µL dNTPs (25 nM)  Step   Temp.  Time (min) 
1.00 µL P1: Gli2-flox C (5 µM) 1. First Denaturing  94°C	   	   	  5:00 
1.00 µL P2: Gli2-flox D (5 µM) 2. Denaturing   94°C	   	   	  1:00 
0.60 µL MgCl2 (1.5 mM)  3. Annealing   58°C	   	   	  1:00 
14.04 µL dH2O   4. Extension   72°C	   	   	  1:30 
0.20 µL Taq Polymerase (1U) 5. Last Extension  72°C   10:00	   	  
19.00 µL Solution (total)  6. Incubation    8°C	  	   	   	  ∞  
     35 x Cycles step 2-4 
Agarose gel: 1.5% 
Wildtype band: 231 nt, mutant band: 247 nt 
 
  3.13.2.3 Gli2 zfd PCR 
PCR Sample solution  Program for Thermal Cycle 
2.00 µL PCR Buffer (1x)   
0.16 µL dNTPs (25 nM)  Step   Temp.  Time  (min) 
1.00 µL P1: Gli2-S (5 µM)  1. First Denaturing  94°C	   	   	  5:00 
1.00 µL P2: Gli2-AS (5 µM)  2. Denaturing   94°C	   	   	  1:00 
1.00 µL P3: Gli2 neo-pA (5 µM) 3. Annealing   58°C	   	   	  1:00	  	  
0.60 µL MgCl2 (1.5 mM)   4. Extension   72°C	   	   	  1:30 
13.04 µL dH2O   5. Last Extension  72°C   10:00	    
0.20 µL Taq Polymerase (1U) 6. Incubation    8°C	  	   	   	  	  ∞ 	  
19.00 µL Solution (total)  35 x Cycles step 2-4 
Agarose gel: 1.5% 
Wildtype band: 300 nt, mutant band: 550 nt 
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  3.13.2.4 SmoM2 PCR 
PCR Sample solution  Program for Thermal Cycle 
2.00 µL PCR Buffer (1x)  
0.16 µL dNTPs (25 nM)  Step   Temp.  Time (min) 
1.00 µL P1: SmoM2-mt1 (5 µM) 1. First Denaturing  94°C	   	   	  3:00 
1.00 µL P2: SmoM2-mt2 (5 µM) 2. Denaturing   94°C	   	   	  0:30 
1.00 µL P3: SmoM2-wt1 (5 µM) 3. Annealing   60°C	   	   	  1:00	  	  
1.00 µL P3: SmoM2-wt2 (5 µM) 4. Extension   72°C	   	   	  1:00 
0.60 µL MgCl2 (1.5 mM)  5. Last Extension  72°C   2:00	    
12.04 µL dH2O   6. Incubation   10°C	  	   	   	  ∞ 	  
0.20 µL Taq Polymerase (1U) 35 x Cycles step 2-4 
19.00 µL Solution (total) 
Agarose gel: 2% 
Wildtype band: 410 nt, mutant band: 173 nt 
 
  3.13.3 Agarose gel electrophoresis 
Agarose gel electrophoresis is a method to determine the presence and size of PCR products 
by separating DNA/RNA based on the rate of movement while under the influence of an 
electric field. The DNA/RNA to be analyzed is forced through the pores of the gel by the 
electrical current. Under an electrical field, DNA/RNA moves away from the negative 
towards the positive electrode. The speed of DNA/RNA movement is influenced by the 
strength of the electrical field, the concentration of agarose gel and the size of the DNA/RNA 
molecules. Smaller DNA/RNA molecules move through the agarose faster than larger 
molecules. The DNA/RNA is visualized in the gel by addition of ethidium bromide (EtBr). 
EtBr is fluorescent meaning that it absorbs invisible UV light and transmits the energy as 
visible orange light. To prepare a 1.5% agarose gel, 2.25 g agarose powder was dissolved in 
150 mL 1xTAE Buffer. For 2% or 0.5% agarose gel, 3 g or 0.75 g of agarose powder was 
dissolved in 150 mL 1xTAE buffer, respectively. The solution was boiled in the microwave 
until the agarose dissolved and became clear. The agarose solution was cooled at room 
temperature and 0.5 µg/mL of EtBr was added to it. The agarose solution was poured into a 
gel-casting tray fitted with a well-forming comb. Agarose gel was submersed in a chamber 
containing a buffer solution (1xTAE) and a positive and negative electrode. The DNA/RNA 
samples were mixed with the gel tracking dye (DNA loading buffer) and loaded into the 
Materials and Methods 
 
 43 
sample wells. The gel with the samples was run at 120 V for 30 min at room temperature. 0.5 
and 1 kb marker was used to identify fragments between 0.1 kb and 0.6 kb. 
 
  3.13.4 Generation of RNA In Situ Probes 
  3.13.4.1 Transformation of E. coli 
To amplify a specific vector, medium competent bacteria (DH5α) were transformed with a 
DNA plasmid containing a cassette with ampicillin resistance. 50 µL of competent cells of E. 
coli (DH5α) were thawed on ice or briefly warmed in hand and 1 µg of the DNA plasmid was 
added. Next, the bacteria were incubated on ice for 5 min and heat-shocked at 42°C for 30 sec 
allowing the DNA plasmid to enter the cells. Finally, the bacteria were chilled on ice for 2 
min and 10 µL of the bacteria were plated on LB agar plates, containing 20 µL/mL ampicillin 
and incubated at 37°C overnight. 
 
  3.13.4.2 Maxi-preparation 
To obtain a bigger amount of pure plasmid, a single colony was picked and first transferred 
into a 10 mL falcon tube containing LB-medium with ampicillin (20 µL/mL). The bacterial 
culture was incubated for 7-8 hrs at 37°C on a shaker (starter culture). After that, the 10 mL 
culture was transferred to a flask containing 100 mL of LB-medium (+ 20 µL/mL ampicillin). 
The culture was incubated at 37°C on a shaker overnight. The bacteria were centrifuged at 
8000 rpm at 4°C for 60 min. The pellet was processed for the maxi-preparation carried out 
with a HiPure Plasmid Maxiprep Kit from Invitrogen according to the manufacturer’s 
instruction. The concentration of the DNA was determined by Nanodrop measurement. The 
plasmid was stored at 4°C. 
 
  3.13.4.3 Digest of plasmid 
Plasmid containing the DNA inserts for creating the anti-sense RNA probes for the RNA In 
Situ hybridization had to be linearized by restriction enzymes before in vitro transcription 
could be performed. In order to do this, solution mix to digest the plasmid was prepared: 
A digestion mix:   20 µg Plasmid 
10 µL 10xNEB1-4 Buffer 
10 µL 10xBSA 
5 µL restriction enzyme (100 U) 
x µL dH2O                    
100 µL Solution (final) 
Materials and Methods 
 
 44 
The digestion mix was incubated at 37°C for 3 hrs. To ensure that the plasmid was cut 
properly, 5 µL of the digestion mix was run on an agarose gel with 1 µg of undigested 
plasmid. To purify the DNA of interest from other nucleic acids, phenol-chloroform 
extraction was performed. 100 µL of phenol-chloroform was added to the digestion mix (100 
µL) and centrifuged at 13000 rpm for 10 min. The upper (aqueous) phase (containing DNA) 
was transferred to a new 1.5 mL tube. Next, 0.3 M sodium acetate (pH 5.2) was added to the 
tube containing the DNA and vortexed. Then 220 µL of ice cold 100% EtOH was added and 
mixed. The DNA was then precipitated at -80°C for 30 min and centrifuged at 13000 rpm for 
10-15 min at 4°C. Afterwards, the supernatant was discarded and the pellet was washed with 
100 µL 70% EtOH and centrifuged at 13000 rpm for another 15 min at 4°C. After discarding 
the supernatant, the pellet was air-dried for 10-15 min. Subsequently, the pellet was 
resuspended in 50 µL RNase free H2O with 0.5 µL RNAse inhibitor and stored at -20°C. 
 
  3.13.4.4 In vitro transcription 
To generate the labeled anti-sense (AS) RNA probes (riboprobes), the digested and purified 
plasmid (containing the marker gene sequence) was transcribed to the AS RNA probe by in 
vitro transcription. To this end, DIG-labeled NTP mix was used, which includes UTP labeled 
with DIG (Digoxigenin-11-uridine-5’-triphosphate) and can be detected with anti-DIG-AP 
Fab fragments. The in vitro transcription solution mix (20 µL) contained: 
1.5 µL Purified DNA (1-2 µg) 
2 µL (10x) Transcription Buffer 
2 µL (10x) DIG-NTP labeling mix 
0.5 µL RNase inhibitor (10 U) 
1.5 µL RNA polymerase (30 U) 
12.5 µL dH2O 
The transcription solution mix was incubated at 37°C for 2 hrs. Next, 1 µL of DNase was 
added to remove the plasmid DNA and the solution was incubated at 37°C for another 15 
min. The RNA was precipitated at -80°C by adding 2 µL of EDTA (4 mM), 2.5 µL LiCl (100 
mM) and 75 mL of 100% EtOH. The suspension was centrifuged at 13000 rpm for 15 min at 
room temperature, washed with 70% EtOH and centrifuged again for another 10 min. The 
pellet was air-dried at room temperature for 3-5 min and resuspended in 50 µL ddH2O + 1% 
RNase inhibitor. Subsequently, the RNA concentration was measured with Nanodrop and the 
RNA was stored at -20°C. 
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 3.14 Histology 
  3.14.1 Dissection of embryos 
Embryos at different embryonic stages (E9.5-E12.5, E14.5 and E18.5) were dissected. 
Pregnant mice were anesthetized with isoflurane and sacrificed by cervical dislocation. A 
midline skin incision was made from the thorax to the pelvis and the uterus was exposed. The 
embryos were removed from the uterus and transferred to a petri dish filled with chilled 
1xPBS on ice. By using fine forceps, the muscular wall of the uterus and visceral yolk sac 
was removed. At stages E9.5-E11.5 whole embryos were collected, while at stages E12.5 and 
E14.5 the heads were dissected. At stage E18.5 the brains were dissected out by removing the 
skin from the head and the skull. Tissue was fixed in 4% PFA (E9.5-E10.5 for 30 min, E11.5-
E12.5 for 60 min and E14.5 and E18.5 for 2 hrs) at 4°C. 
 
  3.14.2 Perfusion of postnatal mice 
Three and six week old animals were used for intracardial perfusion. First at all, mice were 
anesthetized by lethal dose of intraperitoneal injection of Ketamine-Rompun mixture (50:10 
mg/kg of body weight) or by exposure to a tissue soaked with isoflorane. To assure adequate 
depth of anesthesia, the withdrawal reflex was checked by pinching the toes or tip of tail until 
no response was observed. Then, the animal was placed on a corked surface on its back and 
each limb was taped down with a needle. A midline skin incision was made from the thoracic 
inlet to the pelvis, so that the abdomen was open and the liver was exposed. To expose the 
heart, further incision of the sternum was done. The butterfly needle was placed into the left 
ventricle toward the aorta. Using scissors a small cut in the right atrium was made to allow the 
perfusate to exit the circulation. At the same time, using syringe 1xPBS was injected with a 
flow no higher than 0.5 mL/min. When the fluid exiting the mouse was clear and when the 
liver became a light color, the syringe with 1xPBS was exchanged to a syringe with 4% PFA. 
Perfusion was complete when all muscle contractions stopped and the mouse became stiff. 
Afterwards, the mouse was decapitated at the level of the shoulders. The skin of the head was 
cut up to the eyes and the skull was carefully removed with scissors. After most of the skull 
was removed, the brain was dissected by cutting the olfactory and optical nerves as well as 
spinal cord at the level of the brain stem. Subsequently, the brain was postfixed in 4% PFA at 
4°C overnight. 
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  3.14.3 Cryo-embedding 
After fixation in 4% PFA tissue was washed in 1xPBS three times for 10 min. To cryoprotect 
tissue, the brains were incubated in 15% sucrose at 4°C for at least 6-12 hrs, or until tissue 
was submerged. Afterwards the tissue was incubated in 30% sucrose at 4°C overnight or until 
the brains were submerged. All procedures were carried out on a rocking platform. The cryo-
molds were filled with tissue-tek O.C.T. compound medium and placed on dry ice. Once the 
O.C.T. medium starts to solidify (turn white) at the bottom, the cryo-molds were removed 
from dry ice and the brain, heads or embryos were placed in the center of the mold. 
Embryonic tissue (E9.5-18.5) was immediately frozen on dry ice. The blocks with the 
embryos as well as the postnatal brains imbedded in the cryo-molds were stored at -80°C. 
 
  3.14.4 Cryo-sectioning 
About 30 min prior the sectioning, blocks were removed from the -80°C freezer and placed in 
the cryostat to allow them to warm up to the sectioning temperature. The temperature of the 
cryostat was set to -25°C. Embedded tissue was removed from the plastic molds and attached 
to the cryostat object holder with a small amount of O.C.T. The blocks were sectioned 
coronally at a thickness of 12 µm (E10.5-E12.5), 16 µm (E18.5), 20 µm (P21) or 40 µm (P21 
and P48). The 12 µm, 16 µm and 20 µm slices were collected on „superfrost ultra plus“ 
adhesion slides in series of ten slides, in such a way that the slide contained every tenth 
section from the anterior to posterior axis. After cutting, the sections were dried at room 
temperature for 60 min and processed for further immunohistochemistry/RNA In Situ 
hybridization or stored in slide boxes at -20°C. 
40 µm thick slices (P21 and P48) were collected in 96 well plates filled with 1xPBS with 1% 
(final concentration) Sodium azide (free floating sections). The plates were stored at 4°C. 
 
  3.14.5 Paraffin embedding 
 For embedding tissue in paraffin the tissue (E9.5 and E10.5 embryos and E14.5 heads) was 
washed in 1xPBS three times for 5 min. All steps were carried out at room temperature. The 
tissue was dehydrated as follows: (2x) in 70% EtOH, (1x) in 80% EtOH, (2x) in 95% EtOH 
and (2x) in 100% EtOH. Each dehydration step was 10 min for E9.5, 15 min for E10.5 and 20 
min for E14.5 embryos. Next, the tissue was cleared with 1:1 100% EtOH: 100% Xylol two 
times for 10-20 min. Afterwards, tissue was placed in embedding cassettes and transferred 
into 100% Xylol and incubated three times (E9.5: 5 min, E10.5: 10 min, E14.5: 15 min). 
Subsequently, the specimens were transferred into paraffin heated to 58°C in water bath and 
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processed in to fresh paraffin for two more times (E9.5: 10 min, E10.5: 15 min and E14.5: 20 
min). The embedding molds were filled with heated paraffin and the tissue was transferred 
into the molds on a heating plate at 64°C. Using heated forceps, the tissue was properly 
oriented in the mold. Once the tissue was oriented as desired, the mold was covered with the 
labeled embedding cassette and removed from the heating plate. Paraffin blocks with 
embedded embryos or heads were stored at room temperature till they were sectioned at the 
microtome. 
 
  3.14.6 Paraffin sectioning 
After paraffin was solidified hard, block was removed from the mold and attached to the 
microtome chuck. The specimens were sectioned coronally at 7 µm. To unroll the sections, 
they were picked up with a fine paintbrush and floated in water at 37°C. The sections were 
floated onto „superfrost ultra plus“ adhesion slides. The sections were arranged on slides in 
pairs of one (E9.5), two (E10.5) or three (E14.5), in series of ten, in this way adjacent slices 
on every slide had the same spacing on the anteroposterior axis. The slides were allowed to 
dry on a flattening plate at 38°C overnight to bind the tissue to the glass. The sections were 
stored in slide boxes at room temperature or processed further for RNA In Situ hybridization 
and/or immunohistochemistry. 
 
  3.14.7 Immunohistochemistry on frozen and free-floating sections 
Frozen section were thawed at room temperature for 5 min and rinsed with PBS for 5 min to 
remove the O.C.T. Next, the tissue was re-fixed with 4% PFA for 5 min at room temperature. 
After washing two times with PBS and one time with PBT (0.1% TritonX-100 in PBS), 
sections were blocked in 10% normal donkey serum (NDS) in PBT for 1 hr at room 
temperature. After that, they were incubated with primary antibody in 3% NDS/PBT (300 µL 
per slide) for 2 hrs at room temperature or at 4°C overnight. Afterwards, the sections were 
washed again three times in PBT and incubated with secondary antibody 3% NDS/PBT for at 
least 1 hr at room temperature. To visualize the cell nuclei, a Hoechst fluorescent 
counterstaining (Hoechst 33258, 1:10000) was added to the solution with secondary antibody. 
Finally, the sections were washed three times with PBT for 5 min, mounted with 
AquaPolymount and covered with coverslips. The immunostained sections were stored at 
4°C. 
Free-floating sections were washed in 1xPBS for 5 min and blocked in 10% NDS in PBT for 
1 hr at room temperature. All procedures were carried out in 12 or 24 well plates and on the 
Materials and Methods 
 
 48 
rocking platform. Next, they were incubated with primary antibodies in 3% NDS/PBT (500 
µL per well) overnight at 4°C. Afterwards, the sections were washed three times in PBT for 
10 min and incubated with secondary antibody in 3% NDS/PBT for at least 2 hrs at room 
temperature. To the secondary antibody mixture, Hoechst was added to visualize the cell 
nuclei. Subsequently, sections were washed again in PBT three times for 10 min. Sections 
were placed in a petri dish filled with 1xPBS and floated with a fine paintbrush onto 
„superfrost“ adhesion slides. Afterwards, slides were dried for 5 min. Finally, sections were 
mounted with AquaPolymount and covered with coverslips. The immunostained sections 
were stored at 4°C. 
For detection of transcription factors, frozen section were thawed and washed in 1xPBS as 
described above. Next, they were fixed in 4% PFA for 10 min followed by three washing 
steps with 1xPBS for 5 min each, then incubated in 0.1 mM EDTA for 10 min at 65°C water 
bath prior to the immunostaining. The free-floating sections were washed in 1xPBS for 5 min 
and then incubated in 0.1 mM EDTA for 1hr at 65°C. 
 
  3.14.8 Immunohistochemistry on paraffin sections 
Sections were de-waxed and rehydrated as follows: (3x) in 100% Xylol for 3 min, (2x) in 
100% EtOH for 1 min, (2x) in 95% EtOH for 1 min, (1x) in 70% EtOH for 1 min and (2x) in 
1xPBS for 1 min. To break the protein cross-links formed by PFA and paraffin fixation, an 
antigen retrieval method was used. The slides were placed in a coplin jar with citrate buffer 
and boiled in the microwave for 1-2 min. This step was repeated with fresh buffer for two 
more times. Afterwards the slides were cooled to room temperature in the same buffer for 20 
min and then rinsed twice with dH2O. Next, the sections were washed twice with 1xPBS and 
once with PBT for 5 min. Blocking solutions and antibodies were applied as described in 
Subsection 3.14.7. 
For BrdU and Caspase-3 immunostainings, after the antigen-retrieval step, the DNA was 
denatured by treating the tissue with 4 M HCL for 10 min and neutralized afterwards with 0.1 
M borate buffer (pH 8.5) for 5 min. Before applying primary antibodies, sections were 
washed two times with PBS and one time with PBT for 5 min as described above. 
 
  3.14.9 RNA In Situ hybridization 
RNA In Situ hybridization was used to analyze gene expression in the developing mouse 
vMb. Paraffin sections were de-waxed with xylol and rehydrated with 100%, 95% and 70% 
EtOH, as described in Subsection 3.14.8. Frozen sections were thawed at room temperature 
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and washed in 1xPBS for 5 min. Afterwards both kind of sections were postfixed in 4% PFA 
for 10 min, followed by two washing steps with 1xPBS. The slides were incubated in 50 mL 
1xPBS with 4 µL proteinase K (frozen section) for 5 min or with 8 µL proteinase K (paraffin 
sections) for 10 min. Then slides were again fixed in 4% PFA for 5 min and washed three 
times with 1xPBS. Afterwards, only paraffin sections were acetylated in 50 mL acetylation 
solution for 10 min, followed by three washing steps in 1xPBS for 5 min each. Subsequently, 
the sections (paraffin and frozen) were dehydrated in 70% EtOH for 5 min and afterwards in 
95% EtOH for a few seconds. The sections were placed horizontally in a humid box filled 
with 50 mL Formamide/water (in ratio 1:1) and preheated in a hybridization oven at 55°C. 
Approximately 1 µg of the desired RNA probe was added to 1 mL of hybridization solution 
and heated at 80°C for 2 min to denature RNA. 300 µL of riboprobe/hybridization solution 
was applied on the sections and then they were covered with RNase-free hybridization 
coverslips. The humidified box with the slides was inserted into the preheated oven and 
hybridized overnight at 55°C. On the next day, coverslips were removed in pre-warmed 5x 
SSC and washed in pre-warmed 1xFormamide and 2xSSC (in ratio of 1:1) for 30 min in a 
65°C water bath. Afterwards, they were washed three times with RNase Buffer at 37°C and 
incubated in the same Buffer with RNase A (in ratio of 1000:1) for 30 min. Then the slides 
were washed one more time with RNase Buffer for 15 min and washed twice in pre-warmed 
1xFormamid:2xSSC solution for 20 min in 65°C water bath. Two additional washing steps in 
2xSSC and 0.1xSSC for 15 min at 37°C were followed by a washing step with PBT (1xPBS 
with 0.1% Tween-20) for 15 min at room temperature. The slides were placed horizontally in 
a humidified box with H2O soaked tissue (to avoid drying-out of the slides) and blocked with 
10% normal goat serum (NGS) in PBT for 1hr at room temperature. After that, blocking 
solution was removed and the sections were incubated with anti-DIG-AP Fab fragments 
(1:3000) in 1% NGS/PBT for 3 hrs at room temperature. After removal of the antibody, slides 
were washed four times with PBT for 15 min at room temperature, following by two washing 
steps with freshly prepared alkaline phosphatase buffer (NTMT) containing 0.5 mg/mL 
levamisole for 10 min at room temperature. Finally, sections were incubated in BM purple 
solution containing 0.5 mg/mL levamisole at room temperature overnight or till a signal was 
visible. Then the sections were washed with PBS, briefly postfixed with 4% PFA, followed 
by additional PBS and dH2O washing steps. The slides were mounted in AquaPolymount and 
covered with coverslips. Sections were stored in slide boxes at room temperature. 
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  3.14.9 List of RNA In Situ probes 
Probe Description Provided by 
Ahd2 Aldehyde dehydrogenase 
family 1, subfamily A1 
Martin P. Smidt (Rudolf 
Magnus Institute of 
Neuroscience, Utrecht, The 
Netherlands) 
Arx Aristaless related homeobox 
gene 
ImaGenes/SourceBioscience, 
UK 
Corin  ImaGenes/SourceBioscience, 
UK 
Foxa2 Forkhead box A2 
transcription factor 
Alexandra L. Joyner 
(Memorial Sloan Kettering 
Cancer Center, New York, 
USA 
Lmx1a LIM homeobox 
transcriptional factor 1 alpha 
Alexandra L. Joyner 
(Memorial Sloan Kettering 
Cancer Center, New York, 
USA 
Msx1/2 Homeobox, msh-like 1 
transcriptional factor 
Alexandra L. Joyner 
(Memorial Sloan Kettering 
Cancer Center, New York, 
USA 
Shh Sonic hedgehog Alexandra L. Joyner 
(Memorial Sloan Kettering 
Cancer Center, New York, 
USA 
Sim1 Single-minded homolog 1 Jacques Michaud (University 
of Montreal, Canada) 
vGlut2 Solute carrier family 17 
(sodium-dependent inorganic 
phosphate cotransporter) 
member 
Robert Edwards (University 
of California, San Francisco, 
USA) 
 
  3.14.10 Combined RNA In Situ hybridization and Immunohistochemistry 
For combined RNA In Situ hybridization and immunohistochemistry the protocol was 
modified according to Eisenstat (Eisenstat et al., 1999). 20 µm thick frozen sections were 
used. The slides were thawed at room temperature and washed in 1xPBS for 5 min. After 
fixation in 4% PFA for 5 min, slides were washed three times in 1xPBS and then one more 
time in Ampuwater for 5 min each. The sections were incubated for 5 min stirring and for 
another 5 min still in acetylation solution. After washing the sections for 5 min with 
Ampuwater, sections were dehydrated in as follows: 1 min in 70% EtOH, 1 min in 80% 
EtOH, 2 min in 95% EtOH, 1 min in 100% EtOH, 5 min in chloroform, 1 min in 100% EtOH, 
1 min in 95% EtOH. The slides were drained on paper towel and air dried. 2 µL of probes 
(approximately 1 µg) in 1 mL of hybridization solution was heated at 80°C for 5 min and then 
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cooled on ice for another 2 min. The slides were placed horizontally in humidified box filled 
with 50 mL Formamide/Ampuwater (in ratio of 1:1), 300 µL riboprobe/hybridization solution 
mix was applied on each slide and sections were covered with RNase free coverslips. The 
humidified box with the slides was placed in the hyboven at 55°C overnight. Next day 
washing, antibody staining and visualization were carried out as described above (Subsection 
3.14.8). When the signal was visible, the reaction was stopped in TE Buffer. Then, the 
sections were postfixed in 4% PFA for 20 min and washed with 1xPBS three times for 5 min. 
Next, the slides were incubated with blocking solution 10% NDS in PBT (PBS-0.2% Triton 
x100) for 4 hrs and afterwards with primary antibody diluted in 3% NDS/PBT at 4°C 
overnight. Next day, sections were washed with 1xPBS three times for 5 min and incubated 
with secondary antibody in 3% NDS/PBS for at least 2 hrs at room temperature. Finally, 
slides were washed again with 1xPBS three times for 5 min and coversliped with 
AquaPolymount. The sections were stored in slide boxes at 4°C. 
 
 3.15 BrdU injection 
Timed pregnant females were injected intraperitoneally (i.p.) with 100 µg bromodeoxyuridine 
(BrdU) in 1xPBS per g body weight. Pregnant females (E10.5) were injected one hour prior to 
the dissection. 
 
 3.16 High performance liquid chromatography analysis* 
6 week old control and mutant mice were used for high performance liquid chromatography 
(HPLC) analysis. PFC and CPu were quickly dissected following cervical dislocation. To 
extract catecholamine, tissue was placed in 0.4 M perchloric acid. Afterwards it was 
homogenized by sonification and centrifuged at 15000 rpm (4°C). The concentrations of DA 
and 3,4-dihydroxyphenylacetic acid (DOPAC) were determined by reverse phase HPLC, 
coupled with electrochemical detection as described (Kilpatrick et al., 1986). The samples 
were injected into a guard column, connected to a reverse phase column of C18. DA and 
DOPAC were separated at a flow rate of 0.6 mL/min. The composition of mobile phase was 
as follows: 10% acetonitrile, 75 mM sodium dihydrogen phosphate monohydrate, 0.17 mM 
octanesulfonic acid, 2.5 mM triethylamine and 25 mM EDTA, adjusted to pH 3.0 with 
orthophosphoric acid. All reagents were HPLC grade. Catecholamine concentrations are 
                                                
* Isolation of PFC and CPu tissue as well as HPLC analysis was performed by Dr. Ruth 
Musgrove, laboratory of Prof. Donato A. Di Monte, DZNE, Bonn 
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expressed per mg of protein. 
 
 3.17 Viral transduction and Optogenetics 
Cell-type selective expression of Channelrhodopsin-2 (ChR2) and enhanced yellow 
fluorescent protein (EYFP) was achieved using a recombinant adeno-associated virus (rAAV) 
harboring a ChR2-EYFP fusion gene with an inverted open reading frame, flanked by two 
incompatible loxP sites and driven by an EF1α promoter. In the presence of Cre recombinase, 
the ChR2-EYFP fusion gene is inverted, with subsequent deletion of a loxP site leading to 
irreversible Cre-dependent expression of ChR2-EYFP (Cardin et al., 2009; Sohal et al., 2009). 
 
 3.18 Stereotaxic injections of rAAV into the VTA, brain slice preparation  
   and histological analysis of the section* 
Under sterile conditions, three to four week old control (En1Cre/+) and mutant (Gli2ΔMb>E9.0) 
mice were anesthetized (0.1 mL/10 mg body weight) with a cocktail of 0.1 mg/mL 
medetomidine and 10 mg/mL ketamine. After achieving deep anesthesia, animals were 
secured in a stereotaxic frame. Holes the size of the injection needle were drilled into the skull 
(Fine Science Tools) and the rAAV harboring a ChR2-YEFP fusion gene was injected into 
the medial VTA (anteroposterior (AP): -3.44 mm, mediolateral (ML): 0.48 mm and 
dorsoventral (DV): 4.4 mm) (Franklin and Paxinos, 2007) using a 34 g beveled needle. 1 µL 
of viral suspension containing 108 transducing units was injected unilaterally. The injection 
syringe delivered vector at a constant volume of 100 nL/min using a microprocessor 
controlled mini-pump. The needle was left in place for 3 to 5 min after each injection to 
minimize upward flow of viral solution after raising the needle and then slowly retracted over 
a course of 1 to 3 min. Finally, the incision was sutured and the animal was given atipamezole 
(0.05 mg/10 mg body weight). For immunohistochemical quantification of the VTA 
projections to the NAc and the PFC the virus was allowed 14 days to incubate before the 
analysis was carried out. For electrophysiological experiments mice were sacrificed 2 to 6 
weeks post-injection. 
For immunohistochemical analysis, mice were anesthetized and perfused (Subsection 3.14.2). 
Overnight post-fixed brains were processed for cryo-embedding (Subsection 3.14.3). 20 µm 
thick brain sections were collected on „superfrost ultra plus” adhesion slides in series of ten 
slides (Subsection 3.14.4) and processed for combined RNA In Situ hybridization and 
                                                
* Stereotaxic injections of rAAV were performed by Milan Pabst, laboratory of Prof. Heinz 
Beck, Department of Epileptology, University of Bonn, Medical Center 
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immunostaining (Subsection 3.14.11). 40 µm thick free-floating sections were immunostained 
for TH and GFP (Subsection 3.14.7) to analyze the MbDN axonal projections. 
 
 3.19 Electrophysiological analysis* 
For cell-type specific light-based stimulation of VTA neurons mice were sacrificed 2 weeks 
post virus injection. The brain was removed and transferred into cold artificial cerebrospinal 
fluid (ACSF). 300 µm coronal slices of the VTA or the PFC were made using a vibratome. 
Slices were incubated for 30 min at 37°C and subsequently transferred into ASCF. For 
electrophysiology, slices were transferred one at a time into a submerged chamber and 
superfused with ACSF at 35°C. EYFP-expressing neurons were identified using an upright 
fluorescence microscope (filter settings: excitation, 500/24; dichroic, 520; emission, 542/27). 
Whole-cell patch-clamp recordings were then achieved from identified cells using IR-DIC 
microscopy. Voltage- and current clamp experiments were carried out with a Multiclamp 
700B amplifier. Data were sampled at 50 kHz or 100 kHz with a Digidata 1322A interface 
controlled by pClamp Software lowpass filtered at 10 Hz and stored on a hard disk for offline 
analysis. Pipettes were made using a horizontal puller and borosilicate glass capillaries and 
filled with an intracellular solution. Electrode resistance in the bath ranged from 3-5 MΩ and 
series resistance ranged from 17 -24 MΩ for VTA neurons and 12-22 MΩ for PFC neurons. 
Light stimulation of individual neurons in the VTA was carried out via the microscope 
objective using a galvanometer based scanning system coupled to a 473 nm diode-pumped 
solid state laser. EYFP-expressing neurons in the VTA were targeted with brief flashes of 
light (4-15 ms) that caused clear light-evoked responses. For light-based stimulation 
experiments in the medial PFC (mPFC), an identical laser was coupled into a customized light 
fiber that was positioned just above the mPFC slice surface. 
 
3.20 Reconstruction of the morphology of medial PFC neurons and VTA 
neurons† 
For reconstruction of mPFC and VTA neuron morphology, slices were incubated in 4% PFA 
overnight. Next day, slices were washed 3x in PBS (0.1 M) and incubated with α-gt GFP at 
4°C overnight and accordingly incubated with α-gt FITC and streptavidin for 1-2 hrs at room 
                                                
* Electrophysiological analysis and reconstruction of medial PFC and VTA neuron 
morphology were performed by Milan Pabst, laboratory of Prof. Heinz Beck, Department of 
Epileptology, University of Bonn, Medical Center 
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temperature. Imaging was carried out using a confocal microscope and Z-stacks were 
analyzed using ImageJ (1.37c). 
 
 3.21 Image acquisition and optogenetic stimulation* 
To monitor neuronal activation following optogenetic stimulation time series were acquired 
using two-photon excitation fluorescence microscopy using an ultrafast Ti:Sa laser coupled to 
a microscope equipped with a galvanometer-based scanning system and a 20x Objective. 
Videos were acquired with an average frame rate of >3 Hz and duration of approximately 5 s. 
Optogenetic stimulation was achieved using a 473 nm laser coupled to a multimode light 
fiber, which was placed directly above the slice illuminating the entire mPFC. A flash of 20 
ms duration and 50 mW was triggered 2 s following the beginning of image acquisition. 
Blockers were bath applied cumulatively in the following order with three to four videos 
acquired for each of the conditions: 10 µM SCH-23390 and 100 nM L-741.626; 10 µM 
CNQX. 
 
 3.22 Calcium imaging† 
For Ca2+-imaging experiment 300 µm slices were obtained (Section 3.19). Slices were 
perfused in a submerged chamber with carbogen-saturated ACSF (3 mL/min) at 32°C and 
loaded with the Ca2+ indicator dye OGB-1-AM (Oregon green 488 BAPTA-1 AM) as 
described previously (Garaschuk et al., 2006). 50 µg OGB-1-AM was dissolved in 4.5 µL 
20% Pluronic in DMSO. 45 µL simplified Ca2+-free Ringer was added to obtain a final 
concentration of 1mM. The dye was filtered and pressure injected using a patch pipette with a 
resistance of 4 MΩ at four evenly spaced sites within the mPFC. Imaging was commenced at 
least 30 min after dye loading procedure. Standard ACSF was used for recording. 
 
 3.23 Quantification 
  3.23.1 Progenitor domains 
To determine the progenitor domains in control and mutant animals, every tenth section of 
E9.5, E10.5 and E11.5 embryos was processed for fluorescent immunostaining (Lmx1a) or 
RNA In Situ hybridization (Arx, Corin, Msx1). The sections were imaged on a Zeiss Axio 
observer using a 20x objective. For immunostained sections the Apotome setup was used. The 
                                                
* Calcium imaging was performed by Oliver Braganza, laboratory of Prof. Heinz Beck, 
Department of Epileptology, University of Bonn, Medical Center 
† Image acquisition and optogenetic stimulation was performed by Milan Pabst, laboratory of 
Prof. Heinz Beck, Department of Epileptology, University of Bonn, Medical Center 
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domains were outlined in the acquired images and measured using Fiji software (ImageJA 
1.45e). The medial domain was defined as the Corinpos/Lmx1apos progenitor domain, whereas 
lateral domain was defined as the Lmx1apos/Corinneg domain. Sections from three mutants and 
three control animals were analyzed. 
To analyze the proliferation, neurogenesis and cell death in control and knockout mice, the 
total number of BrdUpos/Lmx1apos, Ngn2pos/Lmx1apos and cleaved Caspase3pos/Lmx1apos cells 
was counted in every tenth section using Photoshop Software. The number of BrdUpos, 
Ngn2pos, Caspase3pos cells was normalized for the size of the Lmx1a domain measured by Fiji 
Software (ImageJA 1.45e). Sections were counted from at least three mutant and three control 
animals. The sections were imaged on a Zeiss Axio observer using a 20x objective and an 
Apotome setup. 
 
  3.23.2 MbDN subsets in postnatal brains (P21) 
To quantify the number of MbDNs, sections from four rostrocaudal levels (from Bregma -
2.92, -3.28, -3.64 and -3.88 mm; Franklin and Paxinos, 2007) were immunostained with TH. 
To determine two subpopulations of MbDNs, adjacent sections were immunostained for 
Girk2 and Calbindin, which are expressed in MbDNs of the SNpc and the VTA, respectively. 
Sections from at least three control and three mutant animals were imaged on a Zeiss Axio 
observer using 20x objective and the Zeiss MosaiX Software as well as an Apotome setup to 
assess double labeling (Axiovision, Zeiss). Double-labeled cells for TH and Girk2, and TH 
and Calbindin were counted bilaterally for each level using Photoshop Software. 
 
  3.23.3 MbDN projections to the forebrain, the amygdala and the striatum 
Projections were quantified in sections in three control and three mutant animals at P48. 
Animals were injected with rAAV harboring a ChR2-EYFP fusion gene. To visualize the 
projections, sections were immunostained for TH and GFP. To quantify projections to the 
PFC, TH or GFP positive area in the mPFC (infralimbic cortex) from three rostrocaudal levels 
was selected (H x W: 0.47 mm x 0.36 mm) in coronal sections (AP: 2.58-2.10 mm; ML: ± 0.5 
mm from Bregma; DV: 2.2-2.5 mm from dura; Franklin and Paxinos, 2007). Z-stack images 
(TH and GFP) of the selected areas were acquired on a Zeiss Axio observer using a 40x 
objective and an ApoTome Setup. To quantify projections to the amygdala, TH positive areas 
(H x W: 0.47 mm x 0.36 mm) in the amygdala were selected from three rostrocaudal levels in 
coronal sections (AP: -1.82 to -2.54 mm; ML: ±2.6-3.3 mm from Bregma: DV: 4.6-5.1 mm 
from dura; Franklin and Paxinos, 2007). For each animal, Z-stack images of selected areas 
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were acquired on a Zeiss Axio observer using a 20x objective and an ApoTome Setup. The 
acquisition parameters were kept the same for all images. To identify axonal structures for 
both PFC and amygdala as foreground objects pixel-based segmentations were produced 
using a segmentation algorithm (Advanced Weka Segmentation Plugin, Fiji Software). 
Potential axonal structures (TH or GFP positive) were assigned as class 1 and background 
(TH or GFP negative area) as class 2. The parameters were kept constant across images of 
control and mutant samples. The number of pixels in class 1 was quantified per selected area 
for each image (Fiji Software). MbDN projections to the PFC and amygdala were quantified 
unilaterally for each level. 
Projections to the striatum (CPu, NAc and OTu) were analyzed on four rostrocaudal levels 
(AP: +1.54 to -0.22 mm). Images were acquired using a 10x objective on a Zeiss Axio 
observer and an ApoTome setup. To analyze the projections, Fiji Software was used. The area 
of interest was outlined and average raw integrated intensities or pixels of TH or GFP positive 
MbDN projections were quantified for the three areas (Fiji Software). The average integrated 
intensity above background was normalized for the area. MbDN projections to the striatum 
were quantified bilaterally for each level. 
 
  3.23.4 Quantification of rAAV injections in the VTA 
To analyze injection sites and EYFP expression in the vMb, rAAV harboring a ChR2-EYFP 
fusion gene injected mice were sacrificed two weeks after injections. To visualize EYFP 
expression in MbDNs, TH and GFP immunohistochemistry was performed on coronal 
sections. Four rostrocaudal levels (Bregma: -2.92,  -3.28, -3.64, -3.88; Franklin and Paxinos, 
2007) were analyzed. TH and GFP positive area in the anterior VTA, RLi, CLi, IF and PN 
nuclei were imaged on a Zeiss Axio observer using 40x oil objective and an Apotome setup. 
Cells positive for GFP, as well as double positive cells for TH and GFP were counted for all 
four levels and then normalized to the total number of GFPpos cells. 
 
  3.23.5 Quantification of vGlut2/TH and vGlut2/TH/GFP positive cells in 
     the ventral midbrain 
To analyze co-expression of vGlut2 and TH, and vGlut2, TH and GFP, combined RNA In 
Situ hybridization/Immunohistochemistry was performed on coronal sections. The expression 
of vGlut2 was visualized by RNA In Situ hybridization, while expression of TH and/or GFP 
was detected by immunohistochemistry. The vGlut2/TH expression was analyzed on three 
mutants and three wildtypes (Gli2flox/+) at P21. The number of MbDN (THpos/vGlut2neg), 
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vGlut2-only (THneg/Glut2pos) cells was counted on four rostrocaudal levels (from Bregma: -
2.92 mm, -3.28 mm, -3.64 mm, and -3.88 mm; Franklin and Paxinos, 2007). Cells were 
counted in the entire TH positive areas (SNpc, VTA, RLi, CLi) for each level. 
EYFPpos cells co-expressing TH (MbDN), vGlut2 (vGlut2-only) or vGlut2 and TH (MbDN-
vGlut2) were counted on two rostrocaudal levels and normalized for the total number of cells 
counted (from Bregma: -3.28 mm, -3.64 mm; Franklin and Paxinos, 2007) for three control 
and three mutant animals at P48. The histological analysis was performed two weeks after 
mice were injected with rAAV harboring a ChR2-EYFP fusion gene. Sections were imaged 
on a Zeiss Axio observer, using a 20x objective and a Bright Field Setup for vGlut2 
expression and the Zeiss MosaiX Setup to assess an immunohistochemical labeling for TH 
and GFP (Axiovision Zeiss). For each level, cells were counted in the VTA (RLi, IF, PN and 
PBP).  
 
 3.23.6 Quantification of Calcium imaging data* 
Imaging data were preprocessed in ImageJ and analyzed using Igor. Videos were registered 
and translated to the reference image in order to remove movement artifacts and drift. 
Regions of interest were manually placed on OGB1 positive cell somata. Only cells visible 
over the course of the entire experiment were included. Raw fluorescence intensity traces over 
time of individual cells were extracted and further processed using Igor. Traces of individual 
cells were normalized to baseline. 
 
 3.24 Statistical analysis 
To determine statistical significance between control and mutant animals, unpaired Student’s 
t-test (Excel Software) was used. Statistical significance levels were set at: *p<0.05, 
**p<0.01, ***p<0.001. Error bars indicate Standard error of the mean (SEM). All results are 
expressed as mean ± SEM. 
Statistical analysis of electrophysiological data† was performed as appropriate using paired 
and unpaired Student’s t-test, as well as Mann-Whitney tests, Friedman test with Dunn’s 
multiple comparison, Kruskal-Wallis test with Dunn’s multiple comparison and repeated 
measures ANOVA with Newman-Keuls post test. 
                                                
* Quantification of Ca2+ imaging data was performed by Oliver Braganza, laboratory of Prof. 
Heinz Beck, Department of Epileptology, University of Bonn, Medical Center 
† Statistical analysis of electrophysiological data was performed by Milan Pabst, laboratory of 
Prof. Heinz Beck, Department of Epileptology, University of Bonn, Medical Center 
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4. Results 
 4.1 Inactivation of Gli2-mediated Shh signaling after E9.0 in the midbrain 
GIFM and conditional inactivation studies have demonstrated that the crucial time period for 
Shh signaling in establishing MbDNs is between E8.0 and E10.0 (Blaess et al., 2006 and 
2011; Hayes et al., 2011). As described previously, the timing and duration of Shh signaling 
plays a role in the specification of MbDNp into SNpc versus VTA progenitors (Figure 5) 
(Section 1.16). After E9.0, medially located precursors cease to respond to Shh signaling, 
whereas laterally located precursors continue to respond to Shh signaling up to E10.0. 
Importantly, GIFM studies have shown, that the lateral precursors contribute preferentially to 
MbDN in the vmVTA (Blaess et al., 2011; Hayes et al., 2011), whereas medial precursors 
give rise to all MbDNs. To assess whether Shh signaling plays an instructive role in subset 
specification of MbDNs, mice in which Shh signaling was inactivated during the Shh-
responsive period of MbDNp were analyzed. To this end conditional knockout mice were 
generated in which the zinc finger transcription factor Gli2 was inactivated using Engrailed1 
En1Cre/+:Gli2flox/zfd (further referred to as a Gli2ΔMb>E9.0) (Figure 8) (Kimmel et al., 2000; 
Blaess et al., 2006). 
 
 
Figure 8 Conditional inactivation of Shh signaling. (A) Timeline of Shh expression in the 
vMb. Shh signaling is inactivated at E9.0 in Gli2ΔMb>E9.0 mice. (B) Schematic of the 
conditional inactivation of Gli2 in Gli2ΔMb>E9.0 mice. Cre-recombinase is driven by the En1 
promoter. Cre mediated recombination leads to the exclusion of exons 7 and 8 of Gli2, which 
are flanked by loxP sites. (C) Inactivation of Gli2 results in no transcription of Shh target 
genes. 
 
In these mice, Cre-mediated recombination occurs specifically in the midbrain and the aHb 
starting around E8.5 (Li et al., 2002). Gli2 was inactivated instead of the Shh receptor Smo, 
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since Gli2 is the primary activator downstream of Shh signaling and the main mediator of 
Shh-mediated MbDN induction (Matise et al., 1998; Bai et al., 2001 and 2002; Blaess et al., 
2006). Gli2ΔMb>E9.0 mice have a reduced number of MbDNs at E18.5 (Blaess et al., 2006). 
Despite these defects, Gli2ΔMb>E9.0 mice are viable, allowing the analysis of MbDNs in the 
postnatal and adult brains. In contrast, conditional inactivation of Shh receptor Smo results in 
increased cell death in the vMb and aHb and early postnatal lethality (Blaess et al., 2006). 
 
 4.2 Medial but not lateral MbDNp are induced when Shh signaling is inactivated 
at E9.0 
To investigate whether the inactivation of Gli2-mediated Shh signaling results in altered 
MbDNp generation, the expression domains of the genes known to be involved in MbDNp 
induction and specification of MbDNs were analyzed (Section 1.13 and 1.14). First, the 
expression of Lmx1a in the Gli2ΔMb>E9.0 mice between E9.5 and E14.5 was assessed. In E9.5 
Gli2ΔMb>E9.0 embryos, the Lmx1apos area was not significantly smaller than in control embryos 
(Figure 9A). However, the Lmx1apos domain was significantly reduced in size in E10.5 
Gli2ΔMb>E9.0 embryos compared to wildtype littermates (56.5% ± 4% of wildtype) (Figure 9A, 
10A-B). The expression domain of Arx, another transcription factor expressed in the MbDNp 
domain was only slightly reduced (95.9% ± 5.3% of wildtype) in E9.5 Gli2ΔMb>E9.0 embryos, 
while in E10.5 Gli2ΔMb>E9.0 embryos the Arxpos area was significantly smaller than in the 
control littermates (56.9% ± 3.5% of wildtype) (Figure 9B, 10C-D). These data suggest that 
after E9.0, Shh signaling is required for the expansion of the MbDNp domain. 
 
 
Figure 9 MbDNp domain is significantly decreased in Gli2ΔMb>E9.0. (A) Quantitative 
analysis of the size of the Lmx1apos precursor domain in the vMb of E9.5 and E10.5 embryos. 
(B) Quantitative analysis of the size of the Arxpos precursor domain in the vMb of E9.5 and 
E10.5 embryos. Error bars indicate SEM. Significance (p***<0.001) was determined by 
Student’s t-test. 
 
To investigate whether the remaining MbDNp domain is properly specified in Gli2ΔMb>E9.0 
mutants, the expression of further markers expressed within the MbDNp domain, Shh and 
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Foxa2, was analyzed (Figure 10E-H). In the wildtype vMb, Shh and Foxa2 expression is 
initially restricted to the Lmx1apos domain, but their expression then expands laterally to 
Lmx1aneg precursors between E9.5 and E10.5 (Joksimovic et al., 2009; Blaess et al., 2011). At 
E11.5, Shh expression then starts to be downregulated in the medial MbDNp domain (Figure 
11C) (Joksimovic et al., 2009; Blaess et al., 2011). In E9.5-E10.5 Gli2ΔMb>E9.0 embryos, 
MbDNp in the Lmx1apos domain expressed Foxa2 and Shh (Figure 10E-H, Figure 11A-B; 
E9.5 data for Foxa2 expression not shown). 
 
 
Figure 10 Shh is required for induction of lateral MbDNp domain after E9.0. (A-B, G-
H) Immunofluorescent staining and RNA In Situ hybridization (C-F, I-L) on E10.5 coronal 
sections for markers of MbDNp domain (Lmx1a, Arx, Corin, Msx1/2, Shh, Foxa2) and Nkx6-
1. The dashed line indicates Lmx1apos domain. Scale bar 100 µm. (M) Quantitative analysis 
of the size of the medial (Lmx1apos/Corinpos, yellow) and lateral (Lmx1apos/Corinneg, orange) 
precursor domain in the vMb of E9.5 and E10.5 embryos. Error bars indicate SEM. 
Significance was determined by Student’s t-test. (N) Table indicating significant changes for 
the size of the medial and lateral domains for E9.5 and E10.5 control and mutant embryos. 
(O) Schematic of the medial (yellow) and lateral (orange) MbDNp (green) domains in E9.5-
E10.5 wildtype embryo. 
 
These data show that the remaining Lmx1apos progenitor domain appears to be properly 
specified in Gli2ΔMb>E9.0 mutants. However, at E11.5, Shh expression was still detectable in 
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the medial MbDNp domain in Gli2ΔMb>E9.0 embryos (Figure 11C-D). The lateral 
Lmx1aneg/Foxapos/Shhpos expression domain, which gives rise to non-MbDN (Section 1.18), 
was almost entirely missing in the mutants (Figure 10B, F, H, 11B, D). Furthermore, the data 
indicate that Shh signaling prior to E9.0 is sufficient to induce Shh and Foxa2 in the ventral 
midline, and is not required for the maintenance of their expression. However, Shh signaling 
is required after E9.0 for the further expansion of the Foxa2 and Shh domain into the 
ventrolateral midbrain. 
In the wildtype vMb, Nkx6-1 expression overlaps with Lmx1a up to E9.5, but it is excluded 
from the Lmx1a domain at later stages (Andersson et al., 2006). In E10.5 and E11.5 
Gli2ΔMb>E9.0 embryos, Nkx6-1 expression was shifted ventrally, but as in control animals it did 
not overlap with the Lmx1apos precursor domain (Figure 10 A-B). These results demonstrate 
that the regulation of gene expression in the remaining MbDNp domain of Gli2ΔMb>E9.0 
embryos occurred normally. 
The Lmx1apos MbDNp domain can be further subdivided into a medial and a lateral domain 
based on gene expression and GIFM studies (Joksimovic et al., 2009; Blaess et al., 2011) 
(Section 1.16). The medial MbDNp domain expresses Msx1/2 and Corin, while laterally 
located MbDNp express only Lmx1a (Andersson et al., 2006; Ono et al., 2007; Blaess et al., 
2011; Yan et al., 2011). To examine whether reduction of the Lmx1apos domain can be 
ascribed to a specific loss of either the medial or lateral MbDNp population, the expression of 
Corin and Msx1/2 in E9.5-10.5 control and Gli2ΔMb>E9.0 embryos was analyzed (Figure 10I-
L). Interestingly, in E9.5 and E10.5 Gli2ΔMb>E9.0 embryos, Corin and Msx1/2 domain filled 
almost the entire Lmx1apos domain in the vMb, indicating that the lateral domain 
(Lmx1apos/Corinneg/Msx1/2neg) was lost in the mutant (Figure 10I-L). Indeed, quantification of 
the Corinpos and Lmx1apos areas on adjacent sections of the posterior vMb showed that the 
Lmx1apos/Corinneg domain was severely reduced, in both E9.5 (31.7% ± 12.4% of wildtype) 
and E10.5 (11.2% ± 6.5% of wildtype) Gli2ΔMb>E9.0 embryos (Figure 10M). In contrast, the 
medial domain (Lmx1apos/Corinpos/Msx1/2pos) was not reduced at E9.5 in the mutants. 
However, by E10.5, the medial domain was altered in the mutants (60.3% ± 2% of wildtype), 
compared to control embryos, but was not as severely reduced as the lateral domain (Figure 
10M). In summary, these data indicate that, prior to E9.0, Shh signaling is sufficient to induce 
the Lmx1apos MbDNp domain. After E9.0 Shh signaling is required for the further expansion 
of the MbDNp domain and in particular for the induction of the lateral 
(Lmx1apos/Corinneg/Msx1/2neg) MbDNp domain. 
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Figure 11 Shh signaling is required for Shh domain expansion after E9.0, but not for its 
maintenance. (A-B, C-D) RNA In Situ hybridization for Shh on E9.5 (A-B) and E11.5 (C-D) 
coronal sections. Lmx1a domain is indicated in red. Arrows: medial downregulation of Shh 
expression. Scale bars (A-B) 100 µm, (C-D) 50 µm 
 
Wnt1 has been implicated in an autoregulatory induction loop with Lmx1a (Chung et al., 
2009) (Figure 4, Section 1.14). Since Wnt1 plays an important role in MbDN development 
(Sections 1.13 and 1.14), Wnt1 expression might be affected in Gli2ΔMb>E9.0 mutants.  
 
 
Figure 12 Reduction in Wnt1 expression in Gli2ΔMb>E9.0. (A-F) RNA In Situ hybridization 
for Wnt1 on E9.5 (A-B), E10.5 (C-D) and E11.5 (E-F) coronal sections. Scale bar 100 µm. 
 
Indeed, RNA In Situ hybridization for Wnt1 at E9.5-E12.5 showed that Wnt1 expression 
appeared to be reduced Gli2ΔMb>E9.0 embryos (Figure 12 A-F, E12.5 data not shown). 
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 4.3 Reduction of the lateral MbDN precursor domain in Gli2ΔMb>E9.0 embryos is 
not caused by a decrease in proliferation 
The severe reduction of the lateral MbDNp domain in Gli2ΔMb>E9.0 embryos indicates that Shh 
signaling is required for the expansion of this domain after E9.0. Shh-induced expansion of 
the domain could either be mediated through the regulation of proliferation of pre-existing 
medial Lmx1apos precursors or through the induction of Lmx1a expression in lateral 
precursors previously negative for Lmx1a. To assess proliferation, proliferating cells were 
labeled with an one hour BrdU pulse in E9.5 and E10.5 control and Gli2ΔMb>E9.0 embryos. 
BrdU is an analogue of thymidine and is incorporated into the DNA during the S-Phase of the 
cell cycle. Quantification of BrdUpos cells within the Lmx1apos domain in E9.5 and E10.5 
embryos showed that the proliferation in the MbDNp domain in Gli2ΔMb>E9.0 mutants (E9.5: 
42 ± 4 cells/104 µm2 and E10.5: 55 ± 8 cells/104 µm2) was not significantly different from 
control littermates (E9.5: 70 ± 10 cells/104 µm2 and E10.5: 62 ± 5 cells/104 µm2) (Figure 
13A-B, G; E9.5 data not shown). To exclude that the decrease in MbDNp is caused by an 
increase in cell death, immunostainings for activated Caspase-3 were carried out on E9.5-
E10.5 control and Gli2ΔMb>E9.0 embryos. No changes in the number of apoptotic cells in the 
MbDNp domain in E10.5 Gli2ΔMb>E9.0 mutants (0.95 ± 0.83 cells/104 µm2) were observed 
compared to control littermates (0.97 ± 0.88 cells/104 µm2). These data indicate that the 
reduction in the Lmx1apos domain in Gli2ΔMb>E9.0 mice is likely due to an impaired induction 
of Lmx1a expression in lateral, initially Lmx1aneg precursors, rather than an impaired capacity 
of Lmx1a expressing precursors to proliferate or to survive. 
To assess whether the Lmx1apos cells maintained their proper progenitor fate in Gli2ΔMb>E9.0 
embryos, the expression of hairy and enhancer of split 5 (Hes5) was analyzed. Hes5 is 
downstream of Delta-like 1 in the Notch signaling pathway and suppresses the expression of 
proneural genes (Ohtsuka et al., 1999). Hes5 was expressed in the MbDNp domain in both 
Gli2ΔMb>E9.0 and control embryos at E11.5 (Figure 13 C-D). 
To investigate whether the progenitors in the remaining Lmx1apos domain can undergo normal 
neurogenesis, the expression of the proneural gene Ngn2 was examined (Section 1.14). 
Quantification of the number of Ngn2pos cells within the Lmx1apos domain in Gli2ΔMb>E9.0 and 
control embryos at E11.5 demonstrated that the number of Ngn2pos cells was similar in 
control and mutant embryos when normalized for the size of the MbDNp domain (Figure 
13E-F, H). 
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Figure 13 Proliferation and neurogenesis in the MbDNp domain is not affected in 
Gli2ΔMb>E9.0 mice. (A-B) One hour BrdU pulse to label proliferating precursors in the vMb at 
E10.5. (C-D) RNA In Situ hybridization for Hes5 expressed in the MbDNp domain at E11.5. 
(E-F) Immunofluorescent staining for Ngn2 on E11.5 coronal section. Dashed yellow lines 
indicate the Lmx1apos domain. Scale bars (A-B) 100 µm; (C-F) 50 µm. (G) Quantitative 
analysis of the number of BrdUpos cells normalized to the size of Lmx1apos domain for level of 
section shown in A-B. (H) Quantitative analysis of the number of Ngn2pos cells normalized to 
the size of Lmx1apos domain for level of sections shown in E-F. Error bars indicate SEM. 
Significance was determined by Student’s t-test. 
 
However, analysis at E10.5 showed that the onset of neurogenesis was delayed in the vMb of 
Gli2ΔMb>E9.0 embryos, since Ngn2pos cells were present in the control but not the mutant 
Lmx1apos precursor domain at this stage (data not shown). These results show that the 
remaining MbDNp in Gli2ΔMb>E9.0 embryos are capable of normal neurogenesis. 
 
 4.4 Shh signaling is required after E9.0 for the generation of MbDN 
To investigate how the almost complete loss of the lateral MbDNp domain and the reduced 
size of the medial MbDNp domain affects the generation of differentiated MbDNs, 
immunohistochemistry for TH was performed on coronal sections through the rostrocaudal 
extent of the developing vMb in E10.5, E11.5, E12.5, E14.5 and E18.5 control and 
Gli2ΔMb>E9.0 embryos (Figure 14A-F, 15A-B). The first differentiated MbDNs expressing TH 
appear already at E10.5 in control mice, whereas THpos MbDNs could not be detected in the 
Gli2ΔMb>E9.0 vMb (data not shown). This could be explained by the delayed neurogenesis in 
the Gli2ΔMb>E9.0 embryos (Section 4.3). 
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Figure 14 Shh signaling is required after E9.0 for the proper generation of MbDNs. (A-
F) Immunostaining for differentiating MbDNs (TH) in E11.5 (A-B), E12.5 (C-D) and E14.5 
(E-F) wildtype and Gli2ΔMb>E9.0 embryos. Yellow arrows indicate THpos cells. Red arrows 
indicate loss of MbDNs in the Gli2ΔMb>E9.0 mutants. Scale bar 100 µm. 
 
At E11.5 MbDNs in the Gli2ΔMb>E9.0 vMb were severely reduced (Figure 14A-B). In contrast 
to control embryos, where the newly generated THpos MbDNs are clustered off-midline, THpos 
cells in the mutant were all located medially. At E12.5 and E14.5 MbDNs were still reduced 
and excluded from the ventral midline (Figure 14C-F). In addition, THpos cells were scattered 
and disorganized in Gli2ΔMb>E9.0 mutants. 
At E18.5 vmVTA and dlVTA first can be identified anatomically. MbDNs were severely 
reduced in E18.5 Gli2ΔMb>E9.0 embryos (Figure 15A-B). The decrease in MbDNs was 
particularly obvious in areas that would correspond to the vmVTA and the SNpc in the 
control brains (Figure 15A-F). To exclude that the apparent reduction in MbDNs is due to a 
downregulation of TH expression, rather than a reduction in the number of MbDNs, other 
typical MbDN markers such as Nurr1 and Foxa2 at E18.5 were analyzed (Figure 15C-F). 
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Figure 15 Reduced MbDNs in Gli2ΔMb>E9.0 embryos express MbDN markers. (A-B) 
Immunostaining for differentiated MbDNs (TH) in E18.5 control and Gli2ΔMb>E9.0 embryos. 
Red arrows indicate loss of MbDNs in Gli2ΔMb>E9.0 mutants. (C-F) Immunostaining for Nurr1 
and Foxa2 on E18.5 coronal sections. (C’-F’) Enlarged boxes show co-expression of Nurr1 
and TH, Foxa2 and TH. Scale bar 100 µm. 
 
Nurr1 is expressed in differentiating and mature MbDNs (Section 1.15), whereas Foxa2 is not 
only expressed in MbDNp and MbDNs, but also in the other vMb cells (Kittappa et al., 2007) 
(Section 1.14). Both Foxa2 and Nurr1 are expressed in the MbDNs of Gli2ΔMb>E9.0 mice, 
meaning that remaining MbDNs are properly specified. However, the decrease in 
THpos/Nurr1pos and THpos/Foxa2pos MbDNs was more obvious in areas that correspond to the 
vmVTA and the SNpc in the control animals. Nurr1pos/THneg cells can be found in the 
vmVTA, particularly in RLi. There was no obvious difference between Gli2ΔMb>E9.0 and 
control brains in the amount of THneg, Nurr1pos or THneg, Foxa2pos cells in the RLi (Figure 
15C-F). In summary, these results demonstrate that inactivation of Gli2-mediated Shh 
signaling at E9.0 in the vMb results in severe reduction of MbDNs in Gli2ΔMb>E9.0 mice, 
however the remaining MbDNs are properly specified. 
 
 4.5 Inactivation of Shh signaling at E9.0 results in a preferential loss of Calbindin 
positive VTA neurons 
A detailed anatomical analysis of different subgroups of MbDNs is only possible in the 
mature brain. To quantitatively assess the number and distribution of MbDNs, P21 
Gli2ΔMb>E9.0 and control brains were analyzed. This stage was chosen, since mice 
heterozygous for En1 show degeneration of MbDNs after 8 weeks of age (Sonnier et al., 
2007). In Gli2ΔMb>E9.0 mice (En1Cre/+:Gli2zfd/flox) part of the En1 coding sequence is replaced 
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by the Cre cDNA, making these mice heterozygous for En1 (Kimmel et al., 2000). Therefore, 
THpos MbDNs were counted bilaterally in sections from four rostrocaudal levels 
(approximately from Bregma in mm: -2.92, -3.28, -3.64 and -3.88; Franklin and Paxinos, 
2007) of at least three Gli2ΔMb>E9.0 and three control mice. The total number of THpos MbDNs 
in Gli2ΔMb>E9.0 brains was reduced to 53.5% ± 3.21% of the MbDN number in control brains 
(Figure 16 A-D, E).  
 
 
Figure 16 Severe loss of Calbindin positive cells in Gli2ΔMb>E9.0 mice. (A-D) 
Immunostaining for MbDNs in the SNpc (Girk2pos) and VTA (Calbindinpos) on P21 coronal 
sections. Scale bar 500 µm. (E) Quantitative analysis of the number of THpos cells in sections 
A-D. (F-I) Schematic showing the distribution of Girk2pos (yellow dots) and Calbindinpos 
(orange dots) MbDNs in the vMb (sections in A-D). (J) Plane of section shown in A-D 
represents distinct subpopulations of MbDNs in the vMb. (K) Quantitative analysis of the 
number of Girk2pos and Calbindinpos cells at section levels shown in A-D. Error bars indicate 
SEM. Significance (p**<0.01; p***<0.001) was determined by Student’s t-test. 
 
Interestingly, along the rostrocaudal axis of the vMb the MbDN reduction was more 
prominent rostrally (Bregma -2.92 and -3.28 mm: 48.2% ± 2.09% of MbDNs in control 
brains) than caudally (Bregma -3.64 and -3.88 mm: 61.4% ± 4.3% of the MbDNs in control 
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brains). The distribution of MbDNs in the Gli2ΔMb>E9.0 mutants was comparable to E18.5 
(Figure 15B). Immunohistochemical and morphological analysis revealed that both, SNpc and 
VTA appeared to be affected, but the areas corresponding to the vmVTA (PN and IF) and RLi 
were most severely reduced (Figure 16A-D). 
To investigate whether the reduction in VTA MbDNs was indeed more severe than the 
reduction in SNpc MbDNs in Gli2ΔMb>E9.0 mice, the expression of Girk2 and Calbindin in P21 
brains was analyzed. Girk2 and Calbindin are preferentially expressed in the SNpc and VTA, 
respectively (Section 1.4) (Figure 16A, C). Girk2pos/THpos and Calbindinpos/THpos MbDNs 
were counted bilaterally in sections from four rostrocaudal levels (approximately from 
Bregma in mm: -2.92, -3.28, -3.64 and -3.88; Franklin and Paxinos, 2007) of at least three 
Gli2ΔMb>E9.0 and three control mice. In Gli2ΔMb>E9.0 mice, the number of Calbindinpos/THpos 
MbDNs (41.8% ± 4.6% of wildtype) was significantly more reduced than the number of 
Girk2pos/THpos MbDNs (69.5% ± 7.4% of wildtype) (Figure 16F). Similar to the graded 
reduction of THpos MbDNs along the rostrocaudal axis in Gli2ΔMb>E9.0 brains, the number of 
Calbindinpos/THpos (40.7% ± 5.5% of the MbDNs in control) and Girk2pos/THpos (63.4% ± 
2.9% of the MbDNs in control) MbDNs was more prominently reduced rostrally than 
caudally (Calbindinpos/THpos: 47.7% ± 5.8% and Girk2pos/THpos: 77.06% ± 7.04% of the cells 
in control). These results demonstrate that inactivation of Shh signaling after E9.0 affects the 
generation of Calbindinpos MbDNs in the VTA more severely than the generation of Girk2pos 
MbDNs in the SNpc. 
 
 4.6 Shh signaling is required for the proper distribution of the MbDNs 
Both the SNpc and the VTA appeared to be severely reduced in Gli2ΔMb>E9.0 mutants, however 
MbDNs in the VTA are more affected then MbDNs in the SNpc. To exclude the possible 
change in the cell fates from one population to another, distribution of Calbindinpos and 
Girk2pos MbDNs on four rostrocaudal levels (approximately from Bregma in mm: -2.92, -
3.28, -3.64 and -3.88; Franklin and Paxinos, 2007) in control and Gli2ΔMb>E9.0 animals was 
analyzed. Interestingly, MbDNs located more anteriorly (Bregma -2.92 mm) are distributed 
properly in the mutant mice (data not shown). However, more posterior Calbindinpos/THpos 
MbDNs were mainly located in the area that would correspond to the PN and PBP in the 
wildtype vMb, with only few cells found in the IF (Figure 16D, I). Notably, the RLi nucleus 
appeared to be devoid of MbDNs in the Gli2ΔMb>E9.0 vMb. Interestingly, Girk2pos/THpos 
MbDNs, which can be found in the SNpc in wildtype, were shifted to a more medial position 
in Gli2ΔMb>E9.0 mice that corresponds to the dorsal VTA in the wildtype (Figure 16B, G). 
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MbDNs of the RRF appeared to be localized correctly. These data indicate that in addition to 
a decrease in the MbDN number in Gli2ΔMb>E9.0 mice, remaining MbDNs are disorganized. 
 
 4.7 MbDNs co-expressing vGlut2 are reduced in Gli2ΔMb>E9.0 mice 
In the vmVTA, including the RLi nucleus, MbDNs are intermixed with glutamatergic neurons 
(vGlut2-only) and a subset of MbDNs in the vmVTA even co-expresses vGlut2 (MbDN-
vGlut2), a marker for glutamatergic neurons (Yamaguchi, 2011) (Section 1.5). 
 
 
 
   
Figure 17 MbDN-vGlut2 are reduced in Gli2ΔMb>E9.0 mice. (A-B) RNA In Situ 
hybridization for vGlut2, a marker for glutamatergic neurons. Yellow outlines indicate area 
used for quantitative analysis in E. (C-D) RNA In Situ hybridization for vGlut2 (image color 
was inverted and false colored in green) combined with immunostaining for TH. Scale bar 
500 µm. (E) Quantitative analysis of the number of MbDN, vGlut2-only and MbDN-vGlut2 
cells at the section level shown in A-D. Error bars indicate SEM. Significance (p*<0.05) was 
determined by Student’s t-test. 
 
The developmental origin of these glutamatergic neurons has not been determined, but their 
precursors might also depend on Shh signaling for their induction. Since MbDNs in the 
vmVTA are severely affected in Gli2ΔMb>E9.0 mice, MbDN-vGlut2 could be particularly 
affected in the mutants as well. To this end, RNA In Situ hybridization for vGlut2, followed 
by immunostaining for TH to mark the MbDNs containing areas was performed (Figure 17A-
D). The number of MbDNs (THpos/vGlut2neg) was reduced by 46% in Gli2ΔMb>E9.0 mice 
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(Figure 17E). Interestingly, there were only 30% of MbDN-vGlu2 neurons left in the mutant 
brains (Figure 17E). 
Analysis of the number of vGlut2-only neurons in these areas showed no significant 
difference between Gli2ΔMb>E9.0 and control brains (Figure 17E). These results demonstrate 
that the inactivation of Shh signaling does not affect the generation of glutamatergic neurons 
in the vMb, but leads to a severe reduction of MbDN-vGlut2.  
 
 4.8 Shh signaling is required to establish mesocortical MbDNs 
MbDN, MbDN-vGlut2 and vGlut2-only neurons project to the NAc and the PFC, while SNpc 
MbDNs target primarily the dorsal striatum (Figure 18A) (Section 1.5, 1.6). Since MbDN and 
MbDN-vGlut2 in the vmVTA were severely reduced in Gli2ΔMb>E9.0 mice, it raises a question 
how the preferential reduction of these neurons impacts on the formation of the dopaminergic 
circuitry. First, the projections of MbDNs in control and Gli2ΔMb>E9.0 brains at P48 using 
immunostaining for TH were examined (Pickel et al., 1975). Since En1 drives Cre expression 
and subsequent recombination only in the vMb and aHb, the forebrain targets of MbDNs 
should not be directly affected by the conditional inactivation of Gli2 and any defects in the 
MbDN projections in Gli2ΔMb>E9.0 mutant should be due to changes in the number and/or the 
fate of MbDNs. To quantify the density of the projections, the intensity of TH and glyco-DAT 
fluorescence in the striatum or the number of pixels in the amygdala and PFC were measured 
in wildtype and Gli2ΔMb>E9.0 mutant brains (Figure 18B-K). Glyco-DAT is expressed at high 
levels in MbDN projections to the striatum, but only weakly in projections to the PFC or 
amygdala (Afonso-Oramas et al., 2009). Surprisingly, despite the significant reduction in the 
number of SNpc and VTA MbDNs in Gli2ΔMb>E9.0 brains (Figure 16E), there was no 
significant difference in the fluorescent intensity of TH or glyco-DAT staining in the CPu 
complex of the mutants compared to control brains (Figure 18B-E). Moreover, no difference 
in the number of TH fluorescent pixels in the amygdala between Gli2ΔMb>E9.0 and control 
animals was detected (Figure 18F-H). 
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Figure 18 Mesocortical projections are severely reduced in Gli2ΔMb>E9.0 mice. (A) 
Projections of MbDNs to the forebrain. Levels of sections in B-J are indicated. (B-J) 
Immunostaining for TH to visualize MbDN projections to the striatum (B-C), BLA (F-G) and 
PFC (I-J). (F’-J’) Higher magnification of the boxed area in F-J. White arrows indicate THpos 
fibers in the PFC; yellow asterisks their absence. (D, G, J) Quantitative analysis of relative 
fluorescence (TH) intensity in the striatum (D) and number of fluorescent (TH) pixels above 
background in BLA (H) and PFC (K). (E) Quantitative analysis of relative fluorescence 
(glyco-DAT) intensity in the striatum. The relative fluorescent intensity in the striatum is 
normalized to the area. Error bars indicate SEM. Significance (p**<0.01) was determined by 
Student’s t-test. 
 
MbDN projections to the OTu were only slightly reduced in Gli2ΔMb>E9.0 brains (Figure 18D, 
E). However, quantification of the number of TH fluorescent pixels in the PFC showed that 
the projections to the PFC were severely reduced in the Gli2ΔMb>E9.0 mutants (Figure 18I-K). 
These data demonstrate that despite the significant reduction in the number of MbDNs in 
Results 
 
 72 
SNpc and VTA, MbDN projections to the CPu, NAc and amygdala are not affected in the 
mutants, whereas MbDN projecting to the PFC are severely reduced in Gli2ΔMb>E9.0 mice. 
 
 4.9 Tracing of MbDN axons originating in the ventromedial VTA confirms severe 
reduction in mesocortical projections* 
Since the apparent loss of THpos projections to the PFC could potentially be due to a specific 
downregulation of TH in mesocortical MbDN axons in Gli2ΔMb>E9.0 brains, MbDN axons 
were labeled with a fluorescent protein (EYFP). Strong EYFP expression in MbDN axons 
was achieved through stereotactic injection of rAAV harboring a ChR2-EYFP fusion gene 
into the vmVTA of postnatal brains of Gli2ΔMb>E9.0 and control (En1Cre/+) mice (Figure 19A). 
The rAAV harbors an expression cassette that results in ChR2 and EYFP expression only 
after Cre-mediated recombination (Kravitz et al., 2012). Since En1 drives Cre expression 
primarily in MbDNs in the postnatal vMb (Simon et al, 2001), MbDN cell bodies and axons 
are labeled with EYFP. Immunohistochemical analysis showed that 60% of all EYFPpos cells 
co-expressed TH in both, control and Gli2ΔMb>E9.0 brains (Figure 19B-D). The absolute 
number of EYFP-expressing MbDNs and cells positive for EYFP and TH, was however 
severely reduced in the mutant mice (EYFPpos cells: 34 ± 12; EYFPpos/THpos cells: 22 ± 13) 
compared to control mice (EYFPpos cells: 100 ± 4; EYFPpos/THpos cells: 65 ± 21.9). 
The pixel analysis of EYFPpos fibers in the PFC confirmed that the mesocortical MbDN 
projections are severely reduced in the Gli2ΔMb>E9.0 brains (4.1 ± 0.6 pixels x 105) compared to 
control (14,7 ± 2.2 pixels x 105) (Figure 19G-H, I). As expected VTA MbDN projections in 
control mice innervate only the ventral part of the striatum (NAc and OTu). Interestingly, in 
Gli2ΔMb>E9.0 brains, MbDNs projected into the ventral, as well as the dorsal part of the 
striatum (CPu) (Figure 19E). Since only SNpc MbDNs normally project to the CPu complex, 
these results are consistent with the observation that SNpc MbDN are located in a more 
medial position in the Gli2ΔMb>E9.0 brains. Alternatively, these results could be an indication 
for aberrant projections of the remaining VTA MbDNs in the Gli2ΔMb>E9.0 mice. In 
conclusion, these data show that the population of MbDNs that normally projects to the PFC 
(mesocortical MbDNs) essentially is not formed when Shh signaling is inactivated after E9.0. 
 
 
                                                
* Stereotactic injections of rAAV harboring a ChR2-EYFP fusion gene were performed by 
Milan Pabst, laboratory of Prof. Heinz Beck, Department of Epileptology, University of 
Bonn, Medical Center 
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Figure 19 Tracing of MbDN axons shows severe reduction in mesocortical projections in 
Gli2ΔMb>E9.0 mice. (A) Schematic showing double-floxed rAAV:ChR2-EYFP. Medial 
injection of the virus into the VTA (green area) results in EYFP expression in Cre-expressing 
neurons (red outline) in the VTA. (B-C) Immunostaining for MbDNs (TH, red) injected with 
the rAAV (EYFP, green). (B’-C’) Higher magnification of the boxed area in B-C. Arrows 
indicate cells co-expressing TH and EYFP, asterisks represent cells expressing only TH. (D) 
Quantitative analysis of THpos/EYFPpos cells expressed in percent of all EYFPpos cells. (E-H) 
Immunostaining for projections stained with EYFP (green) and TH (red) into the striatum (E-
F) and PFC (G-H). Arrows indicate presence of MbDN fibers in the PFC, while yellow 
asterisks indicate their absence. Scale bar 500 µm. (I) Quantitative analysis of the number of 
fluorescent (EYFP) pixels in the PFC. (J-L) RNA In Situ hybridization for vGlut2 (image 
color was inverted and false colored in blue) combined with immunostaining for TH (red) and 
EYFP (green) in control. Arrows indicate MbDN positive for TH and EYFP, filled 
arrowheads indicate MbDN positive for TH, vGlut2 and EYFP, arrowheads indicate cells 
positive for vGlut2 and EYFP. Scale bar 30 µm. (M) Quantitative analysis of MbDN (THpos), 
vGlut2-only (THneg/vGlut2pos) and MbDN-vGlut2 (THpos/vGlut2pos) cells co-expressing EYFP 
at this level (J-L). Error bars indicate SEM. Significance (p*<0.05; p**<0.01) was determined 
by Student’s t-test. 
 
 
 
Results 
 
 74 
 4.10 Decreased dopamine content in the prefrontal cortex* 
To determine whether reduction in MbDN projections in the PFC might result in decreased 
DA content in this area, DA level and its metabolites DOPAC were measured using HPLC 
(Section 3.16). Indeed, the levels of DA and DOPAC were reduced to 52.5% and 67.1% of 
control in the PFC of Gli2ΔMb>E9.0 brains, respectively (Figure 20A). Striatal levels of DA 
(81.9% of control) and DOPAC (77.5% of control) were also decreased in Gli2ΔMb>E9.0 mice 
compared to control, but the reduction was less severe than in the PFC (Figure 20B). 
 
 
Figure 20 Dopamine content in the PFC and striatum as measured by HPLC. (A-B) The 
levels of DA and its metabolite DOPAC in the PFC (A) and the striatum (B). Data are 
expressed in ng/mL protein (A-B). Error bars indicate SEM. Significance (p**<0.01; 
p***<0.001) was determined by Student’s t-test. 
 
These data are consistent with the severe reduction observed in mesocortical projections in 
the Gli2ΔMb>E9.0 mice. The mild reduction in DA and DOPAC levels in the striatum indicates, 
that the despite the apparent normal innervation of this region, the remaining MbDNs cannot 
fully compensate for the loss of MbDNs. 
 
 4.11 Functional assessment of mesocortical MbDN in Gli2ΔMb>E9.0 and control 
mice using optogenetic approaches† 
The mesocortical DA system is essential for cognitive and emotional function. However, 
while the neuroanatomical connectivity of mesocortical system has been extensively studied, 
little is known about its functional properties. To examine this, an optogenetic approach was 
used. To stimulate dopaminergic axons, MbDNs in the VTA were injected with rAAV 
                                                
* HPLC analysis was performed by Dr. Ruth Musgrove, laboratory of Prof. Donato A. Di 
Monte, DZNE, Bonn 
† Optogenetic and electrophysiological analysis was performed by Milan Pabst, laboratory of 
Prof. Heinz Beck, Department of Epileptology, University of Bonn, Medical Center 
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harboring a ChR2-EYFP fusion gene, flanked by two loxP sites and driven by EF1α 
promoter. Therefore, the presence of Cre recombinase in control (En1Cre/+) and Gli2ΔMb>E9.0 
mice results in an irreversible expression of ChR2-EYFP. First, to analyze whether both, 
MbDN (THpos/vGlut2neg) and MbDN-vGlut2 (THpos/vGlut2pos) cells expressed ChR2-EYFP, 
RNA In Situ hybridization for vGlut2 followed by immunostaining for TH and EYFP was 
performed. Both MbDN subpopulations in the VTA area expressed EYFP in control and 
Gli2ΔMb>E9.0 mice: 28% ± 0.5% (control) and 62% ± 27% (Gli2ΔMb>E9.0) of all THpos MbDNs 
co-expressed EYFP and 29.6% ± 11% (control) and 26.2% ± 11.1% (Gli2ΔMb>E9.0) of MbDN-
vGlut2 co-expressed EYFP (Figure 19I-M). Only a low percentage of vGlut2-only cells co-
expressed EYFP in the VTA area in both animals (control: 6.6% ± 3.7% and Gli2ΔMb>E9.0: 
17.8% ± 9.7%). These data demonstrate that despite severe reduction in MbDNs in the 
Gli2ΔMb>E9.0 mutants, the percentage of the cells infected with the rAAV was not different 
from control mice. 
Recording from ChR2-EYFPpos VTA neurons, using the patch-clamp method revealed that 
blue light illumination (473 nm) caused large inward currents in VTA neurons (248 ± 43 pA 
for stimulation durations of 12 ms) (Figure 21B, C, firing behavioral and morphological 
reconstruction in Figure 21A). The expression levels of ChR2 were sufficient to induce 
precisely timed action potentials (AP) in VTA neurons at frequencies up to 33 Hz (Figure 
21D). Next, the effects of light-based stimulation of ChR2-EYFPpos axons originating from 
the VTA on neurons within the mPFC using multicell Ca2+ imaging were examined. Light-
based stimulation elicited Ca2+ transients in a subset of mPFC neurons (Figure 21E, F). To 
analyze whether Ca2+ transients were caused by DA or glutamate release, dopaminergic 
and/or glutamatergic blockers were applied. While Ca2+ transients were unaffected by 
dopaminergic antagonists, the AMPA/kainate receptor blocker CNQX completely blocked 
these transients (Figure 21F, G). These results suggest that mesocortical MbDN projections 
exert their predominant effects via release of glutamate. 
To pinpoint the effects of synaptic release of glutamate by MbDN projections, patch-clamp 
recordings from layer IV/V mPFC pyramidal neurons were obtained (Figure 21H). Light-
based stimulation of ChR2-EYFP expressing axons originating from the VTA always caused 
inhibitory postsynaptic potentials (IPSP) in the mPFC pyramidal neurons (Figure 21J, blue 
bar indicates time of light stimulation, average latency from onset of light stimulation to the 
IPSP onset 28.3 ± 13.8 ms, average magnitude of the light-evoked IPSP 5.1 ± 0.7 mV). 
Moreover, application of GABA-receptor blocker gabazine (10 µm) fully blocked the IPSP. 
These results indicate that the light-evoked response is GABAergic (Figure 21J, K). To 
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examine if recruitment of local interneurons might underlie the inhibitory effects of light-
based stimulation of VTA axons, GABAergic interneurons in the mPFC were analyzed. In 
GABAergic interneurons, light stimulation invariably elicited short-latency evoked 
postsynaptic potentials (EPSP) (average latency from onset of light stimulation to the EPSP 
onset 20.7 ± 3.79 ms, average magnitude of the light-evoked EPSP 6.4 ± 0.82 mV) (Figure 
21I). Moreover, some of the EPSP were large enough to trigger AP (Figure 21L). 
Interestingly, the light-evoked excitation of interneurons was completely blocked by the 
glutamate antagonist CNQX (10 µM, Figure 21L, M). These results indicate that mesocortical 
MbDN projections cause glutamatergic excitation of interneurons, as well as inhibition of 
pyramidal neurons. Next, to examine whether IPSPs in the mPFC are caused by a direct 
release of GABA from VTA neurons, light-evoked IPSP were recorded from mPFC 
pyramidal neurons. Application of CNQX, completely blocked light-evoked IPSP (Figure 
21N, O), indicating that IPSP in the mPFC are most likely not due to a direct release of 
GABA from VTA neurons. These results show that VTA MbDN axons are capable of 
generating fast inhibition in mPFC pyramidal neurons via glutamatergic excitation of 
inhibitory interneurons.  
The amount of MbDN fibers in the PFC of Gli2ΔMb>E9.0 mice was severely reduced, 
suggesting that the inhibition of the mPFC neurons might be impaired. Indeed, expression of 
ChR2-EYFP in VTA neurons in Gli2ΔMb>E9.0 mice revealed that the excitation of the mPFC 
interneurons was strongly impaired in these mice (Figure 21Q). Furthermore, the inhibition 
observed in mPFC pyramidal neurons upon light-based stimulation of VTA afferents was also 
strongly reduced in magnitude (Figure 21P). 
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Figure 21 Functional assessment of mesocortical MbDNs in Gli2ΔMb>E9.0 and control 
(En1Cre+/-) mice using optogenetic approach. (A-C) Morphology and intrinsic firing 
properties of a ChR2-expressing VTA neuron (left panels). Blue light stimulation (473 nm) of 
EYFPpos VTA neurons resulted in large inward currents in VTA neurons (rightmost panels). 
(D) Precise stimulation of ChR2-expressing VTA neurons with brief (20 ms) blue light 
illumination, which reliably triggered AP up to stimulation frequencies of 33 Hz. (E) Image 
of an OGB-1-AM pressure-loaded slice showing OGB-1-positive cells in the mPFC. (F) 
Traces of light stimulated Ca2+ transients in a representative subset of mPFC neurons. The 
dashed blue line indicates the light-based stimulation of ChR2-EYFPpos axons originating 
from the VTA. The transients were not significantly affected by DA antagonists, but were 
completely blocked by additional application of the AMPA/kainite receptor blocker CNQX 
(10 µM). (G) Percentage of neurons that respond to optogenetic stimulation before and after 
application of D1 and D2 receptor blockers and subsequent glutamatergic antagonist CNQX. 
Significance (p***<0.001) was determined by Friedman test with Dunn’s multiple 
comparison test. (H-I) Intrinsic properties and neuronal morphology of a representative PFC 
pyramidal neuron (H) and an interneuron (I). (J) Optogenetic stimulation of the axons 
projecting from the VTA caused IPSPs in layer IV/V mPFC pyramidal neurons (blue bar 
indicates time of light stimulation). (K) Light-evoked IPSP were blocked by the GABA-
receptor blocker gabazine (10 µM). (L) Light-based stimulation of EYFPpos axons originating 
from the VTA on PFC interneurons invariably elicited short-latency EPSPs that intermittently 
triggered AP. (M) The excitation of mPFC interneurons is blocked by the glutamate 
antagonists CNQX (10 µM). Significance (p***<0.001) was determined by Kruskal-Wallis 
test with Dunn’s multiple comparison test. (N-O) The inhibition of mPFC pyramidal neurons 
is also blocked by CNQX. Significance (p*<0.1) was determined by ANOVA with Newman-
Keuls post test. (P-Q) Light-evoked IPSPs in mPFC pyramidal neurons (P), as well as EPSP 
in inhibitory interneurons (Q) are significantly reduced in Gli2ΔMb>E9.0 mice. Significance 
(p*<0.1; p**<0.01) was determined by Mann-Whitney test. 
 
Thus, severe reduction of MbDNs capable of glutamatergic transmission in Gli2ΔMb>E9.0 mice 
causes virtually complete loss of an inhibitory motif that normally inhibits mPFC pyramidal 
neurons. 
 
 4.12 Inactivation of Shh signaling at E9.0 affects the generation of other ventral 
neuronal cell types 
Previously it has been shown that after E9.0 Shh signaling is required for the generation of 
more laterally located precursors such as precursors for the OM complex and RN (Blaess et 
al., 2006; Perez-Balaguer et al., 2009) (Section 1.18). OM and RN neurons are derived from 
the Shhpos/Foxa2pos/Nkx6-1pos progenitor domain located laterally to MbDN Lmx1apos 
domain, whereas motoneurons (GABApos) originate from an even more lateral domain, which 
is positive for Nkx2-2 (Figure 7A). Conditional inactivation of Shh signaling at E9.0 results in 
complete loss of OM neurons (Blaess et al., 2006). To analyze whether development of RN 
neurons is dependent on Shh signaling after E9.0, Nkx6-1 expressing progenitors that give rise 
to RN neurons were examined. The wildtype expression pattern of Nkx6-1 at E10.5, and later 
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at E12.5, consists of two positive domains, a medial Shhpos/Foxa2pos/Nkx6-1pos and a lateral 
Shhneg/Foxaneg/Nkx6-1pos domain (Figure 7, 22A). In E10.5 Gli2ΔMb>E9.0 mice, the expression 
of Nkx6-1 was shifted medially (Figure 22B). Both domains are still present in the 
Gli2ΔMb>E9.0 mice, however, the medial Shhpos/Foxa2pos/Nkx6-1pos domain was dramatically 
reduced in size (Figure 22B). Interestingly, at E11.5 the Foxa2pos/Nkx6-1pos domain was 
absent in Gli2ΔMb>E9.0 mice (Figure 22C-D). Another putative marker for precursors of the RN 
and motoneurons is Sim1. Whereas Sim1 overlaps with Foxa2 and Nkx6-1 in the progenitor 
area (VZ) and forms two vertical stripes in E11.5 wildtype mice, it is expressed outside of the 
VZ in Gli2ΔMb>E9.0 mutants (Figure 22E-F). Thus, these data show that Shh signaling after 
E9.0 is required for the further expansion of Foxa2 and therefore for specification of RN and 
OM precursor domains. 
To examine whether RN neurons are reduced in Gli2ΔMb>E9.0 embryos, immunohistochemical 
analysis of the Pou4f1 (POU domain class 4 transcription factor 1) was carried out on coronal 
sections of E18.5 control and Gli2ΔMb>E9.0 brains. The RN is organized in a parvocellular and a 
magnocellular part, which are located in the anterior and posterior midbrain, respectively 
(Massion, 1967) (Section 1.18). Surprisingly, the most anterior parvocellular part was 
maintained in Gli2ΔMb>E9.0 brains. Interestingly, posteriorly located Pou4f1pos neurons in 
Gli2ΔMb>E9.0 mutants were detected medially, while laterally located cells were completely 
missing (Figure 22G-H). In addition the usual compacted round shape of the nucleus was less 
obvious in Gli2ΔMb>E9.0 brains. 
It has previously been demonstrated that the RN contains neurons secreting different 
neurotransmitters, which participate in corticorubral and/or cerebellorubral transmission. One 
of the neurotransmitter playing a role in cerebellorubral transmission is glutamate. To 
investigate whether the apparent reduction in the RN neurons affects a particular population 
of the neurotransmitter the expression of glutamate transporter was examined. RNA In Situ 
hybridization analysis showed that RN neurons positive for vGlut2 were reduced in P21 
Gli2ΔMb>E9.0 mutants compared to control (Figure 22I-J). Moreover, remaining vGlut2pos RN 
neurons were located medially. These data suggest that there might be a temporal requirement 
of Shh signaling for generating laterally located RN neurons, which require Shh signaling for 
their induction after E9.0. It seems that more anteriorly located RN neurons might require Shh 
signaling for their induction before E9.0, since they were less affected in Gli2ΔMb>E9.0 brains. 
Alternatively, generation of the parvocellular part of RN is controlled by different factors than 
Shh signaling or the RN progenitors might be generated in the diencephalon. 
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Figure 22 Requirement of Shh signaling after E9.0 for proper generation of red nucleus 
neurons. (A-D) Immunostaining for Foxa2 and Nkx6-1 in E10.5 (A-B) and E11.5 (C-D) 
control and Gli2ΔMb>E9.0 embryos. Dashed lines and yellow asterisks (control) indicate medial 
Foxa2pos/Shhpos/Nkx6-1pos and lateral Foxa2neg/Shhneg/Nkx6-1pos domains. White bars indicate 
the size of these domains. (E-F) RNA In Situ hybridization for Sim1 in E11.5 control and 
Gli2ΔMb>E9.0 embryos. (G-H) Immunostaining for RN neurons (Pou4f1) on coronal section in 
E18.5 control and Gli2ΔMb>E9.0 brains. (I-J) RNA In Situ hybridization for vGlut2 in P21 
control and Gli2ΔMb>E9.0 brains. Yellow dashed lines outline the area of RN. Arrows indicate 
the missing neurons in the Gli2ΔMb>E9.0 mutants. Scale bars 50 µm (A-B), 100 µm (C-F), 500 
µm (G-J). 
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4.13 Constitutive activation of Shh signaling after E9.0 results in dramatic 
ectopic expansion of MbDN precursor domain 
To further examine the role of Shh signaling in specification of MbDN subpopulations, mice 
that expressed a constitutively active form of the Shh receptor Smo (SmoM2) were generated 
(Section 3.11.6) (Jeong et al., 2004) (Figure 23A). To induce recombination and thereby the 
expression of SmoM2 specifically in the midbrain and aHb after E9.0 (SmoM2↑Mb>E9.0) the 
En1Cre/+ mouse line was used. Inactivation of high level Shh signaling led to a severe 
reduction in the lateral MbDNp domain and almost complete loss of mesocortical MbDNs in 
Gli2ΔMb>E9.0 mutant mice. To investigate if constitutive activation of Shh signaling after E9.0 
might have an opposite effect, the Lmx1apos domain, which gives rise to all MbDNs was 
examined (Section 1.14). The size of the Lmx1apos area was increased in the vMb of the 
SmoM2↑Mb>E9.0 embryos at E10.5, however, the increase in the size of this domain was more 
prominent caudally (146.2% ± 10.8% of control) than rostrally (125.9% ± 17.3% of control) 
(Figure 23C, I and data not shown for rostral vMb). Furthermore, the Arxpos domain was also 
significantly increased in size in SmoM2↑Mb>E9.0 mutants compared to control embryos 
(131.6% ± 3.3% of control) (Figure 23E). To examine whether the lateral MbDNp can be 
induced in presence of fully activated Shh signaling, expression of Corin in E10.5 
SmoM2↑Mb>E9.0 embryos was analyzed. The quantification of the Corinpos and Lmx1apos areas 
on adjacent sections of the posterior vMb showed that the lateral Lmx1apos/Corinneg domain 
was not significantly increased in size compared to control embryos (Figure 23D, H). 
Interestingly, in contrast to control animals, the medial Lmx1apos/Corinpos domain was 
increased in size by 58.6% ± 5.8% in SmoM2↑Mb>E9.0 mice compared to control littermates 
(Figure 23C, H). 
To assess whether constitutive activation of Shh signaling after E9.0 leads to an increase of 
Shh and Foxa2 domains, the expression of these markers was analyzed in E10.5 control and 
SmoM2↑Mb>E9.0 embryos. The Shh and Foxa2 domains were expanded into the dorsal midbrain 
(Figure 23F,G), resulting in ventralization of the dorsal midbrain. Moreover, the midbrain of 
SmoM2↑Mb>E9.0 was dramatically increased in size compared to control. 
Taken together, after E9.0, only a very restricted population of midbrain precursors close to 
the Lmx1apos domain respond to increased Shh signaling by changing their fate to medial 
MbDNp, while a much larger population of precursors can respond by adopting a 
ventrolateral fate. 
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Figure 23 Constitutive activation of Shh signaling at E9.0 leads to dramatic ectopic 
expansion of MbDNp domain. (A) Schematic of the conditional activation of Shh signaling 
in SmoM2↑Mb>E9.0 mice. (B) Schematic of constitutive activation of Shh signaling. SmoM2 is 
active in absence of Shh. (C-G) Immunofluorescent staining (C, F) and RNA In Situ 
hybridization (D-E, G) on E10.5 coronal sections for markers of MbDNp domain (Lmx1a, 
Arx, Corin, Shh and Foxa2). The Lmx1a domain is outlined in sections C-E (dashed line). 
Red asterisks indicate the dorsal expansion of Foxa2 and Shh. Scale bar 100 µm. (H) 
Quantitative analysis of the size of the medial (Lmx1apos/Corinpos) and lateral 
(Lmx1apos/Corinneg) MbDNp domain in the vMb. (I) Quantitative analysis of the Lmx1apos 
domain in E10.5 control and SmoM2↑Mb>E9.0 embryos. Error bars indicate SEM. Significance 
(p**<0.01; p***<0.001) was determined by Student’s t-test. 
 
 4.14 Expansion of MbDN precursor domain is not caused by increase in cell 
proliferation 
To examine whether the expansion of MbDNp domain is a result of increased proliferation, 
proliferating cells were labeled with an one hour BrdU pulse in E10.5 SmoM2↑Mb>E9.0 and 
control embryos. Quantification of BrdUpos cells within the Lmx1apos domain showed that the 
proliferation in the MbDNp domain in SmoM2↑Mb>E9.0 mutants (56 ± 3.6 cells) was not 
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significantly different from control littermates (62 ± 5 cells), indicating that proliferation of 
MbDNp is not affected in SmoM2↑Mb>E9.0 mutants (Figure 24A-C). 
To analyze whether neurogenesis occurs normally in the mutant mice, the expression of the 
proneural marker Ngn2 was examined. Quantification of the number of Ngn2pos cells within 
the Lmx1apos domain in SmoM2↑Mb>E9.0 and control embryos at E10.5 showed that the number 
of Ngn2pos cells was significantly increased in SmoM2↑Mb>E9.0 mutants (46 ± 10 cells) 
compared to control (20 ± 3.4 cells) embryos when normalized for the size of the MbDNp 
domain (Figure 24D-F). These data suggest that prolongated Shh signaling did not affect the 
proliferation of MbDNp, however leads to the upregulated neurogenesis, meaning that 
constitutively active Shh signaling prompts the cell cycle exit of proliferating cells. However, 
the proliferation was not analyzed at later stages, meaning that increase in the neurogenesis 
might be transient. 
 
 
Figure 24 Proliferation in the MbDNp domain is not affected in E10.5 SmoM2↑Mb>E9.0 
mice, whereas neurogenesis is increased. (A-B) One hour BrdU pulse to label proliferating 
precursors in the vMb at E10.5. (C) Quantitative analysis of the number of BrdUpos cells 
normalized to the size of the Lmx1apos domain. (D-E) Immunostaining for Ngn2 on E10.5 
coronal sections. Dashed lines indicate the Lmx1apos domain. Scale bars 100 µm. (F) 
Quantitative analysis of the number of Ngn2pos cells normalized to the size of the Lmx1apos 
domain. Error bars indicate SEM. Significance (p*<0.05) was determined by Student’s t-test. 
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 4.15 Constitutive activation of Shh signaling after E9.0 results in ectopic MbDNs 
in the dorsal midbrain 
To test whether the expansion of the Lmx1apos domain and the increased neurogenesis at 
E10.5 results in an increased number of MbDNs, immunohistochemistry for TH was carried 
out on coronal sections through the rostrocaudal extent of the developing vMb in E10.5, 
E12.5 and E18.5 control and SmoM2↑Mb>E9.0 embryos (Figure 25A-D, Figure 14C, Figure 
15A). 
 
Figure 25 Activation of Shh signaling after E9.0 results in ectopic MbDNs in the dorsal 
midbrain. (A-F) Immunostaining for differentiated MbDNs (TH) in E10.5 (A-B), E12.5 (C) 
and E18.5 (D) wildtype and SmoM2↑Mb>E9.0 embryos. Yellow arrows indicate THpos MbDNs. 
Scale bars 100 µm (A-C), 500 µm (D). 
 
The first differentiated THpos MbDNs in control and SmoM2↑Mb>E9.0 mice were detected at 
E10.5. MbDNs in SmoM2↑Mb>E9.0 embryos seem not to be increased at this time point. 
However, at E12.5 MbDNs were severely increased and expanded towards the dorsal 
midbrain (Figure 25C, Figure 14C). These results correlate with the increased neurogenesis at 
E10.5. In contrast to the controls, in which the newly generated THpos MbDNs are located at 
the ventral midline, the THpos cells in the mutant were expanded laterally. Notably, the 
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increase in MbDNs was more obvious caudally, while there was no change in the rostral 
MbDN population. This phenotype persisted at E18.5. At this stage, the strong increase in the 
MbDNs became even more evident. The THpos cells were almost completely excluded from 
the midline, areas corresponding to the RLi and vmVTA (Figure 25D, Figure 15A). These 
findings demonstrate that constitutive activation of Shh signaling results in a severe increase 
of MbDN and their expansion towards the dorsal midbrain. 
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5. Discussion 
MbDNs in the adult brain are diverse on a functional and anatomical level, but it is largely 
unexplored how this diversity is established during development. To address this question, 
Shh signaling was inactivated in the midbrain immediately after lateral MbDNp start to 
respond to Shh signaling. The conditional gene inactivation was achieved by the removal of 
Gli2, the main transcriptional activator downstream of Shh signaling. In the mutant mice 
(Gli2ΔMb>E9.0) with inactivated Shh signaling, the lateral MbDNp domain was severely 
reduced in size and MbDNs were disorganized and decreased in number in the developing 
and adult brain. Analysis of MbDN subset markers showed that the majority of the remaining 
MbDNs adopted the fate of SNpc MbDNs in mutant mice. Characterization of MbDN 
connections in control and Gli2ΔMb>E9.0 mutant mice using immunofluorescence and axonal 
tracing, showed that the severe reduction of lateral MbDNp in Gli2ΔMb>E9.0 mutant mice is 
associated with the loss of mesocortical projections from the VTA. Optogenetics and 
electrophysiological analysis showed that mesocortical MbDNs modulate a cortical 
microcircuit by inhibiting cortical pyramidal neurons via release of glutamate. 
Furthermore, constitutive activation of Shh signaling after E9.0 results in a massive increase 
in the number of MbDNs. Analysis of MbDNp domain showed that the medial MbDNp 
domain was significantly increased in size, whereas the lateral domain was only slightly 
affected. Due to the perinatal lethality of the mutant mice, investigation of MbDNp 
specification in the adult brains was not possible. This study shows a causal link between 
early developmental induction mechanisms and the connective and functional properties of 
MbDNs in the mature brain. 
 
 5.1 Establishing of specific circuits in the mesocorticolimbic system 
MbDN cell bodies and their projections to the forebrain display a mediolateral topographic 
arrangement. The most laterally located cells (SNpc and lVTA) project to the dorsal striatum, 
mediolateral MbDNs of the lVTA innervate the lateral part of the striatum and medially 
located MbDNs of the vmVTA send their axons to the medial striatum, the PFC and the 
amygdala (Ikemoto, 2007 and 2010). However, significant intermixing of MbDN populations 
with different projection targets, particularly in the VTA, makes it difficult to assess the 
circuitry that determines the function of particular subsets of VTA MbDNs. Recent studies, 
using optogenetic approach revealed that distinct circuits indeed encode different MbDN 
functions (Lammel et al., 2008 and 2012), but how these circuits are established during 
development is still unclear. 
Discussion 
 
 87 
After MbDN neuronal identity is specified in the VZ of the ventral midline, MbDNs 
differentiate and migrate to their final position while extending projections to their forebrain 
targets. It has been proposed that the target and functional specificity of MbDNs is established 
at late embryonic stages, through interaction with their target areas or by receiving specific 
inputs (Hu et al., 2004). However, fate-mapping studies suggest that MbDN populations are 
already pre-specified during their precursor phase. Medial MbDNp co-express Corin and 
Msx1/2 along with Lmx1a and give rise to MbDNs of the SNpc and dlVTA, whereas lateral 
MbDNp domain expresses only Lmx1a and preferentially give rise to MbDNs in the vmVTA 
(Blaess et al., 2011; Hayes et. al., 2011). This study demonstrates that inactivation of high 
level Shh signaling at E9.0 results in reduction of the medial (Lmx1apos/Corinpos) MbDNp 
domain and almost complete loss of the lateral (Lmx1apos/Corinneg) MbDNp domain in 
Gli2ΔMb>E9.0 mice. Analysis of postnatal Gli2ΔMb>E9.0 brains shows that axonal projections to 
the PFC are severely reduced, whereas projections to the ventral striatum and amygdala are 
not significantly altered. These data indicate that the MbDNp population that gives rise to 
mesocortical MbDNs is not induced in Gli2ΔMb>E9.0 mutant mice. Thus, mesocortical MbDNs 
have a different profile in their differentiation phase that results in the distinct physiology of 
these MbDNs and determines the formation of the specialized circuitry in the adult brain 
(Lammel et al., 2008 and 2012). 
The developmental specification of neuronal subtypes has been described in other areas of the 
nervous system. Thus, the different subtypes of cortical interneurons are specified before cells 
become postmitotic (Corbit et al., 2011). The fate of spinal cord neurons and cortical 
interneurons is determined by their location and the timing of origin. Moreover, the identity of 
neural progenitors is defined by combinatorial function of specific sets of transcription factors 
during their precursor or differentiation phase. These sets of transcription factors play a role 
by forming proper connectivities as well as functional integration of these neurons (Livesey et 
al., 2001; Polleux and Ghosh, 2002; Berghuis et al., 2004; Molyneaux et al., 2007). 
 
 5.2 Temporal requirement of Shh signaling in the specification of lateral MbDN 
precursors 
The induction of all MbDNp is dependent on Shh signaling. Analysis of the Lmx1a 
expression domain, which is thought to give rise to all MbDNs, revealed that Shh signaling is 
crucial for the induction of Lmx1a domain before E9.0 but not required for its maintenance 
after E9.0 (Andersson et al., 2006; Nakatani et al., 2010). Furthermore, Shh signaling is 
necessary for the further expansion of the Lmx1a domain, since Lmx1a expression domain is 
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severely decreased in Gli2ΔMb>E9.0 mice. These results are consistent with the gain-of-function 
data (SmoM2↑Mb>E9.0 mutant mice), which show an expansion of the Lmx1apos MbDNp 
domain and further confirm that Shh signaling is crucial for the induction of Lmx1a domain. 
However, inactivation of Shh signaling after E9.0 affects the generation of the lateral MbDNp 
in Gli2ΔMb>E9.0 mutant embryos. This raises the question how Shh signaling regulates the 
induction of different MbDNp domains. 
In the spinal cord, Shh is secreted from a fixed population of cells located in the notochord 
and FP (Dessaud et al., 2007; Ribes et al., 2010). It forms a stable morphogen gradient, i.e. 
Shh acts at a distance from the point source in a concentration-dependent manner. Different 
concentrations of Shh induce distinct transcriptional factor expression domains, which define 
different neuronal precursors. In addition to different concentrations of Shh, changes in the 
duration of active Shh signaling and in the sensitivity of the receiving cells to ongoing Shh 
signaling determine ventral neuronal cell type in the spinal cord (Dessaud et al., 2007; Ribes 
et al., 2010). In contrast, expression of Shh in the vMb is dynamic. A changing competence 
model for the response to Shh would makes more sense in the vMb, since the dynamic Shh 
expression does not lead to a stable morphogen gradient and with different mediolateral cell 
populations being exposed to high levels of Shh signaling, the expansion of the most medial 
cell fate could go ad infinitum until the entire midbrain is ventralized. How the changes in 
competence are regulated is not clear, it could be due to the memory of low levels of Shh 
signaling and/or could be controlled extrinsically through the interaction with other signaling 
pathways in the vMb, such as Wnts (Joksimovic et al., 2009). 
Based on this study’s data the following model on how Shh induces different precursor 
domains in the vMb can be proposed. Initially, the most medial progenitors are exposed to 
high levels of Shh from the notochord starting around E8.0. Their response to Shh signaling is 
rapidly downregulated once they start to express Shh between E8.5 and E9.0. Simultaneously 
they cease to express Gli transcriptional factors, which are necessary for Shh signal 
transduction. In this short time window ventral midline precursors are specified into medial 
MbDNp fate (Shhpos/Foxapos/Lmx1apos/Corinpos/Msx1/2pos). Induction of the medial MbDNp 
fate is only possible with early exposure (starting at E8.0) to high levels of Shh signaling, 
since the medial MbDNp domain is induced in Gli2ΔMb>E9.0 mice. However, reduction in the 
medial MbDNp domain in Gli2ΔMb>E9.0 mice indicates that the inactivation of Gli2 occurs 
within the time window in which Shh is still required for the medial MbDNp domain 
induction. 
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Precursor cells in a slightly more lateral domain initially receive either no or low levels of Shh 
signaling. Once Shh is expressed in the ventral midline (E8.5-E9.0), lateral domain receives 
high levels of Shh signaling that induces the lateral MbDNp fate 
(Shhpos/Foxapos/Lmx1apos/Corinneg/Msx1/2neg). Thus, delayed exposure to Shh signaling is 
necessary to induce lateral MbDNp. This population is severely reduced in Gli2ΔMb>E9.0 
mutant mice. However, constitutive exposure to high levels of Shh signaling in 
SmoM2↑Mb>E9.0 mutant mice does not lead to the expansion of lateral MbDNp, meaning that 
there might be another mechanism controlling cell fate specification. Thus, initial prolongated 
exposure to low levels of Shh signaling could result in desensitization of lateral precursors in 
their response to Shh. Thereby, following exposure to high levels of Shh would not lead to 
full activation of the pathway. Taken together, these findings suggest that the time point of 
exposure to high levels of Shh or level of Shh expression can determine the induction of a 
specific MbDN fate. 
Taken together, the data show that the timing of Shh expression plays a role in defining 
different MbDNp fates. However, it is still unclear which transcriptional factors determine the 
distinct fates of medial versus lateral MbDNs downstream of Shh. Msx1/2 is a transcription 
factor, which is exclusively expressed in medial MbDNp and excluded from the lateral 
MbDNp domain (Blaess et al., 2011), could be involved in determining the fate of medial 
MbDNp. Moreover, it has been demonstrated, that mice lacking Msx1/2 show a 40% 
reduction of MbDNs at E11.5 (Houzelstein et al., 1997; Andersson et al., 2006). However, it 
has not been investigated whether inactivation of Msx1/2 affects specific MbDN 
subpopulation. In addition, Lmx1a and Lmx1b are possible candidates for the determination 
of different precursor domains in the vMb. Thus, Lmx1a and Lmx1b mouse mutants showed 
that Lmx1a is required to establish the medial MbDNp domain, while Lmx1b determines the 
lateral MbDNp (Deng et al., 2011). 
 
 5.3 Proliferation and neurogenesis in the MbDN progenitor domain are not 
affected in Gli2ΔMb>E9.0 mutants 
It has been demonstrated that Shh is involved in regulating the survival of the basal, young 
neuroblasts as well as in enhancing their proliferation (Dahmane et al., 2001; Ingham and 
Placzeck, 2006). A previous study showed that inactivation of Shh receptor Smo in Shh-
expressing cells affects the proliferation of MbDNp (Hayes et al., 2013). Loss of Shh 
signaling at E9.0 resulted in an increase of cells remaining in a proliferative state and a 
reduction in postmitotic MbDNp, showing the role of Shh signaling in regulating cell cycle 
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exit in the vMb (Hayes et al., 2013). In contrast to these results, no changes in the 
proliferation rates in MbDNp in Gli2ΔMb>E9.0 mice were detected in this study, suggesting that 
the observed effects of Smo inactivation could potentially be mediated by non-canonical Shh 
signaling. In contrast to control mice, no postmitotic MbDNp were found in E10.5 
Gli2ΔMb>E9.0 mice, meaning that there might be a delay in the generation of newly 
differentiated MbDNs. However, the number of Ngn2pos cells in E11.5 Gli2ΔMb>E9.0 mice was 
not different from the wildtype. There might be other mechanism or extrinsic factors 
controlling cell proliferation and neurogenesis in the vMb. It has been shown that canonical 
Wnt/β-catenin signaling pathway regulates cell cycle exit and midbrain FP neurogenesis 
(Tang et al., 2009; Joksimovic et al., 2009; Tang et al., 2010; Yang et al., 2013). Depletion of 
β-catenin in MbDNp led to a perturbation of cell polarity and reduced MbDN neurogenesis 
(Tang et al., 2009). It has been suggested that β-catenin mediated Wnt1 signaling suppresses 
Shh levels at the ventral midline around E10.5, creating an appropriate milieu for normal rates 
of proliferation. However, despite the significant reduction of Wnt1 expression and a lack of 
downregulation of Shh in the ventral midline in Gli2ΔMb>E9.0 mice, proliferation and 
neurogenesis are unaffected. These data suggest that in Gli2ΔMb>E9.0 mice reduced Wnt1 
expression still can activate proliferation and neurogenesis in the vMb. In addition, Msx1/2 
has been suggested to control the timing of MbDN neurogenesis. Premature activation of 
Msx1/2 resulted in upregulation of Ngn2 expression, a loss of FP characteristics, and 
premature induction of MbDNs (Houzelstein et al., 1997; Andersson et al., 2006). 
Depletion of canonical Wnt/β-catenin signaling pathway and/or Smo-mediated Shh signaling 
resulted in an increased cell apoptosis (Blaess et al., 2006; Tang et al., 2009), which 
contributes to the reduction of MbDNs. In contrast, no detectable changes in the cell death 
were observed in this study, meaning that the remaining MbDNs proliferate and differentiate 
properly. 
 
 5.4 Normal innervation of non-cortical forebrain targets, but loss of mesocortical 
projections in Gli2ΔMb>E9.0 mice 
Inactivation of high levels of Shh signaling results in a preferential loss of the lateral MbDNp 
domain, which gives rise to the vmVTA (Blaess et al., 2011; Hayes et al., 2011). However, 
both SNpc and VTA MbDNs were reduced in Gli2ΔMb>E9.0 mice by 30% and 60%, 
respectively compared to control. Anatomical and morphological analysis showed that the 
reduction of VTA MbDNs was mainly restricted to the medially located neurons. Moreover, 
cells of the RLi and IF were almost entirely missing in the Gli2ΔMb>E9.0 mice. Furthermore, the 
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PBP MbDNs were severely reduced and intermixed with the SNpc neurons. Moreover, SNpc 
neurons were found in the lateral region of the VTA, practically replacing the neurons of the 
PBP. 
To examine how the reduction of MbDNs in the vmVTA and the SNpc affects the formation 
of dopaminergic circuitry in Gli2ΔMb>E9.0 mice, their target areas were examined. Thus, 
mesocortical projections were severely reduced in Gli2ΔMb>E9.0 mice. However, no significant 
changes in the density of projections to the dorsal striatum, NAc or amygdala were detected. 
MbDNs have huge terminal axonal arborizations in the striatum (Matsuda, 2009). Each 
MbDN might give rise to approximately 150000 presynaptic terminals in the striatum 
(Oorschot, 1996). 6-OHDA lesion of the SNpc MbDNs during postnatal development leads to 
sprouting and extensive arborization of the remaining MbDN axons in the dorsal striatum 
(Finkelstein, 2000), indicating that there could be compensatory axonal arborization when the 
absolute number of MbDN cell bodies and axons is reduced. In Gli2ΔMb>E9.0 mice MbDNs are 
reduced already during embryonic development. Therefore remaining MbDN axons could 
sprout in the dorsal striatum and amygdala to compensate for reduced innervation. Measuring 
DA levels using HPLC, however, shows that DA content was decreased by almost 20% in the 
striatum in the Gli2ΔMb>E9.0 mice, meaning that the remaining MbDNs cannot fully 
compensate for the loss of MbDNs. 
 
 5.5 Mesocortical MbDNs co-releasing glutamate 
The PFC is the major cortical recipient of DA inputs and DA is believed to play a critical 
modulatory role in several cognitive processes conducted by the PFC network, including 
working memory, attention and decision making. To examine the consequences of the loss of 
mesocortical projections in Gli2ΔMb>E9.0 mice on microcircuits in the PFC, ChR2-EYFP 
expressing VTA neurons were activated in slice preparations of mutant (Gli2ΔMb>E9.0) and 
control (En1Cre/+) brains using an optogenetic approach and recorded the activity in the PFC. 
The optical activation of ChR2-EYFP expressing VTA neurons in the control mice resulted in 
glutamate-mediated EPSPs in local interneurons and GABA-dependent IPSPs in pyramidal 
neurons in the PFC. In contrast, upon optical stimulation of VTA neurons no activity in the 
Gli2ΔMb>E9.0 brains mice was detected. These results suggest that VTA MbDN modulate the 
excitability of PFC neurons via interneurons by release of glutamate. 
The mesocorticolimbic pathway originating in the VTA is classically viewed as 
dopaminergic. However, it has been shown that only 30-40% of mesocortical projection 
neurons are dopaminergic (Swanson, 1982), while the rest of neurons express mRNA for 
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vGlut2 (Kawano et al, 2006; Yamaguchi et al, 2011; Gorelova et al., 2012; Hnasko et al., 
2012). Detailed analysis of vGlut2-expressing neurons in the vMb identified three cell 
populations: MbDN, MbDN-vGlut2 and vGlut2-only neurons (Kawano et al., 2006; 
Yamaguchi et al., 2007; Yamaguchi et al., 2011). These cells are located in the vmVTA, in 
particular in the IF and RLi and project to the NAc and the PFC. Interestingly, the loss of 
MbDN and MbDN-vGlut2 in the Gli2ΔMb>E9.0 mice is mostly apparent in the vmVTA. 
However, vGlut2-only neurons were not affected in Gli2ΔMb>E9.0 mutant mice. In the adult 
brain of En1Cre/+ mice, Cre-mediated recombination occurs primarily in MbDNs, including 
MbDN-vGlut2, but also in a small percentage of vGLut2-only neurons. Therefore, the 
glutamate- evoked activation of local PFC interneurons upon optogenetic stimulation of 
ChR2-EYFP expressing neurons could be mediated by vGLut2-only neurons and/or MbDN-
vGlut2. However, in Gli2ΔMb>E9.0 mice in which MbDN-vGlut2, but not vGlut2-only neurons, 
are severely reduced, glutamate-mediated EPSPs in PFC-interneurons were eliminated upon 
light stimulation of VTA neurons. Taken together, these results provide evidence that the 
glutamate-dependent activation of interneurons in the PFC is predominantly mediated by 
glutamate co-release from MbDN-vGlut2 and not vGlut2-only neurons. 
Optogenetic and conditional gene inactivation studies confirmed the ability of DA neurons to 
release glutamate in the NAc (Stuber et al., 2010; Tecualetla et al., 2010; Tritsch et al., 2012). 
Optical stimulation of dopaminergic terminals in the NAc shell resulted in glutamate-
mediated EPSP (Stuber et al., 2010). Glutamatergic responses were eliminated by glutamate 
but not DA antagonists (Lavin et al., 2005; Stuber et al., 2010). Even more direct support for 
glutamate release from the VTA MbDNs was provided by conditional gene inactivation 
studies, showing that selective removing of vGlut2 expression in MbDNs eliminated the 
EPSP in the NAc spiny neurons (Hnasko et al., 2010; Stuber et al., 2010). 
Considerable efforts have been invested in elucidating the cellular mechanisms by which DA 
modulates PFC function. Electrophysiological stimulation of VTA axons can rapidly 
depolarize PFC neurons or evoke EPSP-IPSP sequences (Lavin et al., 2005). It was suggested 
that the IPSP is mediated by VTA-induced feedforward activation of local PFC interneurons. 
The stimulation of the 6-OHDA-lesioned VTA failed to evoke EPSP in the PFC, confirming 
the idea that VTA MbDNs modulate PFC function by release of glutamate (Levin et al., 2005; 
Gorelova et al., 2012). However, this conclusion is somewhat premature given that vGlut2-
only neurons also die as a secondary consequence of the destruction of MbDNs by 6-OHDA. 
Thus, it still not clear whether the evoked responses in the PFC were due to release of 
glutamate from MbDN-vGlut2 or vGlut2-only cells. 
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 5.6 Functional implication of glutamate co-release in the PFC 
Tracing and immunohistochemical studies demonstrated that between 12% and 30% of 
dopaminergic axons in the PFC contain vGlut2pos varicosities, indicating that only a subset of 
dopaminergic synapses are able to co-release glutamate (Gorelova et al., 2012). However, it is 
still unclear how glutamate acts on cortical interneurons. Sequela et al. (1988) reported that 
between 16% and 22% of MbDN terminals in the PFC made asymmetric synapses, which are 
classically viewed as excitatory or glutamatergic. Forming both symmetric and asymmetric 
synaptic contacts, DA as a neuromodulator modulates acts through DA receptors. It has been 
shown that majority of dopaminergic axons form thin, symmetric synapses on distal dendrites 
of interneurons, but a small number of asymmetric synapses were observed as well (Sesack et. 
al., 1995). These data suggest that the EPSPs elicited in PFC interneurons upon stimulation of 
neurons in the VTA might originate from a subset specialized synaptic contacts. 
However, it is still questionable why VTA MbDNs release glutamate to modulate the PFC 
function. MbDN respond by firing a 200 ms burst of spikes to primary rewards, conditioned 
or secondary rewards, rewards that are not predicted and novel or unexpected stimuli 
(Hollerman and Schultz, 1998; Schultz 1998; Hyland et al., 2002). They generate a prediction 
error about reward by emitting brief bursts in response to events that are better than predicted 
or a brief cessation of firing to events that are worse than predicted (Lavin et al., 2005). 
However, DA may not be ideal to transmit this type of fast signal to the PFC. VTA MbDNs 
encode prediction error by changing their firing on the order of 500 ms or less (Schultz et al., 
1997). This leads to an increased PFC DA levels (Watanabe et al., 1997; Ahn and Phillips, 
1999), due to low levels of DAT and, consequently, slow uptake of DA (Garris et al., 1993; 
Lavin at al., 2005). Furthermore, a negative event such stress, which is presumably worse 
than expected, increases PFC DA levels for prolongated periods (Finlay et al., 1995). Thus, 
within the PFC the DA signal is not temporally precise and slow in its response to events of 
positive and negative valence (Gorelova et al., 2012). In contrast, glutamate is tightly coupled 
to neuronal firing and could provide temporally precise prediction error signal in the PFC, 
whereas the slower DA signal might modulate the state of the PFC (Lavin et al., 2005; Lapish 
et al., 2007; Gorelova et al., 2012). 
 
 5.7 Determining of MbDN identity of embryonic stem cell-derived MbDNs 
The pathological hallmark of PD is the preferential loss of the SNpc MbDNs (Barzilai and 
Melamed, 2003). The transplantation studies demonstrated that only MbDNs that form 
synaptic connections with the host striatum exhibit characteristics of the SNpc, are 
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therapeutically useful in cell replacement therapy in animal models of PD (Hudson et al., 
1994; Thompson et al., 2005). In order to provide a scalable pool of MbDNs for 
transplantation purposes in PD patients continued efforts have been made to direct stem cell 
reprogramming and differentiation towards the dopaminergic phenotype. In recent years, a 
number of protocols have been developed to derive dopaminergic neuron-like cells from 
human embryonic or induced pluripotent stem cells (iPSC) (Elkabetz et al, 2008; Koch et al., 
2009; Soldner et al., 2009; Swistowski et al., 2010; Chung et al., 2011; Kriks et al., 2011; 
Jaeger et al., 2011). A more recent breakthrough has been the direct conversion of fibroblasts 
into DA neuron-like cells (Pfisterer et al., 2011; Caiazzo et al., 2011). However, iPSC-derived 
DA neuron-like cells are heterogeneous and do not all exhibit midbrain identity (Marchetto et 
al., 2010). In addition, the final characterization and validation of MbDNs is mostly based on 
the expression of TH and not on the expression of specific markers to distinguish two MbDN 
subpopulations. In order to improve MbDN induction protocols, it is essential to identify 
signaling pathways and transcriptional factors crucial for MbDNs specification. This study 
provides an additional regulatory means to control the specification of MbDN subpopulations 
by changing the cell competence in response to dynamic changes in Shh signaling to produce 
more specific types of MbDNs. The detailed knowledge about the mechanisms underlying the 
specification of MbDN subpopulations will help to improve the successful differentiation of 
stem/iPSC into transplantable MbDNs that can functionally replace neurons generated in PD. 
 
 5.8 Prolongated Shh signaling is crucial for proper generation of red nucleus 
neurons 
Besides MbDNs, the vMb contains other neuronal populations such as OM and RN neurons. 
Due to the clinical relevance of MbDNs, the SNpc and the VTA are the best characterized 
structures in the vMb, whereas little is known about the cues and mechanisms controlling the 
development of RN neurons. Anatomical studies have demonstrated that RN neurons are 
divided into two populations: the parvocellular and the magnocellular part. While the 
magnocellular part projects to interneurons in the brain stem and spinal cord and forms the 
rubrospinal tract, the parvocellular part gives rise to the central tegmental tract, relaying 
information from the motor cortex to the cerebellum through the inferior olivary complex (ten 
Donkelaar, 1988). Developmental studies showed that Foxa2 and Nkx6-1 play essential roles 
in establishing RN neurons (Prakash et al., 2009; Moreno-Bravo et al., 2010). Surprisingly, 
despite the almost complete loss of Foxa2 and Nkx6-1 domain in Gli2ΔMb>E9.0 mutant mice, 
RN neurons are still generated. Interestingly, the rostrally located RN neurons were 
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unaffected, whereas the caudal part of the RN was severely reduced. These data suggest that 
there might be a spatiotemporal requirement of Shh signaling for the induction of RN 
neurons. However, it remains unclear how these two populations are generated. 
Classically both parts of RN are thought to be located in the midbrain. However, expression 
patterns of early RN markers, in particular Nkx6-1, Nkx6-2 and Pou4f1 showed their 
extension into the posterior diencephalon (Massion, 1967; Moreno-Bravo et al., 2010), 
meaning that neurons of the parvocellular RN might arise from diencephalic precursors. This 
idea is supported by the fact that in order to inactivate Shh signaling, En1 was used as a 
promoter, which is specifically expressed in the vMb and aHb. Thus, removal of Shh 
signaling at E9.0 does not affect the forebrain regions and thereby generation of the 
parvocellular RN neurons. 
Another conditional gene inactivation study, in which Shh was inactivated in the vMb and 
aHb at E9.0, shows no defects in the development of RN neurons (Perez-Balaguer et al., 
2008). Expression of Nkx6.1 and Foxa2 in these mutants was almost unaltered, meaning that 
RN neurons still can be specified in the absence of Shh. It was suggested that the induction of 
the RN neurons is independent of Shh function. However, present loss-of-function study 
demonstrated that inactivation of Shh signaling after E9.0 in the Gli2ΔMb>E9.0 mice results in 
severe loss of RN neurons. The differences in the results might be due to not complete 
removal of functional Shh RNA in Shh conditional knockout mice. 
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6. Summary 
Midbrain dopaminergic neurons (MbDNs) in the ventral tegmental area (VTA) and substantia 
nigra pars compacta (SNpc) modulate cognition, reward behavior and voluntary movement, 
respectively. Recent findings indicate that VTA and SNpc MbDNs form subpopulations that 
are divergent in their electrophysiological features, functions and vulnerability to 
neurodegeneration in Parkinson’s disease. This diversity can be correlated with the 
anatomical organization of these two populations and their afferent and efferent connections. 
However, it is largely unexplored how MbDN diversity is established during development. 
Previous studies have demonstrated that the identity of MbDN subtypes can be directly linked 
to their temporal and spatial origin in the embryonic midbrain (Blaess et al., 2011; Hayes et 
al., 2011). Different subsets of MbDNs are derived from a ventral progenitor pool in the 
developing midbrain that is subdivided into a medial and a lateral domain. The relationship 
between developmental origin and the identity of MbDNs in the adult brain is likely reflected 
by the regulated activity of genes inducing cell fate during embryogenesis. Thus, the timing of 
Sonic hedgehog (Shh) signaling might play a role in the determination of the fate of MbDN 
subpopulations, since MbDN precursors respond differently to Shh. 
To address whether Shh signaling regulates the specification of MbDN subtypes, conditional 
gene inactivation approach was used in this study. Removal of Shh signaling at particular 
time point during MbDN induction results in the selective loss of a specific subset of MbDN 
precursors in the embryo. Using viral tracing and immunohistochemical analysis, this study 
demonstrates that this population of MbDN precursors gives rise to mesocortical projection 
neurons in the VTA. Furthermore, optogenetics and physiological analysis reveals that 
mesocortical MbDNs inhibit prefrontal cortical pyramidal neurons via an inhibitory cortical 
microcircuit. Other MbDN-derived projections are largely unaffected. Thus, temporally 
precise Shh signaling in the midbrain is required for establishing a specific mesocortical 
microcircuit. This is the first study establishing a causal link between early developmental 
induction mechanisms and the functional properties of MbDNs in the adult brain. 
Furthermore, constitutive activation of Shh signaling results in a massive increase in the 
number of MbDNs and the ventralization of the dorsal midbrain. Interestingly, analysis of 
MbDNp domain shows that only medial MbDN precursor domain was significantly increased. 
Due to the perinatal lethality of the mutant mice, investigation of MbDN specification in the 
adult brains was not possible. 
In addition, this study demonstrates that the development of the red nucleus (RN) neuron 
subpopulations is determined by the duration of Shh signaling as well. While inactivation of 
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Shh signaling does not affect the generation of the parvocellular RN neurons, the neurons of 
magnocellular RN are severely reduced and disorganized. 
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8. Appendix 
 8.1 Abbreviations 
AC  adenylyl cyclase 
ACSF  artificial cerebrospinal fluid 
ADHD attention-deficit/hyperactivity disorder 
aHb  anterior Hindbrain 
Ahd2  aldehyde dehydrogenase family 1, subfamily A1 
AP  action potential 
Arx  aristaless related homeobox gene (Drosophila) 
bHLH  basic-helix-loop-helix 
BLA  basolateral amygdala 
BMP  bone morphogenetic protein 
BrdU  bromodeoxyuridine 
CA  catecholamine 
cDNA  complementary DNA 
ChR2  channelrhodopsin-2 
CLi  caudal linear nucleus 
CNS  central nervous system 
CPu  caudatoputamen complex 
Cre  Cre recombinase 
DA  dopamine 
DAT  dopamine transporter 
DNA  deoxyribonucleic acid 
dNTP  deoxy-A/C/G/T-trisphosphate 
dlVTA dorsolateral VTA 
DOPAC 3,4-Dihydroxyphenylacetic acid 
E  embryonic day 
EDTA  ethylenediaminetetraacetic acid 
En1  engrailed 1 
EPSP  excitatory postsynaptic potential 
EtBr  ethidium bromide 
EtOH  ethanol 
EYFP  enhanced yellow fluorescent protein 
Foxa2  forkhead box A2 
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Fgf8  fibroblast growth factor 8 
FP  floor plate 
g  gram 
GABA  gamma-aminobutyric acid 
Gbx2  gastrulation brain homeobox 2 
GFP  green fluorescent protein 
GIFM  genetic inducible fate mapping 
Girk2  potassium inwardly rectifying channel, subfamily J, member 6 
Gli1-3  Gli zinc finger transcription factor 1-3 
GliA  Gli protein activator form 
Gli R  Gli protein repressor form 
hrs  hours 
HCl  hydrochloric acid 
HCN  hyperpolarization-activated cyclic nucleotide-gated channel 
Hes5  hairy and enhancer of split 5 (Drosophila)  
HPLC  high-performance liquid chromatography 
Hz  Hertz 
IF  nucleus intrafasciculus 
iPSC  induced pluripotent stem cell 
IPSP  inhibitory postsynaptic potential 
Isl1  LIM homeodomain transcriptional factor islet1 
kb  kilobase 
L  liter 
LB  Luria Bertani Medium 
L-DOPA L-3,4-dihydroxyphenylalanine 
Lmx1a LIM homeobox transcriptional factor 1 alpha 
M  Mol per liter/molar 
MbDNs midbrain dopaminergic neurons 
MbDNp midbrain dopaminergic precursor 
mfb  medial forebrain bundle 
mg  milligram 
MHB  mid-hindbrain boundary 
min  minute 
mL  milliliter 
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mM  millimolar 
µm  micrometer 
Mnx1  motor neuron and pancreas homeobox 1 
mPFC  medial prefrontal cortex 
MPTP  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
mRNA messenger RNA 
ms  millisecond 
Msx1  homeobox, msh-like 1 
NAc  nucleus accumbens 
NDS  normal donkey serum 
ng  nanogram 
Ngn2  neurogenin 2 
NGS  normal goat serum 
Nkx2-2 NK2 transcriptional factor related, locus 2 (Drosophila) 
Nkx6-1 NK6 transcription factor related, locus 1 (Drosophila) 
n.s.  not significant 
nt  nucleotide 
Nurr1  nuclear receptor subfamily 4, group A, member 2 
OB  olfactory bulb 
6-OHDA 6-hydroxydopamine 
OM  oculomotor nucleus  
OTu  olfactory tubercle 
Otx2  orthodenticle homolog 2 (Drosophila) 
P  postnatal stage 
PBP  parabrachial nucleus 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PD  Parkinson’s disease 
PFA  paraformaldehyde 
PFC  prefrontal cortex 
Pitx3  paired-like homeodomain transcriptional factor 3 
PN  paranigral nucleus 
Pou4f1 POU domain, class 4, transcription factor 1 
Ptch  Patched 
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rAAV  recombinant adeno-associated virus 
RA  retinoic acid 
RLi  rostral linear nucleus 
RNA  ribonucleic acid 
RN  red nucleus 
rpm  rounds per minute 
s  second 
SEM  standard error of the mean 
Sim1  single-minded homolog 1 (Drosophila) 
SK  apamin-sensitive small-conductance calcium-activated potassium channel 
Shh  Sonic hedgehog 
Smo  Smoothened 
SNl  substantia nigra lateralis 
SNpc  substantia nigra pars compacta 
SNr  substantia nigra reticulata 
TAE  triethanolamine 
TH  tyrosine hydroxylase 
vGAT  vesicular GABA transporter 
vGlut2 vesicular glutamate transporter 
vMAT2 vesicular monoamine transporter 
vMb  ventral midbrain 
vmVTA ventromedial VTA 
VTA  ventral tegmental area 
VZ  ventricular zone 
Wnt1  wingless-type MMTV integration site family, member 1 
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